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Background: Visual impairment is a major public health problem as it affects 252. 2 
million persons worldwide. In 2015 36 million people were blind and 216.6 million people 
had moderate to severe visual impairment. With the aging population, the number of 
people with VI will increase dramatically, leading to a much heavier disease and 
economic burden in the coming future. 
Purpose: The purpose of thesis was to investigate and characterize the impact of 
vision impairment in selected aspects of the healthcare system and the society. To 
accomplish this purpose five research papers were developed. Three papers are 
considered the main studies and investigated: 1) The access to a new anti-VEGF 
treatment for retinal diseases; 2) The use of informal care and its determinants in persons 
with vision impairment; 3) Productivity losses in persons with vision impairment and its 
predictors. In addition, two complementary studies were conducted to: 4) Investigate 
patient-reported outcome measures using a condition-specific instrument (activity 
inventory) and a generic health-utilities instrument (EQ5D); 5) Investigate the profile of 
the participants in the face-to-face interviews that were conducted as part of the main 
studies. 
Methods: Two different data sources were used to perform the investigations reported 
in the research papers. A national database of inpatient and day cases episodes was 
used to investigate access to anti – VEGF treatments. Data from the Prevalence and 
Costs of Visual Impairment in Portugal: a Hospital Based Study (PCVIP-study) were 
used to investigate informal care, productivity losses, to characterize patient-reported 
outcome measures and to investigate the profile of the participants. Different strategies 
were used to select our participants/cases and to collect information. 
Descriptive statistics was used to summarize socio-demographic and clinical 
characteristics of the participants. Chi-square tests were used to compare the 
composition of groups. T-tests were used to compare normally distribute variables and 
the Mann-Whitney–test or Kruskal-Wallis were used for other non-parametric 
comparisons between groups. Spearman Correlation was used to determine the 
association between variables. Generalised linear modelling was used to investigate 
determinants of the geographical diffusion of anti-VEGF. Logistic regression was used 
to determine explanatory factors associated with the use of informal care and to 
determine explanatory factors of productivity losses. Linear regression was used to 
determine factors associated with the amount of informal care. 
x 
Results: The diffusion and consequently the access to new eye care treatment was 
found to be large but unequally distributed and associated with availability of healthcare 
delivery services. The reduced number of treatments found in some counties is 
worrisome since it can lead to an increased number of people becoming visually impaired 
due to treatable causes. We also found that vision impairment in Portugal has substantial 
socioeconomic implication since it affects individual’s autonomy levels that are 
associated with an intensive use of informal care. It also affects individual’s participation 
in society, namely employment status and health related quality of life that led to 
significant productivity losses. 
Conclusion: Vision impairment in Portugal has a wide ranging impact. Many of the 
causes of vision loss could be reversible and preventable with currently available 
healthcare technology.  Eye care has a range of proved, low risk, high success and cost 
effective health interventions so the key element is to guarantee that these interventions 
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Enquadramento: A deficiência visual é um importante problema de saúde pública que 
afeta 252,2 milhões de pessoas no mundo. Em 2015 existiam globalmente 36 milhões 
de pessoas cegas e 216,6 milhões de pessoas com deficiência visual severa a 
moderada. Dado o envelhecimento da população estima-se que o número de pessoas 
com deficiência visual irá aumentar dramaticamente provocando uma maior carga de 
doença e um maior impacto económico no futuro. 
Objetivos: Com a realização desta tese pretendeu-se investigar e caracterizar o 
impacto da deficiência visual em aspetos selecionados do sistema de saúde e da 
sociedade. Para alcançar este objetivo foram desenvolvidos cinco artigos de 
investigação. Considerou-se que três artigos constituíam a componente principal do 
trabalho realizado investigando: 1) O acesso de doentes com doenças da retina a um 
novo tratamento com anti-VEGF; 2) A utilização de cuidados informais em pessoas com 
deficiência visual e os fatores associados a essa utilização; 3) Perdas de produtividade 
e os seus determinantes em pessoas com deficiência visual. Foram ainda desenvolvidos 
mais dois artigos complementares que pretendiam: 4) Investigar medidas de resultados 
auto-reportadas utilizando um questionário específico para a deficiência visual (activity 
inventory) e um questionário genérico (EQ5D);5) Investigar o perfil dos indivíduos que 
aceitaram participaram nas entrevistas realizadas no âmbito dos estudos apresentados 
nos artigos principais.  
Metodologia: Foram utilizadas duas bases de dados. A base de dados nacional de 
morbilidade hospitalar foi utilizada para investigar o acesso a tratamentos com anti-
VEGF. Dados do estudo sobre a Prevalência e custos da baixa visão em Portugal foram 
utilizados para os artigos referentes aos cuidados informais, perdas de produtividade, 
análise de medidas auto-reportadas e análise do perfil dos entrevistados. Utilizaram-se 
diferentes estratégias para selecionar os casos e para a recolha de informação. 
Utilizou-se estatística descritiva para sintetizar a informação sociodemográfica e 
clínica. Utilizou-se testes de chi-quadrado para comparar a composição de grupos. 
Utilizou-se testes T para comparar variáveis com distribuição normal e testes não-
paramétricos nomeadamente teste de Mann-Whitney e teste de Kruskal-Wallis para 
comparar grupos. Para analisar os determinantes associados à difusão dos tratamentos 
anti-VEGF recorreu-se a modelos lineares generalizados. Utilizou-se modelos de 
regressão logística para investigar fatores associados à utilização de cuidados informais 
e às perdas de produtividade. Recorreu-se a modelos de regressão linear para 
determinar fatores associados à intensidade de utilização de cuidados informais. 
xii 
 
Resultados: Verificou-se que a difusão e consequentemente o acesso a um novo 
tratamento ocular foi significativo, distribuído de forma desigual e associado à 
disponibilidade de prestadores de cuidados de saúde. O número reduzido de 
tratamentos encontrado em alguns concelhos é problemático na medida em que pode 
conduzir a um aumento do número de indivíduos com deficiência visual por causas 
tratáveis. Verificou-se também que a deficiência visual tem repercussões significativas 
a nível socioeconómico dado que afeta o nível de autonomia dos indivíduos que está 
por sua vez associado à necessidade de cuidados informais. Afeta também a 
participação dos indivíduos na sociedade, afetando, a situação no mercado de trabalho 
e a qualidade de vida produzindo perdas de produtividades avultadas.  
Conclusão: A deficiência visual em Portugal produz um impacto diverso e 
significativo. Muitas das causas de perda de visão podem ser preveníeis ou tratadas 
através da tecnologia existente. Os cuidados de saúde oculares dispõem de um 
conjunto de intervenções de saúde baseadas na evidência, custo-efetivas e de baixo 
risco pelo que a medida mais importante a tomar é a de garantir que estas intervenções 
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Chapter 1 – Introduction 
Vision impairment (VI) is a public health problem with substantial burden worldwide. 
The number of people with VI is likely to increase due to the aging population and that 
can lead to a deeper impact of the condition for individuals and societies.  
Studies measuring the impact from an economic and societal perspectives are 
important to alleviate the burden of VI and here we name a few reasons. The first reason 
is that these studies inform policy makers and decision-makers on the relative impact of 
this condition at the population level. The second reason is because they assist in the 
projections of future health care costs. A third reason is explained by the importance of 
these studies to support measures to improve patient outcomes and patient care. The 
last reason that we would like to mention is that studies measuring the impact of VI from 
an economic and societal perspectives are important to contribute and support resource 
allocation decisions that are unavoidable and crucial to reduce the burden of VI.  
The purpose of thesis was to investigate and characterize the impact of vision 
impairment in selected aspects of the healthcare system and the society.  
The thesis is organized in 7 chapters. It begins with the present chapter were the 
subject is introduced and the structured of the thesis is presented. The next chapter 
starts with the definition of VI, presents the latest prevalence estimates and characterizes 
the main causes of VI. Then an overview of the impact of vision impairment in the 
perspective of the individual, healthcare system and society is presented. The third 
chapter describes the objectives of this thesis and the fourth chapter provides a 
description of the research methods. The fifth chapter report the results and includes 5 
manuscripts that have been published or are under review. In 5.1 we report results from 
an analysis of the access to a new eye care treatment (anti-VEGF); In 5.2 we report 
estimates of the use of informal care and its determinants in this population; in 5.3 we 
estimate and characterize productivity losses in persons with vision impairment. In 
addition to these 3 papers with me, the PhD candidate, as first author I also contributed 
to two more papers. Section 5.4 report results of a study comparing patient-reported 
outcome measures using a condition-specific instrument (activity inventory) with a 
generic health-utilities instrument (EQ5D) and section 5.5 reports the findings of an 
analysis of the participants and non-participants profiles and the levels of participation in 
face-to-face interviews. The sixth chapter provides the key findings, a discussion of the 
work performed, limitations and suggestion to future work. The final chapter provides the 
conclusion of the thesis.  
2 
Research findings of this thesis has been previously published as: 
Marques AP, Macedo AF, Perelman J, Aguiar P, Rocha-Sousa A, Santana R. 
Diffusion of anti-VEGF injections in the Portuguese National Health System. BMJ Open 
2015;5:e009006.doi:10.1136/bmjopen-2015-009006  
Marques AP, Macedo AF, Hernandez-Moreno L, Ramos PL, Butt T, Rubin G, 
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doi:10.1111/aos.13430 
Ramos PL, Santana R, Moreno LH, Marques AP, Freitas C, Rocha-Sousa A, Macedo 
AF; Portuguese visual impairment study group. Predicting participation of people with 
impaired vision in epidemiological studies. BMC Ophthalmology. 2018 Sep 4;18(1):236. 
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R.Productivity losses and their explanatory factors amongst people with impaired vision. 




Chapter 2 – Background 
 
This chapter starts with the definition of VI, presents the latest prevalence estimates 
and characterizes the main causes of VI. Then an overview of the impact of vision 
impairment in the perspective of the individual, healthcare system and society is 
presented. Adopting the perspective of the individuals we describe how VI affects daily 
living activities, how is associated with depression and anxiety and how it is related to 
risk of falls and fractures. Adopting the perspective of the healthcare system we describe 
the healthcare resource utilization of visually impaired persons, we review the 
determinants of access to healthcare services and describe the factors that influence the 
adoption of new healthcare treatments. The societal impact of VI is characterized by the 
economic impact of vision impairment and its main components. 
 
2.1- Definition of Vision Impairment  
To better understand the concepts of visual acuity and visual field here is given 
a superficial and oversimplified description of the eye and the visual system. As shown 
in Figure 1 the visual system has many levels of information processing but the first organ 
that process physical stimuli is the eye. For our purpose we consider the eye analogous 
to a camera that focus the external world trough optics on a light-sensitive element (the 
retina).  
The retina is an elaborate neural structure that actively analyses the image that 
is focused on it. The signal travels from the retinal to the brain trough a complex neural 
pathway and then, in the brain, a representation of the retinal image is perceive (1). 
Visual function includes a series of aspects of the visual system that can be quantified 
and that includes visual acuity, visual field, contrast sensitivity, colour vision, binocular 
function, visual search, glare and light adaption (2, 3). In this thesis is important to 





Figure 1 - A schematic view of the visual system. The image shows the eye as 
the first organ of the system receiving input from the external stimuli (physical world). 
The extend of the physical word that can be seen with both eyes open is shown by the 
almost elliptical shaped line surrounding the coloured green and brown half-parts. The 
centre of the ellipse is depicting the fixation point were the lines of sight of both eyes 
converge. The size extent of the ellipse defines the visual field, that is, the amount of 
physical world stimuli that can be perceived around the fixation point without moving 
the eyes. The extent of the field is variable according with the lighting conditions, but as 
the image shows can be up to 100 degrees to each side of the fixation point in the 
horizontal meridian (1) 
 
Visual acuity referrers to the ability of the visual system to resolve spatial details 
of objects (see details as separate parts) that correspond to a known visual angle. Acuity 
is typically measured by asking a person to resolve the details of visual symbols called 
optotypes forming an acuity chart as shown in Figure 2-A. As the person reads down in 
an acuity chart, the optotypes become smaller and their details become finer a point is 
reached where the details of the optotypes can no longer be resolved, this limit of 
resolution define the limit of visual acuity. Visual acuity can be expressed using what is 
known as the Snellen fraction e.g. 6/6 (20/20), 6/24 (20/80), etc., in which the numerator 
is the testing distance, usually expressed in metres (or in feet), and the denominator is 
the distance (in the same units as the numerator) at which the smallest Snellen letter 
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read by the eye has an angular size of 5 minutes-arc. The reference of 5 minutes-arc is 
used because letters are formed of 5 elements of 1 minute-arc each and that is expected 
to be the limit of resolution of a normal eye. Acuity scales have been designed in such a 
way that when an individual can see a line with letters marked with 20/20 (distances in 
feet) or 6/6 (distances in meters) its acuity is considered normal. When acuity is, for 
example, 6/18 (or 0.33 when we compute the fraction, we have acuity in what is called 
the decimal scale) it is considered to be below the normal limits. In simple terms this 
fraction tells us that the individual needs to be at a testing distance of 6 meters to be able 
to read a letter that should be visible to him / her at 18 meters (denominator).  
The visual field is defined as the extend of the physical world with visual stimuli 
(visual field does not matter in the absence of stimuli such as in a complete dark room) 
that can be perceived around the point of fixation without moving the gaze. A typical 
visual field is shown in Figure 2-B and the extent of a binocular visual field (when keeping 




Figure 2 - A - Snellen acuity chart. Each line is designated by its foot-size (small 
numbers of the right-hand side, which is the distance at which each of its optotypes 
subtends an visual angle of 5-minute arc. Is important to mention that acuity can be 
measured with other type of symbols that do not require ability to recognize letters. 
Adopted from:(1) B – Binocular visual fields of stimuli recognition (heavy lines) and 
stimuli detection (doted lines) for a healthy subject. To understand the concept of visual 
field that is going to be discussed in this thesis the relevant limits are defined by the 
doted lines and they can be called isopters defining the limit of the visual field for each 
eye. The right doted isopter represents the visual field of the right eye and the left 
doted isopter represents the limit of the visual field for the left eye. The monocular 
vertical extent of the visual field is approximately 100 degrees and the horizontal extent 




Vision loss can be defined as a measurable reduction of visual acuity or visual field 
and that can lead to vision impairment. In the 10th revision of the World Health 
Organization (WHO) International Statistical Classification of Diseases, Injuries and 
Causes of Death vision impairment has been divided in ‘low vision’ and ‘blindness’. ‘Low 
vision’ is defined as visual acuity of less than 6/18 but equal to or better than 3/60, or a 
corresponding visual field loss to less than 20°, in the better eye with presenting visual 
acuity. ‘Blindness’ is defined as visual acuity of less than 3/60, or a corresponding visual 
field loss to less than 10°, in the better eye with the best possible correction. ‘Visual 
impairment’ or ’vision impairment’ includes both low vision and blindness  (5, 6). A person 
with vision impairment is one who has impairment of visual functioning even after 
treatment and/or standard refractive correction. However, people who are visually 
impaired retain some vision, even if is only light perception, and that allows them to a 
certain extent planning and/or execution of tasks that rely on vision. Because of that a 
few levels of vision impairment have been defined and are summarized in Table 1. 
Table 1 - Vision impairment definition - 2010 
Categories Notation Type Presenting distance visual acuity 
Worse than: Equal to or better 
than: 
0 Mild or no 
Visual 
Impairment 
6 metre notation*  6/18 
Decimal notation** 3/10 (0.3) 




6 metre notation 6/18 6/60 
Decimal notation 3/10 (0.3) 1/10 (0.1) 
U.S.A * notation 20/70 20/200 
2 Severe visual 
impairment 
6 metre notation 6/60 3/60 
Decimal notation 1/10 (0.1) 1/20 (0.05) 
U.S.A * notation 20/200 20/400 
3 Blindness 6 metre notation 3/60 1/60**** 
Decimal notation 1/20 (0.05) 1/50 (0.02) 
U.S.A * notation 20/400 5/300 (20/1200) 
4 Blindness 6 metre notation 1/60* Light perception 
Decimal notation 1/50 (0.02) 
U.S.A * notation 5/300 (20/1200) 
5 Blindness No light perception 
9 Undetermined or unspecified 
*  commonly used in United Kingdom; **  commonly used in Europe; **** commonly used in United States 
of America  **** or count of fingers at 1 metre 





At this stage is also important to define 4 concepts that are often used as synonyms, 
but, whilst related, they are expected to express different aspects of vision loss. The 4 
concepts that need to be defined are: (1) disorder or injury, (2) impairment, (3) disability 
or loss of ability and (4) handicap. The separation between these concepts has been 
recommended by the International Council of Ophthalmology and is summarised in Table 
2. Two of the aspects refer to the organ system, the first aspect is that of anatomical and 
structural changes. Defects are described as diseases, disorders or injuries. The second 
aspect is that of functional changes at the organ level. Defects are described as 
impairments. The other two aspects refer to the individual. One aspect describes the 
skills and abilities of the individual. Defects are described as ability loss. The last aspect 
points to the social and economic consequences (7). Defects are described as handicaps 
and as lack of participation. This separation into: disorder or injury, impairment, disability 
or loss of ability and handicap is important to understand this thesis because it covers 
aspects of vision impairment very briefly and most of the investigations have been about 
the consequences of vision impairment, in particular, social and economic 
consequences of VI. 
When trying to understand impairment from its consequences it also important to 
distinguish visual functions from functional vision. The term “visual functions” is used to 
refer to the concept of impairment. Visual functions such as visual acuity and visual field 
can be assessed quantitatively, and they are usually measured for each eye separately. 
In contrast, abilities such as reading, orientation and mobility refer to the person, not to 
the eye. Although some aspects, such as reading speed, can be readily quantified, other 
aspects, such as reading enjoyment are highly subjective. Because of this it was need 
to define also the term "functional vision" and this is used to refer to these visual abilities, 
as they are needed for the proper performance of activities of daily living (2, 8-10). This 
separation is also needed because two persons with similar levels of visual functions can 










Table 2 - Aspects of vision loss according with the recommendations of the 
International Council of Ophthalmology 
 
Source: Colenbrander (7) 
There has been some debate in the literature if vision impairment should be 
defined according to presenting visual acuity or best corrected visual acuity. Presenting 
visual acuity is the acuity measured regardless the amount of refractive error that may 
be incorrected. Resnikoff et al. (11) defines “presenting vision as the visual acuity in the 
better eye using currently available refractive correction, if any” and best corrected vision 
“as the visual acuity in the better eye achieved by subjects tested with pinhole or 
refraction”. To understand why presenting vs best corrected acuity can create polemic 
when quantifying the number people with vision impairment lets consider an example. 
An individual with a relatively common refractive error such as 4 dioptres of uncorrected 
myopia in both eyes would almost for sure have acuity below 6/18 and therefore would 
be classified as visually impaired if presenting acuity is considered. In contrast, this 
individual would reach 6/6 vision when wearing correcting lenses.  Many studies at 
regional or global level have concluded that uncorrected refractive error account for a 
high number of cases with mild to moderate levels of VI (11-14) and that forced 
authorities to redefining the rules to determine the number of people with vision 
impairment. 
Since 2010 the ICD-10 - World Health Organization (WHO) version uses 
presenting vision when determining the number of people with VI. This has been adopted 
following recommendation by the Resolution of the International Council of 
Ophthalmology and the Recommendations of the WHO Consultation on “Development 
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of Standards for Characterization of Vision Loss and Visual Functioning". This new 
recommendations emphasize that the use of “best corrected” vision misses or excludes 
a large proportion of persons with VI, including blindness, due to uncorrected refractive 
error (7, 15, 16).  
VI caused by uncorrected refracted errors may occur due to the lack of 
awareness of this problem from the family, community or public health services, 
insufficient or inadequate screening services and/or provision of affordable corrective 
lenses, lack of continuity of eye care, delays in access to specialist eye care among other 
reasons (11, 17). In terms of consequences it may lead to many short or long term 
penalties, both in children and in adults, such as loss of opportunities in education or 
employment, income losses and quality of life losses (11, 17, 18). Therefore, another 
way to classify VI is to distinguish uncorrectable VI, the amount of vision impairment that 
remains after appropriate treatment or intervention, from uncorrected or avoidable vision 
impairment defined as the amount of vision impairment that could be improved by 
currently available treatments (19, 20). 
Vision impairment has been defined based on visual acuity and visual field, 
amongst other reasons, for legal purposes. For example, in case of accidents insurance 
companies need to establish compensations to be paid to people that will face 
permanent vision impairment that will, eventually create disability and/or handicap. 
Although, the legal limit to what is considered vision impairment is different in different 
nations. For instance the legal definition of blindness in the United States of America, 
Australia and Portugal is visual acuity worse than 0.1 decimal (20/200 or 6/60) whereas 
for WHO blindness correspond to a visual acuity worse than 0.05 decimal (20/400  or 
3/60) (17). The existence of different levels for what is considered vision impairment can 
cause difficulties when comparing, for example, the prevalence of VI. 
In summary, the different definitions of vision impairment make prevalence 
numbers somewhat difficult to discuss and compare.  In addition,  there are other 
methodological options adopted by researchers that need to be considered too such as 
the type of visual acuity scale, data collection methods (e.g. self-reported acuity or 
measured acuity or registered in medical records), the age range considered (e.g. all the 
population, children only, adults above 40 years old or adults above 65 years old) or the 
method used to extrapolate and infer unknown prevalence (16, 21). The next section 
covers relevant aspects of prevalence of vision impairment in Portugal and in other parts 
of the world. 
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2.2 - Prevalence of Vision Impairment and Blindness 
 The most recent estimate of the number of visually impaired at a global scale was 
reported in 2017 by Bourne et al. (22) on behalf of the Vision Loss Expert Group. The 
Vision Loss Expert Group is an international group of mainly ophthalmologists and 
optometrists that has convened with WHO to assist with the development of 
epidemiological estimates for blindness and vision impairment that would be included in 
the Global Burden of Disease study. In this latest report blindness was defined as 
presenting visual acuity in the better eye worse than 3/60, moderate to severe vision 
impairment was defined as presenting visual acuity in the better eye worse than 6/18 to 
3/60 inclusive and mild vision impairment was defined as presenting visual acuity in the 
better eye worse than 6/12 to 6/18 inclusive. Based on these definitions Bourne et al. 
(22) reported that globally in 2015: 36 million people were blind (prevalence ratio of 
0.49% 80% UI 0.18-0.89 UI – uncertainty interval); 216.6 million people had moderate to 
severe visual impairment (prevalence ratio of 2.95%: 80% UI 1.34-4.89) and 188.5 
million had mild visual impairment (prevalence ratio of 2.57%: 80% UI 0.88-4.77). 
Figure 3 illustrates prevalence ratios in the world. Accordingly with this illustration the 
burden of VI was not uniformly distributed throughout the world. South and East Asia 
regions have the highest prevalence whereas the lowest prevalence is reported in most 
European countries (Portugal included), Australia, United States of America and 
Canada. The lowest prevalence ratios are in the interval of 1% to 1.5%. 
 
Figure 3 - Vision impairment prevalence ratio for moderate to severe vision impairment 
in the World - 2015. Each country is painted with a colour that represents the estimated 
prevalence ratio. The legend gives us the correspondence between the colours and the 
prevalence ratios. There are 8 different prevalence ratio intervals ranging from 1% to >4.5% 
(23) 
 1.0% - 1.5% 
 1.5% - 2.0% 
 2.0% - 2.5% 
 2.5% - 3.0% 
 3.0% - 3.5% 
 3.5% - 4.0% 




VI is strongly associated with age and because of that the authors of the most 
recently reported data reported, in addition to age standardized prevalence ratios, 
prevalence to population aged 50 years and older. Those results are summarized in 
Table 3. In the population aged 50 years in 2015 there were 31 million blind people (86% 
of all age blind population), 172·3 million people with moderate and severe vision 
impairment (80% of all age moderate to severe visually impaired population), 140·3 
million people with mild vision impairment (74% of all age mild visually impaired 
population) in the world (20). It is important to mention that in many cases prevalence 
values have been extrapolated or inferred as is the case of Portugal. To our knowledge 
there is a lack of exact numbers about the prevalence of VI in Portugal and the authors 
used data from other countries in the same global burden of disease region. Portugal is 
included in the Western Europe global burden of disease region which includes a total 
of 21 countries. In Western Europe region only 10 countries had prevalence data.  The 
estimates for Portugal show a prevalence of blindness, moderate and severe visual 
impairment that is in general inferior to the global values. Although, the uncertainty 
interval, for example, for moderate and severe VI ranges from 0.58 to 2.22 which 
indicates that these estimates are a very gross picture of the situation in Portugal and 
further studies are necessary. 
Table 3 - Blindness and Moderate and Severe Visual Impairment age 
standardised prevalence ratios and uncertain interval for aged ≥50 years and all ages 
in Portugal and in the world 
Age standardised prevalence 











(80% UI; 0.67-3.39) 
0.54% 





(80% UI; 4.93-17.13) 
5.06% 
(80% UI; 2.3-8.61) 






(80% UI; 0.17-0.87) 
0.13% 





(80% UI; 1.31-4.8) 
1.3% 
(80% UI; 0.58-2.22) 
Source: Adapted from: Bourne et al (22) 
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2.2.1 - Trends of Blindness and Visual Impairment  
Since 2002 there have been several reports on global prevalence estimates using 
different definitions of VI. Results of 6 recently published studies are summarized in 
Table 4. Best corrected visual acuity was only reported in two of the six studies whereas 
presenting visual acuity was reported in five studies. It is important to point that the 
numbers reported are crude prevalence using best corrected visual acuity and 
presenting visual acuity. This reflects the Resolution of the International Council of 
Ophthalmology issued in 2002 (7) and the Recommendations of the WHO Consultation 
on “Development of Standards for Characterization of Vision Loss and Visual 
Functioning" issued in 2003 (15) that led to a modification on the WHO definition of 
blindness and visual impairment in 2010. The estimates and the trend summarized are 
variable because of a spectrum of reasons that are mentioned below. 
Table 4 - Summary table of estimated number and crude prevalence of blind, 
moderate and severe visual impairment and mild visual impairment between 2002-
2015 
Year  20021* 20022* 20043* 20104* 20105** 20156 
Global population 
(Nr. in million) 




Nr. 36.86 n.a n.a 38.18 n.a n.a 
% 0.59 n.a n.a 0.55 n.a n.a 
Presenting 
VA 
Nr. n.a 42.01 45.08 39.37 32.4 36 
% n.a 0.67 0.7 0.57 0.5 0.49 
MSVI  Best 
Corrected 
VA 
Nr. 124.26 n.a n.a 142.69 n.a n.a 
% 1.98 n.a n.a 2.07 n.a n.a 
Presenting 
VA 
Nr. n.a 217.19 269.24 246.02 191 216.6 






Nr. n.a n.a n.a n.a n.a n.a 
% n.a n.a n.a n.a n.a n.a 
Presenting 
VA 
Nr. n.a n.a n.a n.a 155 188.5 
% n.a n.a n.a n.a 2.4 2.57 
1 Resnikoff et al (2004); 2 Dandona e Dandona (2006); 3 Resnikoff et al (2008); 4 Pascolini e Mariotti 
(2012); 5 Stevens et al (2013); 6 Bourne et al (2017).* Blindness: VA<0.05 decimal (20/400 or 3/60); 
MSVI Moderate and Severe Visual Impairment: VA<0.3 (20/60 or 6/18)> 0.05 decimal (20/400 or 3/60); 
Mild visual impairment VA<0.5 (20/40 0r 6/12)> 0.3 (20/60 or 6/18) 
Source: Adapted from: Resnikoff and Keys (16) 
    
Estimates based on best corrected visual acuity (VA) give us a smaller prevalence 
when compared with presenting visual acuity estimates. Accordingly with Resnikoff and 
Keys (16) this is explain by the fact that when corrected VA is considered that leads to 
13 
 
an underestimation of the prevalence caused by, for example, uncorrected refractive 
error. Mild vision impairment was only reported in two recent studies. These reports 
wanted to expand global estimate by including a mild category that incorporates 
presenting visual acuity less than 0.5 decimal (20/40 or 6/12) but higher than 0.3 decimal 
(20/70 or 6/18) in the better seeing eye. Stevens et al. (24) reports the smallest 
prevalence even when compared with Pascolini and Mariotti (25) which reports results 
for the same year. Accordingly with Stevens et al. (24) their estimate is within the same 
uncertainty range as Pascolini and Mariotti (25) in most world region. The main difference 
is in China where Pascolini and Mariotti (25) estimated 8.2 million blind people and 67.2 
million people with low vision in 2010 versus 5.4 million blind people and 32.4 million 
people with low vision.  The differences between this two studies rely on data collection 
methods. In a big and heterogeneous country like China extrapolating data from a 
smaller sample may increase uncertainty level (24, 25).  
An additional source of uncertainty and eventual lack of agreement between 
studies is the way authors deal with missing data. Pascolini and Mariotti (25) used 
economic status to extrapolate data, Stevens et al. (24) used country´s development 
status whereas Dandona and Dandona (26) extrapolated data based on epidemiological, 
socioeconomic, ecological and eye care services characteristics.  
Other explanation to these differences is related with the time frame of the surveys 
and papers included in each study. In Dandona and Dandona (26) studies used to 
estimate prevalence range from 1980 to 2003 in Stevens et al. (24) range from 1980 to 
2012 and Pascolini and Mariotti (25) range from 2001 to 2008.  
In short, trends are difficult to interpret due to limited comparability between global 
estimates over the years. Nevertheless, estimates on blindness seems to have a 
relatively clear pattern with blindness decreasing from 0.67 in 2002 to 0.49 in 2015 when 
using presenting distance visual acuity definition. For moderate to severe VI the best 
way to analyse trends is to consider studies that used only comparable data as Stevens 
et al. (24) and Bourne et al.(22) did. In both studies global age-standardized all-age 
prevalence ratio of blindness and moderate to severe VI decreased worldwide. However, 
because of the rapid increase in the older adult population, the number of people with 
blindness and with moderate to severe VI did not decrease. Bourne et al.(22) project that 
in 2020 the number of people suffering with blindness reach 38.5 million and the number 
of people suffering with moderate to severe VI can reach 237·1 million. For 2050 the 
projection is 114.6 million people with blindness and 587.6 million people with moderate 
and severe VI (22). 
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2.3 - Causes of Vision Impairment and Blindness 
The most recent estimate of the causes of vision impairment and blindness at a 
global scale was reported in 2017 by Flaxman et al. (27) on behalf of the Vision Loss 
Expert Group of the Global Burden of Disease Study. In this systematic review and meta-
analysis the authors use the definition of vision impairment proposed by WHO which is 
based on visual acuity for distance (27). Figure 4 shows the main causes of blindness, 
defined as presenting visual acuity of less than 3/60 in the better eye and Figure 5 shows 
the main causes of vision impairment, excluding blindness, for population aged 50 years 
or more, both represent the global causes of impairment.  
 
 
Figure 4 - Global causes of blindness among adults 50 years and older in 2015. 






















Figure 5 – Global causes of vision impairment among adults 50 years and older 
in 2015. Adapted from Flaxman et al. (27). 
 
 
The two images show that the top causes of vision impairment, including 
blindness, in 2015 were cataract, uncorrected refractive error, glaucoma, age-related 
macular degeneration, corneal opacity, trachoma and diabetic retinopathy. Cataract 
together with uncorrected refractive error account for 55% of blindness and 77% of other 
levels of vision impairment in adults aged 50 years and older in 2015 in the world. A brief 































Table 5 – Brief description of common causes of blindness and other levels of vision 
impairment 
Age-related macular degeneration (AMD) 
Affected structure Macula 
Definition, risk 
factors and general 
actions for 
treatment 
AMD is a degenerative eye disease that causes damage to the macula. AMD can be 
divided into two stages: early AMD, characterized by sub-retinal pigmented epithelium 
deposits (drusen) and pigmentary changes, and advanced AMD (28). Advanced AMD 
has atrophic and neovascular forms. Although neovascular AMD comprises only 10% 
of the burden of the disease, it is responsible for 90% of severe vision loss years. 
Increasing age and history of smoking are considered risk factors of AMD. Anti-VEGF 
therapy for neovascular AMD has substantially changed the management of the 
disease. These drugs are injected into the vitreous chamber to reduce neovascular 
formation in the macula (29, 30) 
Cataracts 
Affected structure Lens of the eye  
Definition, risk 
factors and general 
actions for 
treatment 
A cataract is a clouding of the lens. This cloudiness may decrease vision and may 
lead to eventual blindness if left untreated. Cataracts often develop slowly and 
without pain, so vision can be affected without a person realizing it. Cataract 
prevalence increases with age. In addition to age the risk of cataract increases 
also with history of smoking and diabetes mellitus. Cataract treatment includes 
lens removal by surgery which may be followed by lens replacement (31, 32) 
Diabetic retinopathy 
Affected structure Blood vessels in retina 
Definition, risk 
factors and general 
actions for 
treatment 
Diabetic retinopathy is a common complication of diabetes mellitus. It is 
characterized by “signs of retinal ischemia (micro aneurysms, haemorrhages, 
cotton woolspots, intraretinal microvascular abnormalities, venous calibre 
abnormalities, and neovascularization) and/or signs of increased retinal vascular 
permeability. Vision loss can occur from different ways including macular edema, 
neovascularization that leads to vitreous haemorrhage and/or retinal detachment. 
It can be prevented by aggressive control of hyperglycemia and hypertension. The 
most important risk factor is duration of diabetes. Poor glycaemic control, insulin 
use, and elevated blood pressure are other important risk factors. Eye injections 
are used to control macula edema and laser treatment for growth of new blood 
vessels (32, 33) 
Glaucoma 
Affected structure Optic Nerve 
Definition, risk 
factors and general 
actions for 
treatment 
Glaucoma is an ocular disease that causes optic nerve damage which leads to 
peripheral vision loss and in some cases to vision loss. There are two major types 
of glaucoma: primary open angle glaucoma and angle closure glaucoma. Primary 
open angle glaucoma is the most common type. 
Elevated intraocular pressure (IOP) is one of the clinical symptoms associated 
with loss of visual function although not every patient experience IOP. The 
diagnosis is based on evaluating, IOP, optic nerve and retinal nerve changes and 
by performing visual tests, in particular, vision field tests to assess peripheral 
vision loss. High intraocular pressure, thin central corneal thickness, positive 
family history, increasing age, corticosteroid use, and possibly myopia and 
diabetes are risk factors or associations for development of glaucoma. Treatment 
includes medication to control IOP and surgery (31). 
Refractive errors 
Affected structure Cornea, lens or eye shape 
Definition, risk 
factors and general 
actions for 
treatment 
State in which “the optical system of the non-accommodating eye fails to bring 
parallel rays of light to focus on fovea”.  Myopia and hyperopia consist on 
refractive errors where the optical system brings parallel rays of light into focus 
anterior and posterior of the fovea respectively. This results in blurred vision. 
Myopia is much more prevalent in younger age and higher education level. Risk of 
hyperopia appears to increase with age, less education, and is most prevalent in 
white men. It can be relieved by the use of glasses, contact lenses or refractive 




The main causes for blindness in the population aged 50 years or more in 
Western Europe are shown in Figure 6. Figure 7 shows the main causes for other vision 
impairment levels for the same region and age range. In Western Europe, where 
Portugal is included, in 2015 cataract and uncorrected refractive error combined 
contribute to 36% of blindness and 65% of other levels of vision impairment for those 
aged 50 years and older (27).For vision impairment alone, uncorrected refractive error, 
reversible with spectacle correction, represents 50% of total cases in adults aged 50 
years and older. For blindness, and also in Western Europe cataract, reversible with 
surgery, accounts for 21% of cases in the same age range and year. Cataracts is 
followed by Age-related macular degeneration (AMD) and glaucoma that are responsible 
for 15% and 14% respectively of blindness cases whereas uncorrected refractive error 
accounts for 13%.  
There are differences in the distribution of causes of blindness and other levels 
of vision impairment in the world (27).The proportion of blindness and other levels of 
vision impairment caused by cataract was smaller in high income regions and in Europe 
than in some sub regions of Asia and sub-Saharan Africa (27). It ranges from less than 
22% in Western Europe and high income regions of North America and Asia Pacific and 
higher than 44% in Central, West and East sub-Saharan Africa for blindness and less 
than 15% in Western and Eastern Europe and in high income regions of North America 
and Asia Pacific and higher than 34% in Central sub-Saharan Africa for other levels of 
vision impairment, respectively. Uncorrected refractive error has a larger proportion of 
blindness and other levels of vision impairment in south Asia than in other regions of the 
world. It is responsible for 36% of the cases of blindness and 66% of other levels of vision 
impairment in this sub-region of the world. In Europe and high income North America 
uncorrected refractive error is responsible for 13% of blindness and about 50% of other 
levels of vision impairment. 
The proportion of vision impairment (including blindness) attributed to AMD in 
Europe and high income North America ranges from 19.5% to 15.4% for blindness and 
from 13.4% to 10.7% for other levels of vision impairment. AMD causes a lower 
proportion of cases of blindness and other levels of vision impairment is the rest of the 
world, 5.93% and 4.38% respectively (27). Glaucoma follows a similar pattern as AMD 
with a higher proportion of cases for blindness and other levels of vision impairment in 
Europe and high income North America than in other world sub regions (27). In Europe 
and North America 13.5% of cases of blindness and 3.6% for other levels of vision 





Figure 6 – Causes of blindness among adults 50 years and older in 2015 – 
Western Europe. Adapted from Flaxman et al. (27)   
 
 
Figure 7 - Causes of vision impairment among adults 50 years and older in 










































2.4 - Impact of vision impairment on individuals, healthcare system and 
society  
Vision impairment (VI) can lead to a large spectrum of difficulties. VI is associated 
with difficulties performing activities of daily living (35-37), mobility and autonomy (38-
40), depression and anxiety (41, 42), social isolation (40, 43), decreased quality of life 
(44-46), a high number of falls, injuries and trauma related with falls and injuries (47, 48), 
a high risk of car accident (31, 40), a higher levels of dependency (35), high need of 
informal  and formal care (49-51), an increase risk of healthcare resource use (52, 53), 
leading to an economic burden for individuals, healthcare system and society.  
This subsection provides an overview of the main impacts of VI. It describes how 
VI affects daily living activities, how is associated with depression and anxiety and how 
it is related to risk of falls and fractures. The impact of VI on healthcare systems is 
characterized in terms of healthcare resource utilization, what are the determinants of 
access of visually impaired persons to healthcare services and how is the adoption of 
new healthcare treatments. The societal implications of VI is characterized by the 
economic impact of vision impairment and its main components. 
 
2.4.1 - Impact of vision impairment on individuals  
2.4.1.1 Impact of vision impairment on daily living activities  
The activities and performance of daily living activities of persons with vision 
impairment are likely to be affect by their disability (35-37, 54). For example, when 
compared with participants without vision problems, older people with vision impairment 
were 3 times more likely to report walking difficulties, 3.3 times more likely to report 
problems getting outside, 4.3 times more likely to report difficulties managing money and 
4.9 times more likely to report difficulties to use a telephone (54). Visual acuity, contrast 
sensitivity and visual field losses are associated with difficulties in performance of 
everyday activities including, walking around, inserting a plug or dialling a telephone or 
visually intensive tasks like reading speed or face recognition (35-37). Likewise, different 
levels of visual acuity and contrast sensitivity are associated with different levels of 
difficulties depending on the task. Figure 8-A shows an example of a relationship 
between contrast sensitivity and the score of speed of inserting a plug. Figure 8-B 
illustrates an example of a linear relationship between presenting visual acuity measured 




Figure 8 - A, Smoothed graph of the relationship between contrast sensitivity in 
the better eye and the score of inserting a plug. B, Smoothed graph of the relationship 
betweem visual acuity in the better eye and the number of faces read correctly on the 
face recognition test (35) 
Different eye diseases affect visual function (see section 2.1) differently leading 
to typical limitations in functional vision with different impacts on daily living activities (55, 
56). For example, reduction in contrast sensitivity and visual field in old adults with 
glaucoma is associated with weaker limb strength, lower self-reported physical activity 
and lower overall functional status score (57). People with cataracts have reduced visual 
acuity and contrast sensitivity that has been associated with difficulties performing 
several activities like reading, inserting a key in a lock or reading a medicine bottle (37).  
The type of activities or tasks are relevant when assessing the impact of vision 
impairment on everyday life activities. Some studies have divided everyday life activities 
into two groups: Activities of daily living (ADL) and Instrumental activities of daily living 
(IADL). ADL are usually defined as basic tasks of everyday life including bathing, 
dressing, brushing teeth, and eating while, IADL are more complex tasks including 
cooking, using the telephone or computer, shopping, household maintenance and 
managing medication. Berger et al. (56) reported that IADL are more challenging and 
required better visual acuities than ADL activities. ADLs and IADLs require also different 
skills and are associated differently with patient characteristics such as age, gender, 
marital status, race, income level and comorbidities. Haymes et al. (55) also concluded 
that visual functions had a higher correlation with performance with IADL such as, 
reading, writing and using the telephone, than with basic ADL like dressing and eating. 
Many of the reported results took into consideration other variables that may influence 
the ability to perform everyday life activities besides vision impairment including age, 
gender, presence of comorbidities, depression among others (35, 56).  
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Reduced performances in activities of daily living and instrumental activities of 
daily living may have a number of consequences in everyday life such as increased 
frustration and embarrassment and shortened feeling of personal competency. In 
addition, limitations in daily living activities affect negatively the independence of visually 
impaired persons and result in a higher need of family and community support as well 
as a higher use of long term care facilities (51, 58). 
2.4.1.2 Impact of vision impairment on depression and anxiety  
Vision loss is a disabling, disturbing and stressful consequence of aging for many 
elderly individuals (59, 60). It is associated with, declining ability to live independently, to 
depression and social isolation (35, 40). Depression has also been associated with 
reduced ability to perform daily living activities, diminished capability to socialize and 
reduced quality of life. Untreated depression has been linked to limitation in everyday 
activities, to various systematic diseases including metabolic disorders, cardiovascular 
diseases (61) imunoendocrine dysregulation, increased risk of death and higher need of 
long term care (62, 63). 
Vision loss is one of the most common chronic condition associated with 
depression in old age, with both increased odds ratio and relative risk (64). According to 
a meta-analysis, comparing depression between participants with and without vision 
loss, there is an association between depression in old age and poor vision. Figure 9 
shows  the results of pooling 15 studies, 12 studies comparing subjects with and without 
good vision and three studies comparing incidence rates of depression between subjects 
with poor and good vision, and presents a pooled odds ratio of 1.94 (95% CI: 1.68 – 
2.25) and a relative risk of 2.39 (95% CI: 1.23 – 4.6) respectively (64). More recently the 
association between vision loss and depression was also demonstrated and generalized 
in individuals with 20 years of age and older (65). The prevalence of depression and 
depressive symptoms among eye diseases was also estimated an the overall pooled 
prevalence was 25% (1502/6589; 95%CI: 0.20-0.3) ranging from 5.4% to 57.4% (61). It 
can be said that the prevalence of depression amongst people with impaired vision is 




   
Figure 9 - Forest plot of Odds Ratio and Relative Risk from 15 studies comparing 
the prevalence and incidence rates of depression in persons 65 years old and more with 
poor and good vision (64) 
Depression may occur at any level of vision impairment (62, 66) and even patients 
with minimal vision loss are at risk for depression (67). For example Goldstein et al. (67) 
reported that from 764 patients recruited at low vision rehabilitation clinics 22% were 
depressed, 23% were experiencing anxiety even though 65% had mild to moderate 
vision impairment. Brody et al.(62) also demonstrated that visual acuity had little 
correlation with the severity of depressive symptoms. Accordingly to the authors this 
finding could be related to the fact that depression associated with AMD may occur 
earlier in the course of AMD and at low levels of vision loss and not only in those with 
very poor vision. Moreover, Rovner et al. (68) in a prospective study concluded that as 
depressive symptoms increased over time and there was a corresponding decline in the 
performance of vision related activities, regardless of visual acuity. Another study 
demonstrated that vision- specific distress including, amongst others, feelings like 
loneliness and isolation, anxiety about the future and worries that eyesight gets worse 
were the predictors of depressive symptoms. The emotional consequences of vision loss 
seems a critical factor for depression independently of the severity and duration of vision 
impairment (69). In addition, Tournier et al. (70) also suggested that severity of vision 
impairment may not be associated with risk of depression. In summary, vision 
impairment is a risk factor for depression but depression may be an avoidable 




2.4.1.3 Vision impairment and risk of falls and fractures  
Vision impairment has been shown to be associated with an increased risk of 
falls and different types of fractures in multiple studies. Falls are part of the snowball 
effect triggered by vision impairment putting pressure on health care services. For 
example, falls can lead to increased needs of medical interventions and long term care 
due to trauma. In the Framingham Eye Study participants with moderate VI had an 
increased risk of subsequent fractures over a 10-year period (Risk Ratio, RR 1.5) (71). 
Dargent - Molina et al. (72) in a large multicentre prospective study (EPIDO) with women 
aged 75 years or older reported that the risk of hip fracture increased with visual acuity 
3-4/10 in decimal scale (Risk Ratio of 1.9) (95% CI 1.1 to 3.1) and was even higher in 
subjects with visual acuity equal or bellow 2/10 (decimal scale) with a Risk Ratio of 2.0 
(95% CI 1.1 to 3.7). These values are summarized in Table 6. In another study with older 
white women the risk of hip fracture was considered multifactorial. Both poor depth 
perception and reduced perceive contrast sensitivity were independent predictors of hip 
fracture (73). In this study participants who had five or more risk factors had an incidence 
of hip fracture of 19 per 1000 woman-year whereas women who had two or fewer risk 
factors had an incidence of only 1.1 per 1000 woman year (73).  
Table 6 - Relative risk of fall related factors including visual acuity presented in 
decimal scale  
Explanatory variables Relative Risk (RR) 
95% C.I. for RR 
Lower Upper 
Visual acuity (vs >7/10)    
5-7/10 1.5 0.9 2.4 
3-4/10 1.9 1.1 3.1 
<= 2/10 2.0 1.1 3.7 
Source: Adapted from: Dargent – Molina et al. (72) 
 
Functional limitations and physical performance appear to mediate these 
relationship between impaired vision and recurrent falling (74). Patino et al. (75) showed 
that central visual impairment (defined as visual acuity > 20/40) and peripheral visual 
impairment (defined as mean deviation < -2 dB) were independently associated with 
increased risk of falls and falls with injuries in Latino participants aged 40 years or older. 
The study found that individuals with central moderate to severe visual impairment 
(visual acuity < =20/80) were 2.36 more likely to report a fall and 2.76 more likely to 
report a fall with injuries when compared with participants without central visual 
impairment. Similarly those with moderate to severe impairment (mean deviation  < =6 
dB in worse eye)  where 1.42 times as likely to report falls and 1.40 times as likely to 
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report falls with injury, compared with individuals without any peripheral visual 
impairment (75). Reduced contrast sensitivity and visual acuity were also associated with 
an increase rate of falls and with injurious in a prospective study conducted in older 
adults with age macular degeneration (48). Falls caused by deficits in central and 
peripheral vision can be explained by many factors such as incorrect judgments about 
distance or spatial information such as a shadow or a ground surface and reduced 
postural stability (72, 74, 75). Visual inputs are also important to help individuals to 
coordinate and plan movements and to maintain balance (47, 76).  
Older adults who fall are at greater risk of hospital admission and nursing home 
placement (58, 77). Compared with younger controls, older adults have a higher injury 
related mortality rate, poorer diagnosis, more complications and subsequently higher 
health care costs (39, 78-80). Hip fracture is one of the most serious injury caused by 
falls. The majority of patients with a hip fracture do not return to the level of activity of 
daily living experienced before the fracture. Psychological difficulties associated with a 
fall may cause loss of self-confidence, activity avoidance or self-imposed restrictions on 
physical activities (47). In short, falls are common amongst the elderly with VI and that 
can cause serious injuries such as fractures which increase physical and psychological 
difficulties. 
2.4.1.4 Vision impairment and its association with comorbid conditions  
Comorbidities in visually impaired individuals are common but the knowledge 
about its implications is sparse (81, 82). The causal pathway between comorbid 
conditions is also unclear, for instance, diabetes and stroke are likely to contribute to 
vision loss while others, like depression and falls, may result from severe vision loss (83). 
People with several chronic conditions such as diabetes and cardiovascular conditions, 
may have cumulative risk of vision loss due to vascular, neurodegenerative, biochemical 
or inflammatory conditions (82). Cataracts have been related to arthritis and diabetes. 
Diabetic retinopathy is a consequence of diabetes, hypertension and 
hypercholesterolemia which may indicate cumulative effects of comorbid conditions (82). 
Crews et al. (83) estimated the frequency of nine conditions (breathing problems, 
diabetes, hearing problems, heart problems, hypertension, depression, joint problems, 
lower back pain and stroke) in older people with comorbidities and with visual impairment 
concluding that older adults with vision impairment had a high prevalence of comorbid 
conditions. 
 Comorbidities are associated with further barriers to remain active and maintain 
social participation. Comorbidities create difficulties to walk and climbing steps, 
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shopping, socializing, accelerate the declining of perceived health and increase 
disabilities caused by VI (62, 83, 84).  
 
2.4.2 - Consequences of vision impairment for the healthcare system  
 
2.4.2.1 Vision impairment: hospital resource use and long-term care   
Hospital resource use is higher in persons with vision impairment when compared 
with persons without vision impairment (52, 53, 85-88). For example, Crewe et al. (86) 
reported that, when compared with age-matched controls, blind people went to the 
hospital more frequently, more often to the emergency department. Visually impaired 
persons also have longer lengths hospital stays compared to persons without VI (53, 89). 
As summarize in Table 7 an additional 2.4 days to the average length of stay was 
reported in patients with vision impairment after controlling for age, sex, payer type, 
disease, disorders and ophthalmological procedures (89). Authors speculate that 
problems in room orientation, confusion in finding the bathroom or safely walking in 
corridors and additional difficulties in managing new prescriptions may delayed 
discharge (89). In addition, Crewe et al. (86) and Wang et al. (90) demonstrated that 
blind individuals had a higher number of emergency department utilization or costs when 
compared with controls.  
Table 7 - Hospital Average Lengh of Stay (ALOS) for  patients with and without 
vision impairment. Vision impairment was identified using ICD9 CM codes 
 No Visual Impairment Visual Impairment ALOS 
Difference 
(days) 
 Number ALOS  
(days) 




21456586 8.2 5764 13.4 5.2 
Case Mix-
Adjusted * 













*Case mix adjusted to provided matching disease categories in both populations 
** Multivariate analysis adjusted for age, sex, payer type, disease, disorders and ophthalmological 
procedures 
Source: Adapted from: Morse et al. (89) 
Long term care needs such as nursing home placement, home help or skilled 
nursing facilities use is higher in persons with impaired vision (52). Javitt et al.(52) and 
Bramley et al.(91) reported an increased odds of utilization of skilled nursing facilities 
and long term care admission in persons with any degree of progressive vision loss. For 
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example, progression from normal vision to blindness is associated with 2.5 to 3 
increased odds of utilization compared with persons without VI (52). Bilateral VI  was 
associated with an increased risk of nursing home placement over 6  years following 
baseline examinations in an Australian population (51). An increased odds of admission 
to a nursing home has also been found in participants with VI in an population-based 
study conducted in the United States of America (Beaver Dam eye study) (92). 
Some studies reported an excess cost both for eye-related resource utilization 
and non-eye related resource utilization in patients with vision impairment (52, 90). 
These studies reported that non-eye related medical care was significant in the total 
excess costs of vision impairment when comparing participants with and without visual 
impairment. Furthermore, Javitt et al. (52) showed that those progressing from a normal 
vision state at baseline incur higher non-eye costs than those who remain in the same 
level. Cost distribution by type of care varied also across severity of VI (90, 91). Figure 
10 provides an example of mean total and component annual health care costs per 
patient and by vision impairment categories. In this example costs increased with the 
degree of vision loss, ranging from $8157 for no vision loss to $18670 for blindness and 
inpatient care was the major component of costs. In another study, excess cost of 
blindness were driven by inpatient care whereas for moderate to severe visually impaired 
patients outpatient care was the main cost component (90). Other studies demonstrated 
that the excess costs of vision impairment decreased from the first year to the second 
year after diagnose. This may result from a large amount of resources used initially in 
eye-related conditions or complications from vision loss, such as falls or depression, 





Figure 10- Mean total and component annual health care costs per patient and 
by vision impairment categories. Vision impairment is categorized in 4 categories based 
on their worst degree of vision loss during follow-up using 57 ICD-9-CM codes: no vision 
loss, moderate vision loss (ICD-9-CM codes 369.6-369.9), severe vision loss (ICD-9-CM 
codes 369.1-369.4), and blindness (ICD-9-CM codes 369.0-369.08) (91) 
The main focus of all the studies mentioned previously was to analyse the use of 
hospital resources between those with and without vision impairment. Therefore, these 
studies were based on realized access of eye care rather than “potential” access. By 
focusing on realized access none of these studies assessed if resource utilization was 
adequate to meet health needs of this population, if there are visually impaired 
individuals who are not getting eye care, or if there is underutilization or overutilization of 
those who are in the healthcare system. These aspects will be briefly reviewed further in 
section 2.4.2.3. 
2.4.2.2 Vision impairment, comorbid condition and its association with resource 
utilization  
Vision loss can have a magnifying and acceleration effect on comorbid conditions 
leading to increased health care needs and costs (52, 83). Multiple comorbidities are 
associated with high mortality, have a negative impact on quality of life and increase the 
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use of inpatient and ambulatory healthcare services (84, 94). This may be driven by 
complications, complexity to define treatment strategies and higher risk of readmissions. 
As severity of VI increases, resource consumption, adverse consequences and intensity 
of care may also increase (91). For example, the coexisting of ocular conditions, 
including primary open-angle glaucoma  and cataracts, and other comorbidities, such as 
hypertension and diabetes, is associated with higher eye treatment costs in patients with 
AMD as summarize in Table 8  (95). 
Table 8 - Adjusted estimates from the multiple linear regression model for other 
eye diseases and comorbidities with Medicare costs for any eye-related visit during 
1995 to 1999. Subjects were Medicare beneficiaries with AMD and controls were 
Medicare beneficiaries with no AMD. Cost ratios were calculated by exponentiation of 
regression coefficient estimates 
 Cost ratio 95% CI P Value 
Lower Upper  
Primary Open-angle glaucoma 2.12 2.04  2.20 < 0.001 
Cataracts 1.67 1.63  1.71 < 0.001 
Hypertension 1.04 1.01  1.06 0.001 
Cardiovascular disease 1.22 1.07  1.13 < 0.001 
Diabetes 1.10 1.18  1.26 < 0.001 
Hyperlipidemia 1.08 1.05  1.11 < 0.001 
Source: Adapted from: Coleman et al.(95) 
 VI may complicate the management of other comorbidities and comorbidities 
may also affect the management of ocular diseases leading to a closed-loop feedback. 
Individuals with VI may experience difficulties to properly administrate medications, 
prepare healthy meals, use of medical devices to measure and control hypertension or 
glycaemia as well as, for instance, foot checks in diabetics. Transportation to and from 
medical appointments may also be more difficult to visually impaired individuals (19) and 
caregivers capacity to support patients getting to several medical appointments and 
treatments in different places and different times may also be more limited (96). From 
other perspective, comorbidities may also influence the capacity to cope with VI.  
Comorbidities may affect vision rehabilitation outcomes and adherence to treatments, 
may amplify communication barriers, delay treatments and follow-up medical 
appointments (96). For example, the exacerbation of a chronic disease like asthma may 
increase difficulties on breathing and therefore reduce the capacity of a patient to engage 
vision rehabilitation sessions. In addition, administration of eye drops can be more 
difficult for patients with cognitive impairments, limited movements of the neck, arthritis 
or neuropathy in the hands (19, 97). Therefore, some aspects of eye care may be 
challenging due to comorbidities. At the same time, comorbidities may become worse 
due to limitations to its management imposed by impaired vision.  
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2.4.2.3 Vision impairment and access to eye care 
Eye diseases and subsequent vision loss poses a big challenge to healthcare 
systems and are a public health concern since most vision loss may be avoidable (27, 
98-100). Even though there are available many cost-effective interventions for 
prevention, treatment and control of major eye diseases access to eye care remains 
problematic in many countries (100-103). For instance Vela et al. (100) reporting eye 
care utilization in 70 countries concluded that only 18% of older adults have seen an eye 
care professional in the last year. As summarized in Table 9 eye care utilization rates 
ranged from less than 10% to higher than 40% depending on the income status of the 
country. In addition, several studies reported geographical variability in rates of eye care 
use within developed countries (103-105) while others have reported low compliance of 
examination routines defined in clinical guidelines even in risk groups like patients with 
diabetes (100, 106-108). Adequate access to care is essential to reduce vision related 
morbidity and mortality and to improve health related quality of life (109). 
Table 9 - Use of glasses or contacts lenses and eye care utilization in low, 
middle, and high income countries 
 Overall LIC LMIC UMIC HIC 
Within last 12 months 18% 10% 24% 22% 37% 
1-2 years ago 16% 9% 21% 20% 27% 
3-4 years ago 9% 5% 11% 12% 13% 
5 years ago 3% 3% 4% 3% 3% 
More than 5 years ago 16% 12% 20% 17% 15% 
Never 38% 61% 20% 26% 5% 
LIC = low income countries (Bangladesh, Burkina Faso, Chad, Comoros, Congo, Cote d’Ivoire, Ethiopia, Ghana, India, Kenya, Lao, 
Malawi, Mali, Mauritania,Myanmar, Nepal, Pakistan, Senegal, Vietnam, Zambia, Zimbabwe) 
LMIC = lower middle income countries (Bosnia Herzegovina, Brazil, China, Dominican Republic, Ecuador, Georgia, Guatemala, 
Kazakhstan, Morocco, Namibia,Paraguay, Philippines, Russian Federation, South Africa, Sri Lanka, Swaziland, Tunisia, Ukraine) 
UMIC = upper middle income countries (Croatia, Czech Republic, Estonia, Hungary, Latvia, Malaysia, Mauritius, Mexico, Slovakia, 
Uruguay) 
HIC = high income countries (Slovenia, Spain, United Arab Emirates) 
Source: Adapted from: Vela et al. (100) 
Access is a multidimensional concept which may be defined as “those dimensions 
which describe the potential and actual entry of a given population into the healthcare 
system” (110). In this definition potential and actual (or realized) access are two different 
parts of access. Potential access refers to the probability of using health care services 
while realized access refers to the effective use of health care services. Accordingly with 
Andersen’s Behavioural Model of health services access is driven by contextual and 
individual characteristics including both predisposing, enabling and need factors (111). 
A modified model was applied in the context of access to eye care by Zhang et al. (102) 
to review the theoretical and empirical literature on access to eye care. In this modified 
model “predisposing individual characteristics exist before the onset of vision problems, 
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enabling characteristics are the potential financial and medical resources available to 
allow use of eye care” and need factors may include perceived need (by the patient) and 
evaluated need (professional assessment of need of medical care). Table 10 summarize 
examples of factors associated with access separating individual and contextual 
characteristics. 
Table 10 - Predisposing, enabling and need factors associated with access to 
eye care aggregated into individual and contextual level 
Predisposing factors Enabling factors Need factors 
Individual level 





continuity and regular 









characteristics such age 
and sex distribution, 
education and 
employment level 
Community income and 
health care system factors  
like health insurance 
“carve outs” for eye care, 
number of eye care 
professionals 
Population health index   
  Source: Adapted from: Zhang et al. (102) 
Predisposing individual factors such as age, gender, race or ethnicity, education 
and income has been consistently associated with differences in access to care (101). 
Women are more likely to attend eye care services than men (101, 112).  Utilization of 
eye care services has been reported to increase with age (87, 113, 114). Race or 
ethnicity has also been associated with access with non-whites being less likely to have 
an eye examination compared with whites (87, 101, 107). Individuals with higher 
education and higher incomes are more likely to use eye care services (101, 104, 115). 
Disparity in access to health care related to differences in socioeconomic status is 
widely recognized. Low socioeconomic status has been consistently related with lower 
access and poorer outcomes (106). Income and health insurance are among the 
socioeconomic determinants related to socioeconomic status. Regarding health 
insurance coverage, many studies have reported a positive association between 
insurance coverage and access to eye care services (103, 106, 116). Nevertheless, a 
study from Australia showed that despite the existence of universal health insurance 
nearly half of patients with diabetes did not receive screening or follow-up for diabetic 
screening (103). Other studies reported that the lack of private health insurance beyond 
governmental health coverage emerged as barriers to the access of eye services (103, 
116, 117). Table 11 summarizes the results of a study that shows that patients with public 
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and private insurance had three times the odds (OR 3.39, 95% CI 1.82– 6.31) of having 
their vision tested compared with those with only public insurance. 
Table 11 - Effects of insurance status on having vision tested in patient age 65 
years old or older 




None N/A N/A N/A 
Public only 1   
Private only 2.6 0.9 7.5 
Public and private 3.39 1.82 6.31 
Public with Medicare supplement 1.78 1.14 2.77 
Source: Adapted from: Puent et al. (116) 
 Differences in patterns of utilisation seemed also to be associated with 
availability of eye care services with lower utilisation rates found in rural areas (103). 
Sloan et al. (114) reported that the probability of having an eye exam was higher with 
greater geographic density of eye care professionals and that different provider 
organizational models and different levels of integration between providers also affect 
access to eye care services. Lee et al. (108)  referred that difficulties finding an eye care 
provider, transportation problems and caregiver time constraints may have act as barrier 
in access to eye care. That may play a major role in the compliance of clinical guidelines 
related to annual eye care examinations in people with diabetes and chronic eye 
diseases (108). Rural areas are more likely to have shortage of eye care professionals 
and that may decrease healthcare utilization, cause longer waiting lists and increased 
transportations costs for patients (101). Transportation problems or lack of social support 
have been extensively reported as important factors that act as barriers to access eye 
care (98, 109, 115, 118).  
Need factors measured by, general health factors such as diabetes and 
hypertension and eye health factors like visual impairment, diabetic retinopathy, 
glaucoma, cataract, history of cataract surgery and retinal vein occlusion were found to 
be important determinants to increase usage of eye care services  (87, 101, 113). 
Although, it is relevant to emphasize that evidence shows that there is a lack of 
compliance of clinical guidelines for preventive care and follow-up care even amongst 
people with sight threatening eye and systemic health conditions with lower access than 
recommended. For example, accordingly with Zhang et al. (101) and Spencer et al. (109) 
persons with vision and eye problems and persons with diabetes were the ones who 
were more likely to need visual aids and the ones who most often could not afford it. 
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Figure 11 shows an example where a group of high risk patients have a higher 
percentage of persons who cannot afford eyeglasses. 
 
Figure 11 - Estimated eye care use among adults at high risk for serious vision 
loss (include patients with diabetes, those having self-reported vision or eye problems, 
or those aged 65 years and older) vs those at low risk of vision loss. The percentage 
refers to those who visited an eye doctor in the past 12 months, had a dilated eye 
examination in the past 12 months, or cannot afford eyeglasses when needed. Numbers 
in parentheses represent the number of millions of persons to which the percentage 
applies for the high-risk and low-risk subpopulations; error bars represent 95% 
confidence intervals (101)  
 
Perceived benefit of eye care services by patients may also influence the decision 
to seek eye care. People frequently cited “no need to go” or “can´t afford prescription 
drugs, co-payment or eyeglasses” “no insurance coverage” as reasons for not seeking 
eye care (98, 101, 118). Furthermore the asymptomatic nature of many eye diseases in 
their early and treatable stage may also influence the decision of patients to postpone 
eye care (119).  
Interestingly, some authors associated gender disparities in access to eye care 
with distinct attitudes with health. Women seems to have “greater awareness of 
symptoms, lower threshold of symptoms before seeking care and social support and 
differences in comfort levels in seeking care” so different perception of need and 
therefore different health service use (112).  
Eye care providers reporting their impressions of older patients attitudes about 
vision care mentioned as barriers to eye care: the lack of awareness of the importance 
of preventive care, routine examination and prescript treatments by patient as well as 
the patients perception that other medical problems have higher priority than eye 
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problems (101).  The lack of awareness and knowledge about health and diseases has 
been related to health illiteracy that may also be associated to education level. For 
instance health illiteracy measured by inadequate knowledge about basic symptoms, risk 
factors and available treatments has been presented as one of the explanatory factors 
of the less likelihood to receive routine comprehensive eye examinations in minority 
groups such as African Americans and Latinos  (87, 98, 119). 
 
2.4.2.4 Vision impairment and access to new treatments  
Access to eye care services remains as a topic of special concern for a few 
reasons.  The firs reason is related to the growing demand for vision and eye care mainly 
due to an ageing population with multimorbidity that needs to be under clinical 
observation, to be treated or to be rehabilitated. Furthermore the adoption and 
development of new healthcare technologies that will emerge from advances in medical 
science will also result in greater use of eye care and that may increase pressure in 
healthcare system capacity and therefore influence access to eye care. For instance, 
antivascular endothelial growth factor (anti-VEGF), licensed and clinically available in the 
last decade, have change the management of age macular degeneration that was largely 
untreatable before the introduction of this new medicine posing considerable resource 
allocation issues to the healthcare system (120). 
 The adoption and diffusion of new healthcare technology is a complex process 
shaped by a multiplicity of determinants performing at the professional, organizational 
and regulatory level (121, 122). Professional and organizational level has been 
associated to the timing and pattern of diffusion. Regulatory levels, more specifically, the 
mechanism to assess reimbursement at a national level as well as the payment system 
to providers may also play a substantial role affecting provider’s behaviour (121, 122). 
Few studies have analysed the cross-country variations in the diffusion of healthcare 
technology considering differences in national regulatory policies, such as coverage, 
reimbursement and pricing, and payment mechanism to professionals or to 
organizations (122, 123). Among the determinants associated to the adoption and 
diffusion of new healthcare technology more commonly reported there are: the features 
of the technology; the attitudes and skills of the healthcare professionals; the features of 
the organizations and the features of the regulatory system specially the reimbursement 
of healthcare providers (124, 125). 
The perceived benefit of the innovation and its relative advantage compared with 
existing technology have a major influence on the acceptance and diffusion of a new  
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and innovative technology in the health care services (125, 126). For instance Stein et 
al.(120) reported that the lack of a more effective treatment for age macular degeneration 
was one of the key element to the rapid diffusion rate of anti-VEGF in the United States. 
Health care professionals are more likely to adopt a new technology if they think it can 
help them, if it is relevant to the patient they treat and if the innovation is appealing to 
use (127, 128). The more knowledge health care professionals have about a new 
technology the more likely they are to adopt it (129). 
Technologies that required additional resources like special lighting, extra training 
for healthcare professionals or special technical requirements like mandatory use of 
operating room may have slower rates of diffusion (130). Furthermore, innovations have 
a faster rate of adoption if it possess 4 attributes: simplicity, compatibility, triability and 
observability (126-128). Commonly, simple innovation spread faster than more complex 
ones. Innovations there are compatible with the values, standards, principles and past 
history of the adopters are adopted easily (126).Triability and observability also influence 
the spread of innovation and are related to the capacity to test the innovation in a small 
sample and to observe its implementation by other health care professionals respectively 
observability (127, 128). 
Beyond the features of the technology the attitudes and skills of the healthcare 
professionals are another important factor to explain the adoption and diffusion of new 
healthcare technology. Berwick and Mathews based on the work of Roberts classified 
adopters into 5 categories: innovators, early adopters, early majority, late majority and 
laggards (127, 130). These categories were built taking into consideration the time of 
adoption and more specifically the mean and standard deviation (SD) of the time taken 
to adopt a new technology are shown in Figure 12(127). Innovators are those whose 
time to adopt is bellow two SD bellow the mean time of adoption and correspond to 2.5% 
of the population. Usually they are tolerant to the risk, always available to learn 
something new and fascinated by novelties. Early adopters correspond to 13% of 
population and are usually key opinion leaders that communicate with innovators and 
other key opinion leaders and are willing to take some risks to try new technology. Early 
majority correspond to 34% of population and are more risk-adverse than early adopters 
and incorporate innovations that are relevant to their local problems and learn mostly 
with people they know well. Late majority correspond to 34% of the population and 
professional included in this categories are more conservative than the early majority 
and only adopt a new health technology when it became standard of practice. The last 
category, laggards are the last to adopt a new technology and correspond to 16%. 
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Usually laggards are traditionalists and choose only technologies that are well 
established and that has been proven to be safe and produces good outcomes.   
 
Figure 12 - Adopter categorization on the basis of innovativeness. There are 
five categories built taking into consideration the time of adoption and more specifically 
the mean and standard deviation of the time taken to adopt a new technology (127) 
Among the determinants related to organizational features that influence the 
adoption and diffusion of new healthcare technology Fleuren et al. (128) reported that 
the organization capacity to implement innovation, availability of expertise and staff and 
the nature of collaboration between departments involved in the implementation of the 
innovation are some of the features more often reported to influence the diffusion of 
innovation. An organization will assimilate innovation more rapidly and easily if it 
encourages, promotes and support the spread of innovation, if it has risk tolerance to 
incorporate failures and unexpected costs, if it has available resources to try new 
technologies in terms of human resources, financial and technical capacity (126, 127). 
More specifically, studies on hospital characteristics have reported that specialization in 
intensive treatments is likely to influence the diffusion of new healthcare technology 
(131). In fact, there is evidence that the diffusion across regions and hospitals is not 
optimal and there are often under-and-overutilization of new healthcare technologies. 
Factors such as, teaching status, urban location, degree of specialization, multispecialty 
practice setting, hospital size (large hospitals compared with small hospitals) and the 
presence of competition influences positively the spread and rate of diffusion (131). For 
example teaching hospitals, higher volume hospitals, hospitals with high skill and better 
reputation physicians may have better capacity to disseminate information on new 
healthcare technologies.  
The influence of the reimbursement system on the diffusion of healthcare 
technology is an ongoing debate with several approaches and different results. Fixed- 
global budget systems, especially if based on historical expenditures, are expected to 
slow down the spread of new technology (132). Diagnosis related groups (DRG) based 
hospital financing schemes, including DRG-based hospital case payment or DRG-based 
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budget allocation, also face challenges to adopt new technologies because hospitals are 
exposed to financial risks of having costs above the established price/budgets. There 
are two basic and consensual incentives related to DRG payment systems: incentive to 
reduce costs per admissions and increase number of admissions (133). So, if new 
technologies are associated with increased costs per admissions, there are impediments 
or disincentive for the hospital to adopt new technology until DRG system is updated to 
account for the additional costs imposed by the use of the new technology (122, 123). 
Accordingly with a recent study, financing systems with frequent updates and 
adjustments of their DRG system, including the introduction of new codes to incorporate 
current practice patterns or the adjustment of costs weights reflecting new treatment 
costs, are in a better position to introduce new healthcare technologies (134). 
Diffusion is a cumulative process in which the rate and direction has been 
described as having an “S shape with an early slow phase affecting a very few adopters, 
a rapid middle phase with wide spread and a third phase with incomplete penetration in 
the end” (127). It is considered to be a passive, untargeted and unplanned spread of new 
technology and opposite of dissemination which is an active and planned spread of a 
new technology to a target audience (130). 
This S curve as a “tipping point”, often around 15% to 20% adoption rate, after 
which it becomes difficult to stop the diffusion of the innovation. This 15% to 20% usually 
happens with innovators and early adopters, meaning that as the spread comes near to 
the early majority most certainly the others will follow. This dynamics explain that 
diffusion depends on how an organization deals with innovators and early adopters as 
well as the relationship between them, rather than with any other type of adopters (127).  
 
2.4.3 - Impact of vision impairment to the society  
2.4.3.1. Economic impact of v ision impairment  
The economic impact of vision impairment and blindness has been characterized 
in countries such as Australia, United States of America, France, Italy, Germany, Japan, 
Canada and in the United Kingdom (135-142). Table 12 shows the economic burden of 
vision impairment (blindness is included in vision impairment) estimates reported in these 
8 countries. Reported costs were grouped in 6 categories:1) Direct medical costs that 
include mostly inpatient and outpatient care and all the resources used for diagnosis and 
treatment; 2) Formal care costs that include long-term care and nursing home costs, 
community care and paid assistance provided by professionals; 3) Other direct costs that 
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comprise costs related to vision aids and devices and home modifications. 4) Productivity 
costs that include absenteeism, loss of income, loss of work, lower workforce 
participation and in some studies lower productivity due to premature mortality; 5) 
Informal care costs that includes a monetary estimate of the hours spent by caregivers 
to help/care visually impaired persons; 6) Other indirect costs comprised mostly dead-
weight loss generically defined as an excess financial burden on society caused by an 
illness or condition.  
Cost values were transformed for better comparison across studies. Costs were 
inflated to 2013 using a country specific gross domestic product deflator and then 
converted to USD purchasing power parities (PPP). Purchasing power parities are the 
rates of currency conversion that make equal the purchasing power of different 
currencies by accounting for differences in price levels between countries. 
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Table 12 - Summary of reported economic burden of vision impairment in 8 countries, 2013 billion USD PPP 
  








All ages All ages All ages All ages All ages All ages 
bn $ % bn $ % bn $ % bn $ % bn $ % bn $ % bn $ % bn $ % bn $ % 
1. Direct 
medical costs 
1.73 36% 19.48 46% 7.9 28% n.r 0% n.r 0% n.r 0% 10.43 44% 7.83 55% 3.95 29% 
2. Formal care 
costs 
n.r 0% 13.18 31% 0.14 1% 2.69 20% 3.22 27% 2.22 14% 8.61 36% n.r 0% 0.43 3% 
3. Other Direct 
Costs 
0.35 7% 0.07 0% 6.66 24% 0.62 5% 0.73 6% 2.36 14% 1.71 7% 0.28 2% 0.93 7% 
(1)+(2)+(3) 2.09 44% 32.74 76% 14.71 53% 3.31 25% 3.95 33% 4.58 28% 20.75 87% 8.10 57% 5.31 39% 
4. Productivity 
losses 
1.69 35% 9.63 23% 12.41 44% 5.62 42% 3.16 27% 4.16 25% 0.70 3% 4.02 28% 3.92 29% 
5. Informal 
care costs 
0.80 17% 0.44 1% 0.61 2% 3.11 23% 3.88 33% 6.24 38% 0.71 3% 0.63 4% 3.69 27% 
6. Other 
Indirect costs 




1% 1.20 9% 0.91 8% 1.39 9% 1.57 7% 1.59 11% 0.59 4% 
(4)+(5)+(6) 2.69 56% 10.07 24% 13.21 47% 9.93 75% 7.94 67% 11.79 72% 2.99 13% 6.24 43% 8.20 61% 
Total 
Estimates 
4.78 100% 42.81 100% 27.92 100% 13.24 100% 11.89 100% 16.37 100% 23.74 100% 14.34 100% 13.51 100% 
n.r – not reported; bn – billion 





Total estimates on the economic burden of vision impairment ranged from 42.81 
billion US PPP in 2013, reported in the United States of America for persons over 40 
years, to 4.78 billion US PPP in 2013 in Canada (Table 12). United States of America 
and Japan were the countries reporting the highest estimate of economic burden. In both 
countries direct medical costs, formal care and other direct costs accounted for the 
majority of costs representing over 50% in the United States of America and in Japan 
87% of total estimates for each country.  
In the United States of America and Australia direct medical costs of eye diseases 
and vision problems are considered one of the leading sources of medical expenditures. 
Eye care costs are seventh and fifth highest disease expenditure respectively (135, 142). 
In Australia only cardiovascular disease, musculoskeletal, injuries, mental disorders, 
cancer and dementia had higher direct medical costs than VI (135). In the United Sates 
direct medical costs for eye diseases were exceeded only by heart conditions, trauma, 
cancer, and mental health disorders (143).  
In France, Italy and Germany direct medical costs were not reported therefore the 
sum of all direct costs was lower and represented less than in all of the other countries 
reported in Table 12. Interestingly in these countries as well as in the United Kingdom 
formal care costs had a lower contribution to total estimates than informal care costs. 
The highest difference was observed in Italy were informal care accounted for 38% of 
total estimates while formal care contributed only to 14% of costs (138). Australia and 
Canada did not report formal care (135, 140).  
Productivity losses, informal care and other indirect costs were major contributors 
(corresponding to more than 50%) to total estimates in Australia, France, Italy, Germany 
and United Kingdom. In France productivity losses alone were responsible for 5.62 billion 
US PPP in 2013 representing 42% of total estimate in this country. In the United States 
of America productivity losses were much higher for persons under the age of 40 years 
reaching 44% of total estimate in this age-category. These results are in agreement with 
a systematic review that included not only cost of illness of vision impairment but also 
disease-specific studies like glaucoma or diabetic retinopathy. The authors of the review 
found that productivity losses and informal care were major contributors to the economic 
burden of vision impairment and blindness (144). 
Loss of Quality Adjusted Life Years (QALYS) were also reported in the United 
States of America in population under the age 40 years (142) and older than 40 years 
(137). In the first case 215,173 quality adjusted life years were lost corresponding to an 
economic value of 10.93 billion US PPP in 2013. For adults with more than 40 years of 
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age, 209,202 quality adjusted life years were lost corresponding to an economic value 
of 12.55 billion US PPP in 2013. If QALYS were added to the values reported in Table 
12 they would represent 28% and 23% of total estimates in the United States  in 
population under the age 40 years and older than 40 years respectively.  
Loss of well-being estimated with Disability Adjusted Life Years (DALYs) were 
reported in Australia, Japan, Canada and United Kingdom (135, 139-141). For instance, 
in Australia 41,187 DALYS were loss due to vision disorders of which 40.068 
corresponded to Years of Life with Disability and 1119 to Years of Life Lost. Reports of 
DALYS and its conversion into a monetary value using the value of a statistic life 
available and transformed to USD PPP for 2013 in each country are shown in Table 13.  
Table 13 - Loss of well-being in Australia, Japan, Canada and United Kingdom, 
2013 expressed in DALYS and USD PPP 
  
Australia Japan Canada 
United 
Kingdom 
Nº/$ % Nº/$ % Nº/$ % Nº/$ % 
Monetary of 
Loss of Well 
Being (DALYS) 
(billion USD ppp) 
4,58 49% 13,23 36% 10,61 43% 11,26 45% 
Total 
Estimates 
9,35 100% 36,97 100% 24,95 100% 24,77 100% 
Loss of Well 
Being (DALYS)  
41187 229085 77306 81033 
Per capita 
estimates 
(USD ppp)*  
45161 48861 41564 22745 
Sources: Australia (135); Japan (139); Canada (140); United Kingdom (141); * per capita 
estimates from Australia and Japan were obtain from Roberts et al (139) and values from Canada 
and United Kingdom were obtain from Pezzullo et al. (141) – adapted 
 
If values reported in Table 13 were added to the values reported in Table 12 loss 
of well-being would have a considerable impact on the economic burden corresponding 
in Australia to 4.58 billion US PPP (49% of total estimates), in Canada to 10.6 billion US 
PPP (43% of total estimates), in the United Kingdom to 11.3 billion US PPP (45% of total 
estimates) and in Japan 13.23 billion US PPP (36% of total estimates). Per capita costs 
including DALYS and all costs components reported in Table 13 ranged from 48,861 US 
PPP in Japan and 22,745 US PPP in the United Kingdom. However, attributing a 
monetary value on QALYS and DALYS is controversial (137, 145) and because of that 
often these impacts are reported as non-monetary measures (144).  
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Despite of the efforts made to ensure comparability between studies it is important 
to highlight that methods, sampled population and reported costs components varied 
widely between studies. For instance some studies reported costs for all population with 
vision impairment (140) while others restricted their analysis to adults aged 40 years and 
older (136). Additionally, estimates were made accordingly with medical treatments 
available at that time. This may have major implications on estimates. Koberlein et al. 
(144) emphasized that in their systematic review published in 2013 none of the reviewed 
studies included antivascular endothelial growth factor treatment. The authors assumed 
that it is likely that economic estimates made after the introduction of this treatment will 
report higher direct medical costs. In Table 12 only one study, reporting estimates from 
United Kingdom, included anti-VEGF treatment. Accordingly to the authors direct 
medical costs increased 39%, compared with a previous estimate reporting 2008 data in 
the country, mostly due to an increase of costs with anti-VEGF treatment (ranibizumab) 
as well as costs with outpatient care and other non-admitted expenditures (141). 
Additionally, productivity losses rised 49% mainly because there was a fall in the 
employment rate of people with vision impairment. In contrast, costs with formal care 
decreased from 2008 to 2013 most likely due to a decline in the number of people 
registered as visual impaired (including blindness) and due to cuts in social care budgets 
that have occurred in the United Kingdom during the analysed period (141). The authors 
reported also considerable differences in the prevalence of eye diseases. Prevalence of 
AMD, cataracts, glaucoma and diabetic retinopathy increased and the prevalence of 
under-corrected refractive error decreased.  
There is only one economic estimate of vision impairment that reports direct 
costs, productivity costs and health burden for all world regions (146). In this global 
estimate a prevalence approach was adopted, vision impairment was defined using 
presenting visual acuity and all causes of vision impairment were considered, including 
uncorrected refractive errors. Costs and the health burden were estimated using 
published disease prevalence rates, mortality rates, health care expenditures and 
economic data including employment rates and gross domestic product (GDP) per capita 
(146). The total costs of VI globally was estimated in 2954 billion US$ in 2010 and 118 
million DALYS. Direct costs were estimated in 2302 billion US$ in 2010 representing 
78% of total estimates (146). Productivity losses in developed countries were estimated 
in 168.3 billion US$ and included lower employment rates for people with vision 
impairment and premature mortality. Informal care was estimated in 246 billion US$ and 
deadweight welfare loss in 238 billion US$.  
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In the global estimates of the burden of vision impairment, the lack of data for 
many countries required methodological assumptions that may have influenced the 
results. For instance, informal care estimates were calculated based on studies from 
Australia and the UK and under the assumption that all countries had similar formal care 
availability. These assumptions may have led to a conservative estimate of the informal 
care costs. Estimating productivity losses only in developed countries may have also 
contributed to a conservative estimate of productivity costs and for such a high 
percentage of direct costs in total estimates.  
Overall reported estimates showed that, even in developed countries, vision 
impairment causes a considerable economic burden for affected individuals, for the 
healthcare system and for the society. It is also clear that countries updated estimates 
both on prevalence and costs are needed to better analyse the impacts of treatments 
and prevention strategies over time (141).  
The introduction of new healthcare technology may also impact eye care use and 
costs (147). It is likely that costs component distribution (direct costs versus productivity 
costs) will change as well as costs distribution by causes of vision impairment. Efforts to 
screen for and treat for currently undiagnosed and untreatable eye disease may increase 
direct costs but, if effective, may improve vison outcomes, health related quality of life 
and potentially decrease DALYS, QALYS and productivity losses (137). Many eye care 
interventions have proven to be cost-effective so it is likely that higher costs may lead to 
better outcomes (148). 
2.4.3.2. Productivity losses associated with vision impairment  
Productivity losses are given a detailed description in this thesis because they 
were one of the topics investigated in this thesis. Productivity losses were reported by a 
specific eye condition, uncorrected refractive error (18), in a specific region, Europe 
(149), and in a sample of nine countries representing different global regions (150). 
These reports will be presented in the next paragraphs. 
 The global economic productivity losses associated with uncorrected refractive 
error were estimated using purchasing power parity gross domestic product losses 
attributable to individuals with vision impairment (18). For each country it was assumed 
that individual productivity losses of persons aged 16 and older were equal to a disability 
weight of 0.6 for persons with blindness and 0.282 for persons with other levels of vision 
impairment (moderate to severe visual impairment). Caregiver’s productivity losses were 
also added to this estimation assuming a 10% productivity loss for the care of each 
person with blindness and a 5% productivity loss for the care of each person with other 
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levels of vision impairment. Productivity costs were adjusted accordingly with the labour 
force participation rate and employment rate of each country.  
Globally productivity losses for uncorrected refractive error were estimated in 
268.8 billion dollars representing 0.25% of GDP at the global level (18). The distribution 
of cases of uncorrected refractive error by regions, using prevalence data was obtained 
from Bourne et al (20), correlates positively with productivity costs estimates. In Europe 
and in particular subregion A, where Portugal is included, productivity losses were 
estimated in 38.9 billion dollars and represented 0.3% of the GDP of this subregion 
assuming a population-weighted regional labour force participation rate of 0.583 and a 
population-weighted regional employment rate of 0.88.  
Productivity losses due to vision impairment were estimated in Europe only for 
individuals with 50 or more years (149) and were made using three models reported in 
the literature: 1) minimum wage; 2) gross national income; 3) purchasing power parity 
adjusted GDP. Productivity losses were assumed to be 100% for blind individuals and 
30% for those with other levels of vision impairment (moderate to severe vision 
impairment) in the first two models and it was assumed that individuals worked only until 
65 years old and then retired. In the third model losses were assumed to be 70% for 
blind individuals and 34.5% for those with moderate to severe vision impairment adjusted 
for general employment rates and labour force participation rate but including all 
individuals aged 50 years and above. The most conservative estimate was produced by 
the minimum wage model followed by the purchasing power parity adjusted gross 
domestic product model.  
Productivity losses from blindness and other levels of vision impairment in Europe 
were estimated in 25.8 billion euros by the minimum wage model, in 31.1 billion euros 
by the purchasing power parity adjusted GDP model and in 56.5 billion euros by the 
gross national income model (149). These findings demonstrate, independently of the 
model used in estimation, that vision impairment has a significant economic impact in 
Europe despite the relatively low prevalence of blindness and moderate and severe 
vision impairment.  
Productivity losses from blindness and other levels of vision impairment were 
estimated in a sample of nine countries representing different global regions and based 
on two economic models; 1) minimum wage model; 2) gross national income model 
(150). Productivity losses were defined as the loss of income incurred in individuals aged 
50 years and above with blindness or other levels of visual impairment who were not 
able to work (100% productivity losses - blind individuals) or worked at reduced 
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productivity (30% productivity losses – individuals with moderate to severe VI) as a 
results of their vision impairment. With minimum wage model a more conservative 
estimate was obtained in the majority of countries and cost of blindness ranged from 0.1 
billion in Honduras to 2.5 billion Us dollars in the United States of America while cost of 
moderate to severe visual impairment ranged from 0.1 to 5.3 million UD dollars in the 
same countries (150). With gross national income model cost of blindness ranged from 
0.1 billion in Honduras to 7.8 billion Us dollars in the United States of America and cost 
of moderate to severe visual impairment ranged from 0.1 to 16.5 million UD dollars in 
the same countries (150). The authors concluded that although blindness and vision 
impairment occurs more frequently in developing countries, the economic burden is still 
high in developed countries like the United States and Japan (150). 
Global estimates on productivity losses related to vision impairment have 
limitations. For instance, some studies have considered in their estimates persons age 
16 and above (18), while others have restricted their analysis for persons within age 
range of 50 to 65 years old (149). Other studies assumed 100% productivity losses for 
blindness (149, 150) which can be considered a bit extreme in the majority of developed 
countries. Others studies, have used disability weights for moderate to severe visual 
impairment obtained from Global burden of disease (18, 141). For example Smith et 
al.(18) used values from Global burden Diseases of 2002 report (a disability weight of 
0.282 for persons with moderate to severe visual impairment) while Pezullo et al. (141) 
used Global burden Diseases of 2004 and 2010 by applying for example a disability 
weight of 0.191 for persons with severe visual impairment accordingly to 2010 report. 
Eckert et al. (150) used a weight of 0.3 for persons with moderate to severe visual 
impairment. Recently, considerable debate as emerge surrounding disability weights 
updates since vision disorders weights have been declining over the years with 
arguments being used against the methodologies used to determine this weights (151, 
152).  
 Methods used to attribute monetary value to productivity losses also influence 
estimates. In general, the minimum wage model gives a more conservative estimate 
which may lead to a substantial underestimation of the true cost of these conditions to 
the society. Estimates on productivity losses from different countries have shown great 
variability with productivity losses ranging from 0.2 billion US dollars in Honduras and 
11.12 billion euros in Germany (149, 150). Apart from economic estimates, several 
studies  involving persons with visual impairment have reported low rates of employment, 
high rates of unemployment, job loss and early retirement (153) and documented barriers 
and factors associated with reduced labour force participation in this population (154). 
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Accordingly to the literature there are three groups of variables namely 
demographic characteristics, socioeconomic status and aspects of disability and health 
that may influence the chances of impaired persons to be in the labour market (154).  
Age and gender are among the demographic factors that may affect the probably 
of being employed in persons with disabilities. Men are more likely to be in paid 
employment than women as shown for instance in Sherrod et al. (155) possibly because 
women are more likely to choose social roles, like staying at home to take care of the 
house and family, or because women are less likely to engage in vocational training 
necessary to facilitate entering to the labour market or maintaining a job. The relationship 
between age and employment in persons with disability varies across studies. For 
instance, some studies have found that older individuals were more likely to lose their 
jobs or to stay longer as unemployed (156) had a lower rate of employment or reported 
to be early retired (ages between 50 and 64 years old) (154) while others demonstrated 
that visually impaired younger individuals (under 55 years old) were less likely to have a 
paid employment possibly because decided not to enter the labour market (155) or 
because are more likely to report being student (ages between 18 and 29 years old) 
(154) .  
Amongst socioeconomic variables education level is considered an important 
factor positively associated with the probabilities of being employed. A study in the United 
Kingdom showed that visually impaired individuals with higher education level had a 
greater likelihood of being employed (above 50%) compared with visually impaired 
individuals less educated (154).  
Severity of vision impairment, age of onset and the presence of additional 
comorbidities are reported as aspects of disability and health that may influence 
employment status in these population (154). Severity of vision impairment has been 
reported to negatively influence the odds of being in the labour market. Accordingly with 
a study in the United Kingdom,  being registered as legally blind rather than having other 
levels of vision impairment (sometimes mention as partly sighted) reduced in 36% the 
probability of being at the labour market (154). In the same sample population later onset 
of vision impairment was also associated with lower rate of employment.  Age of onset 
of vision impairment may also play an important role because it may influence the ability 
to cope vision loss and may also reduce the effects of support programs and 




2.5 - Summary of the background 
Visual impairment is a major public health problem as it affects 252. 2 million 
persons worldwide (22, 99). In 2015 36 million people were blind and 216.6 million 
people had moderate to severe visual impairment. Globally blindness as a standardized 
prevalence rate for those with 50 years and above of 1.87% and moderate to severe 
vision impairment as a prevalence rate of 10.47% (22). In Portugal accordingly with 
Vision Loss Expert Group  estimate blindness as a standardized prevalence for the same 
population of 0.54% and other levels of vision impairment (moderate to severe vision 
impairment) has a prevalence of 5.06% (22).  The top causes of vision loss in Western 
Europe, the world region were Portugal is included, vision impairment (including 
blindness) are cataract, AMD, glaucoma, uncorrected refractive error and diabetic 
retinopathy (27).  
Vision impairment has wide-ranging negative effects on health affecting visual, 
physical and mental health (41, 42, 47, 48). It also has major socioeconomic implications 
since it can affect individuals participation in society, individuals employment and 
personal income, autonomy levels and quality of life (38, 44, 46, 155). This increases the 
need of Informal care (49, 50). Informal care leads to loss of income and lower 
productivity in visually impaired individuals and in caregivers (146). If informal care is not 
provided, formal care assistance will eventually occur either in the form of home 
assistance or with inpatient services in long term care facilities (141). 
Vision impairment has a wide impact on the healthcare system (52, 53, 89, 91). 
In addition to the amount of eye care provided, VI imposes extra resource utilization and 
costs related to complications of vision loss and its effects on comorbid conditions (52, 
90). VI may effect or may be affect by comorbid conditions (52, 83). Access to eye care 
services remains as a topic of concern due to the population aging and the expansion of 
medical technologies posing significant pressure on healthcare delivery systems (120). 
In the only worldwide economic estimate the total costs of VI was estimated in 
2954 billion US$ in 2010. Direct costs were estimated in 2302 billion US$ in 2010. 
Productivity losses were only estimated in developed countries and ascended to 168.3 
billion US$. Informal care costs were estimated in 246 million US$ (146). Productivity 
losses estimates have shown that although VI occurs more frequently in developing 
countries the economic burden is still high in developed countries like the United States, 
Japan and Germany (149, 150). Understanding the cost of vision impairment is 
necessary to know its socioeconomic impact, for making an economic argument and 




Chapter 3 – Aim of this thesis 
Eye diseases and subsequent vision loss poses a big challenge to the healthcare 
system and are a public health major concern. Many of the cases of vision loss may be 
avoidable since there are available cost-effective intervention for prevention, treat and 
control of major eye diseases, although the access to these intervention remains 
problematic in many countries. Adequate access to care is essential to reduce vision 
related morbidity, to improve health related quality of life and to reduce social and 
economic impact caused by vision impairment. Losing vision at any age may have a 
wide-ranging impact. People with vision impairment have reduced independence, higher 
health costs and higher unmet health needs, lower wages and lower workforce 
participation, when compared with people without vision impairment. These 
consequences produces a widespread impact that goes beyond the affected individuals, 
producing also significant effects on the healthcare system and to the society. 
The aim of this thesis was to investigate and characterize the impact of vision 
impairment in selected aspects of the healthcare system and the society. To do so we 
decided to investigate the access to a new eye treatment for retinal diseases – anti-
VEGF, informal care use, and productivity losses in visually impaired people in Portugal.   
 
Thesis specific objectives: 
1. To assess the access to a new eye care treatment for retinal disease – anti-VEGF 
2. To estimate and characterize the use of informal care by people with vision 
impairment 
































Chapter 4 – Research Methods 
In this thesis are reported five research papers. Three papers are considered the main 
studies and investigated: 1) The access to a new anti-VEGF treatment for retinal 
diseases; 2) The use of informal care and its determinants in this population;3) 
Productivity losses in persons with vision impairment and their explanatory factors. In 
addition, two complementary papers are presented resulting from investigations 
necessary to develop the methodology and knowledge used in the main manuscripts. 
The first complementary paper included in this thesis investigated patient-reported 
outcome measures using a condition-specific instrument (activity inventory) with a 
generic health-utilities instrument (EQ5D) and the second investigated the profile of the 
participants in the face-to-face interviews that were conducted as part of the main 
studies. Four papers have been published and one is under review in a peer-review 
journal, the contents of these papers are given in chapter 5. 
A summary of the papers and research methods involved is Table 14. The table 
provides a description of the, study perspective, aims, data source, setting, outcome 
measures, and statistical analysis. A more detail version of the research methods is 






Table 14 - Summary of the research methods 
Study 
perspective 
Aim Data source Setting Outcome 
measures 
Statistical analysis 


















 Number of 
hospital 
episodes  
 Number of 
patient treated  
 Yearly rates of 
hospital 
episodes 
 Mean, minimum and maximum values of the rates of hospital 
episodes per 100.000 population to analyse the diffusion of 
treatments across areas was evaluated with 
  Relative variation coefficient to measure the dispersion of 
the diffusion 
 Generalized linear modelling more precisely Generalized 
Estimating Equations (GEE) to investigate the determinants of 
geographical diffusion of anti-VEGF treatments  
                                           Study Designation: The use of informal care by people with vision impairment 
Societal 
Estimate the 
use of informal 
care and its 
determinants 
PCVIP Study 4 hospitals 
in the north 
of Portugal 
 Use of 
informal care 
 Number of 
hours of 






 Chi-square tests to compare groups.  
 T-tests to compare visual ability between groups 
  Mann-Whitney–test or Kruskal-Wallis for non-parametric 
comparisons between groups.  
 Spearman Correlation to determine association between 
variables  
 Logistic regression to determine explanatory factors 
associated with the use of informal care  
 Linear regression to determine factors associated with the 
amount of informal care needed (intensity of care). 






PCVIP Study 4 hospitals 







 Chi-square tests to test differences between participants 
working and not-working. 
  Independent t-tests to compare visual ability and Mann-
Whitney tests were performed to compare visual acuity in the 
better eye and in the worse eye and HRQoL 
 Logistic regression was used to determine explanatory 





Aim Data source Setting Outcome 
measures 
Statistical analysis 















PCVIP Study 4 hospitals 
in the north 
of Portugal 
 Visual ability 
 EQ5D score 
 ANOVA for multiple comparisons 
 t-test to compare groups  
  Kruskal-Wallis or Mann-Whitney U tests for comparisons 
when variables failed normality tests. 
 Pearson correlations and Spearman’s rank-order correlation 
to test associations between variables 
 Linear regression to investigate if final scores of Activity 
Inventory and Eq5D were associated with the same factors 











PCVIP Study 4 hospitals 
in the north 
of Portugal 




 Chi-square tests to compare groups.  
 Multiple logistic regression to determine the effect of 
independent variables in participation rates. 




As mentioned in Table 14, we used two different data sources to perform the 
investigations reported in the reported manuscripts. A national database of inpatient and 
day cases episodes from public hospitals in mainland Portugal provided by 
Administração Central do Sistema de Saúde was used to investigate access to anti – 
VEGF injections. Anti-VEGF injections were considered a new treatment when the study 
was conducted. Data from the Prevalence and Costs of Visual Impairment in Portugal: a 
Hospital Based Study (PCVIP-study) were used to investigate informal care and 
productivity losses. In addition, data collected during this study was also used to 
characterize patient-reported outcome measures using two instruments and to 
investigate the profile of the participants in the study itself. A general description of these 
two data sources, participants/case selection and of the ethics procedures is provided in 
subtitles 4.1 and 4.2.  
4.1- Administrative inpatient and day-cases database 
To evaluate the access to anti – VEGF injections we used a national database of 
inpatient and day cases episodes admitted in Portuguese public hospitals from 2002 to 
2012. This administrative database includes demographic, administrative and clinical 
information from all in-patient and day cases episodes performed in public hospitals. The 
basic unit of measurement of this database is the episode of care.    
Demographic data includes: sex, date of birth, age and county of residence. We 
also had access to the admission and discharge dates, hospital department and services 
provided. Information about services provided includes, episode type (eg in-patient or 
day cases), admission type (e.g. elective or emergency admissions) and treatment type 
(e.g. medical or surgical). Diagnoses (principal and secondary) and procedures 
(maximum of ten) are classified according with the International Classification of 
Diseases 9th revision Clinical Modification (ICD-9-CM).  
 
4.1.1 - Cases selection 
We selected the cases (episodes) related to intravitreal injections for anti-VEGF 
treatments based on four procedures of ICD-9-CM codes: 1414, 1475, 1479, 149. Given 
that these procedures are not specific for intravitreal injections we have implemented two 
strategies to increase our precision: 1) years 2002-2006 were included as baseline as 
before 2006 intravitreal anti-VEGF treatments for ophthalmologic use were not licensed; 
and 2) we crossed information of age with principal diagnosis.  
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Baseline years provide the picture of the number of cases associated with the 
codes but not related with anti-VEGF treatment. We considered that AMD only affects 
people in the range of 50-59 years or above (157) and anti-VEGF are used for specific 
diagnosis, such as AMD or diabetic macular oedema. Since 2007 the number of patients 
older than 50 years have increased and represented 90% of cases. 75% of cases are 
concentrated in seven diagnoses that have indication for treatment with anti-VGEF and 
these are also the diagnoses responsible for the majority (around 80% of cases) of 
additionally cases observed after 2007 in age categories 20-39 40-49 and 50 years old 
and above. Patients below 19 years of age remain constant in absolute values during 
the analysed period and the proportion reduced from 3.6% in 2006 to 0.4% in 2012. 
 
4.1.2 - Ethic procedures    
Authorization to use these information was obtained from Escola Nacional de 
Saúde Pública, Universidade Nova de Lisboa. At inpatient and day-cases national 
database the cases are irreversibly anonymized. Patient identification numbers are 
subject to a recode procedure made by Administração Central do Sistema de Saúde that 
attributes an anonymous key identifier per patient per year therefore it is not possible to 
identify individuals. Only aggregate data at regional level, more specifically county of 
residence was considered in this study. County of residence was used to compute rates 
of hospital episodes per year (crude and standardized) and to create a dichotomous 
variable about the availability of an ophthalmology department in the hospital of the 
patient county of residence. Regional aggregate data are sufficiently large to guarantee 
individual privacy.  
  
4.2 - PCVIP study 
4.2.1 - Setting 
The PCVIP-study was designed according to guidelines published by the 
Vancouver Economic Burden of Vision Loss Group (158) and was conducted in 4 public 
hospitals in the north of Portugal. The hospitals were selected accordingly with the level 
of differentiation of their ophthalmology departments (159).Two hospitals, Hospital de 
Santa Maria Maior – Barcelos and Centro Hospitalar do Alto Ave  are classified as 
primary level hospitals providing only basic care services to all the inhabitants living in 
their catchment area. One hospital, Hospital de Braga is classified as a secondary level 
hospital that offers a wide range of eye care and is responsible to provide care both to 
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patients living in its direct catchment area as well indirect catchment area. Hospital de 
Braga receives the more complex patients referred by the two primary level hospitals 
also included in this study. A hospital, Centro Hospitalar de São João is a tertiary level 
hospital with a highly differentiated ophthalmology department which includes highly 
specialized staff and technical equipment and is responsible to provide eye care 
including rare diseases, ocular cancers, transplantation and paediatric glaucoma, 
cataract and premature retinopathy. This hospital as its own direct catchment area as 
well as an indirect catchment area that includes among others the secondary level 
hospital mentioned earlier. In total these hospital are expected to provide eye care to a 
total population of 2 million inhabitants belonging to 3 districts in the north of Portugal 
namely Porto, Braga and Viana do Castelo. 
4.2.2 - Participants selection 
4.2.2.1 Vision impairment definition  
The definitions for vision impairment includes low vision and blindness. In this study 
we followed the definitions given in the International statistical classification of diseases, 
injuries and causes of death, 10th revision (ICD-10): H54 (5). Definitions are: i) low vision 
is defined as visual acuity of less than 6/18, but equal to or better than 3/60, or a 
corresponding visual field loss to less than 20 degrees in the better eye with presenting 
visual acuity (ICD-10 visual impairment categories 1 and 2); ii) blindness is defined as 
visual acuity of less than 3/60, or a corresponding visual field loss to less than 10 degrees 
in the better eye (ICD-10 visual impairment categories 3, 4 and 5) (5). 
4.2.2.2 Participants selection description 
Each week, members of the hospital staff with biomedical qualifications and hired for 
this purpose searched files of patients attending ophthalmology medical appointments 
for potential new cases of vision impairment. Records of all patients assisted at the site 
(Department of Ophthalmology) were analysed weekly during one calendar year. From 
clinical records we collected information about visual acuity, cause of vision loss 
(classified according with International Classification of Diseases 9th revision Clinical 
Modification), date of birth and gender. This information was registered in a secure 





Figure 13 - PCVIP platform: print screen of tables were information about 
selected participants information was introduced 
Contact was tried initially by letter with a reply-paid envelope addressed to Escola 
Nacional de Saúde Pública (National School of Public Health (ENSP), Lisbon). The 
envelope contained the information booklet and consent form. The consent form was 
expected to be returned to the ENSP. If the consent was not mailed back to ENSP in 
approximately 2 weeks, potential participants were contacted by telephone. If the letter 
did not reach the home address people were invited by telephone. Similar methodology 
has been adopted by other epidemiological studies conducted in Europe (EUREYE study 
group (160)). Refusals were not contacted again.  
Those returning the consent form were considered participants and most were 
able to attend an interview that was scheduled at the hospital. 
 
4.2.3 - Data collection methods    
4.2.3.1 Visual acuity measured during face-to-face interviews 
Distance visual acuity (VA) reassessment was made using an internally 
illuminated ETDRS chart (Lighthouse International. NY. USA) at 4. 2 or 1m according 
with the severity of their vision loss. The room lights where extinguished during 
measurements. Letter by letter scoring was employed to specify final measured acuity. 
The formula VA = 1.1–0.02xNL, where NL represents the number of letters read, was 




4.2.3.2 Comorbidities assessment 
Participants were asked to report comorbidities based on a list of 16 categories: 
cancer, diabetes, heart condition, hypertension, musculoskeletal disorder, pulmonary 
disease, stroke or brain haemorrhage, hearing impairment, thyroid condition, 
psychological problems, neurological problems, chronic allergies, gastrointestinal 
condition, liver disease, autoimmune disease and endocrine condition. The list of 
comorbidities was based on previous studies that analysed the association between 
vision impairment and self-reported comorbidities (8, 161-164). 
4.2.3.3 Patient reported outcome measures 
Participants were also asked to respond to a functional vision questionnaire to 
assess visual ability, the Activity Inventory and to respond to EUROQol-5D (EQ5D) in 
Portuguese to determine health related quality of life.  
4.2.3.3.1 Assessment of Visual Ability  
The Activity Inventory is an adaptive visual function questionnaire designed to provide 
an individualized assessment of difficulties of a visually impaired respondent when 
performing valued activities. Patients differ from one another in terms of the reported 
importance and difficulties to perform different activities. Disabilities, or activity limitations 
according to the World Health Organization’s International Classification of Functioning, 
occur when a person reports abnormal difficulties in achieving important goals. 
Difficulties achieving a goal are said to depend on the difficulty experienced in the tasks 
that underlie each goal (165-168).  
In the Activity Inventory participants are asked to rate goals in a four point scale 
that ranged from “not important” to “very important. Whenever goals are scaled different 
than “not important”, participants are ask to rate the difficulty to perform tasks related to 
that goal in a five point scale that ranged from “impossible to do” to “not difficult” (168). 
Figure 14 shows a print screen of PCVIP platform to illustrate how Activity Inventory 
answers were register in our database. Participants rate the importance of each goal, 
but rate only the difficulty of the tasks that are related to the goals that were of some 
importance to them. Therefore, each participant respond to a relevant set of questions 
that is unique to her/him, meaning that for each participant we have done a personalized 
functional assessment. For minors, when necessary, parents or guardians served as 
proxies for the interview. An example of the content of the Activity Inventory is presented 
in Table 15.  
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Table 15 - Questions and answers categories of Goal 3 “choose your clothes 
and dress yourself” as an example of the type of words used in Activity Inventory 
 Type of question   Answer categories  
Goal 
importance 
How important is it for you to be able to 
choose your clothes and dress yourself 





If the participant responded "not important" , the interviewer moved to the next Goal;                                                      
If the Goal was rated with any other importance category, than the participant was asked to rate 
difficulty achieving the Goal 
Goal 
difficulty 
How difficult is it for you to choose 
your clothes and dress yourself without 





5= impossible to do  
 
 
Figure 14 - PCVIP platform: print screen of tables were information about 
Activity Inventory was register 
 
In our translated version of the Massof activity inventory participants were 
questioned about difficulties with 46 goals (presented in appendix 1) and the “difficulty” 
responses were Rasch analysed to produce a continuous measure of visual ability given 
by the variable ‘person measure’ (Program Winsteps. v3.9). Visual ability is considered 
a composite variable since incorporates both goal importance and task difficulties. 
Rasch analysis is used to estimate the magnitude of an attribute shared by a set 
of items. The inputs of rash analysis are ordinal rates given to a group of items in a 
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questionnaire by a group of respondents. The outputs are estimated measures of both 
the items and the respondents (169).  In Activity Inventory rash analysis takes ordinal 
ratings assigned to the tasks and estimates the relative abilities of the persons that rated 
the items. We use the term ‘visual ability’ to define the overall ability of each person to 
perform activities that depend on vision (8).  
4.2.3.3.2 Assessment of Health-Related Quality of Life 
Participants also responded to EUROQol-5D (EQ5D) to determine health related 
quality of life (presented in appendix 2). The EQ-5D is a generic preference-based 
measure of health that has five domains: mobility, self-care, usual activities, pain or 
discomfort, anxiety and depression. Each dimension is rated on a three-point scale with 
categories “no problems”, “some problems”, or “extreme problems”, producing a 
descriptive health profile. A respondent´s health state is then defined by combining the 
levels on each of the five dimensions which will provide a 243= (3^5) health profile´s. For 
every patient a single health state value, or utility, can be calculated. These health sate 
values are set on a scale ranging from 0 to 1 corresponding to death and perfect health 
respectively. Negative values correspond to a health state worse than death. 
Respondents’ health profiles were valued using valuations derived from the general 
population in Portugal (170). Figure 15 shows a print screen of PCVIP platform to 
illustrate how EQ5D answers were register in our database. 
 





4.2.3.4 Informal care and productivity losses questionnaires  
We used the questionnaire method, administered by trained members of the 
research team, to collect data about informal care needs, absenteeism, and workforce 
participation. Informal care use and absenteeism were asked with a 2 week recall time 
period as propose by Severens et al (171) with the view to minimised recall biases.  
The questionnaire was drawn from previously validated instruments (172, 173) it 
underwent pilot testing and revisions to clarify wording, and to simplify data recording 
and to remove redundant items. The final version of the questionnaire is summarized in 
Table 16.  
Table 16 - Questions used to collect information about sociodemographic information, 
informal care need and absenteeism. Absenteeism questions were applicable to participants in 
the working age range (17-64 years). In all questions, there was 1 option with: do not know or 
do not want to answer 























1. What is your marital status? 
a) Single 
b) Married or living as married 
c) Divorced or separated 
d) Widowed 
e) Other (please specify) 
2.  What is the highest level of 
education you completed? 
a) Up to university 3rd cycle (PhD) 
b) Up to university 2nd cycle (Master) 
c) Up to university 1st cycle (undergraduate)  
d) Up to 12 years of education 
e) Up to 9 years of education 
f) Up to 6 years of education 
g) Up to 4 year of education 
3. What best describes your 
living environment? 
a) Live alone 
b) Live with spouse (including children) 
c) Live with parents 
d) Live with children (sons/daughters) 
e) Live with other relatives 
f) Live with others 
4. What is your employment 
status? 
a) In full-time work  
b) In part-time work  
c) Currently seeking work 
d) Homemaker 
e) Retired 
f) Early retired 
g) Student 
h) Other (please specify) 
5. Please provide an estimate 
of your month household income 
from all sources (after tax and 
other deductions and including 
your partner/spouse) 
a) less than €485* 
b) between € 485 and €1000 
c) above €1000 
 
















6. Over the last two weeks 
have you been helped and/or 
cared for by a relative or friend 
because you have poor vision? 




Categories Questions Options 
6.1. Over the last two weeks 
how many relatives/friends have 
helped and/or cared you? 
Number of caregivers  
6.2. Over the last two weeks 
how many hours were spend by 
caregivers to support you? 
Number of hours 
6.3 What would that person 
normally have been doing as the 
main activity if they had not been 
helping and or caring you? 
a) Paid Job 















For those reporting 
employment (part-time or full-
time) we asked 2 questions 
 
6. Over the last two weeks how 
many hours per week do you 
spend working?  
Number of Hours 
 
  7. Over the last two weeks 
how many days have been absent 
from work owing to your visual 
condition? 
Number of days 
For those reporting  two weeks 
of  absenteeism in the last two 
weeks we asked 
7.1 How long were you in sick 
leave? 
a) less than three months 
b) three months or more 
 
4.2.3.5 Cost categories and cost calculation  
4.2.3.5.1 Informal care cost assessment 
Informal care costs represent a monetary estimate of the hours spend by 
caregivers to help/care visually impaired persons. The number of reported hours were 
extrapolated from the 2 weeks recall period included in the questionnaire to 12 months. 
To estimate the economic impact of informal care we used the opportunity costs in which 
time spent providing informal care is valued based on competing use, in this case paid 
labour. This method is commonly used to do these economic estimates including in eye 
care studies (174, 175). Total informal care costs were calculated by multiplying the 
number of annual hours by the average Portuguese hourly pay rate of full time 
employees in the year 2014 (€6.63). This value is within the interval €4.10 to €19.18 
reported by Costa et al (176). 
4.2.3.5.2 Productivity losses assessment 
Absenteeism was measured by the number of absent workdays due to health. 
Total annual absenteeism costs were calculated by converting reported working days 
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missed due to visual impairment into hours and then valuated with the average hourly 
pay rate obtain by the three categories of income level also reported by the participants. 
In category 1 (less than €485) we considered the maximum value €485, in category 2 
(between € 485 and €1000) we considered the mean value  €742,5 and in category 3 = 
above €1000 we considered the  minimum value €1000. We extrapolated the 2 weeks 
recall period to an annual level multiplying by 24 working weeks adjusting for annual 
leave and public holidays. Absenteeism was divided into short term and long term 
absenteeism. Long term absenteeism includes all the individuals that reported being 
absent for more than three months. All the other cases were considered short term 
absenteeism.  
Reduce workforce participation refers to the loss of production caused by visual 
impaired persons who are out of the labour market. It was calculated for participants who 
were aged more than 17 and less than 64 years old (working age) and reported being 
early retired due to visual impairment or unemployed. It was only included the excess 
number of unemployed calculated by the difference between unemployment rate of 
active population adjusted by sex and age of 2014 in Portugal reported by Eurostat, 
presented in Table 17, and the unemployment rate by sex and age observed is this 
sample.  
Table 17 - Unemployment by sex and age (% of active population) - annual 
average, 2014 
 Unemployment rate Total Male  Female 
Portugal 14,10% 13,80% 14,50% 
Less than 25 years old 34,70% 33,90% 35,50% 
25-74 years old 12,50% 12,20% 12,80% 
Source: Eurostat. (177) 
 
These two figures were, in turn applied against the average Portuguese monthly 
wage adjusted by sex and education level shown in Table 18. There was also other 
participants that were out of the labour market categorized as homemaker and others 
(which includes students and other reasons not specified) that were not considered in 
this estimation because it can be a choice of the individual and therefore cannot be 





Table 18 - Monthly wage adjusted by sex and education for year 2014 used to 
calculate productivity costs due to reduced workforce participation rate 
Education level Male Female 
Did not attend school        731,60 €         604,40 €  
4 years of education        858,60 €         639,60 €  
6 years of education        878,70 €         653,70 €  
9 years of education        954,60 €         728,80 €  
12 years of education     1.267,40 €         923,80 €  
University undergrad or more     2.259,20 €      1.580,00 €  
Source: CITE (178) 
 
4.2.4 - Ethic procedures    
The present study was conducted in accordance with the tenets of the Declaration 
of Helsinki, reviewed and approved by the ethical commission for Life Sciences and 
Health of the University of Minho, by Comissão Nacional de Protecção de Dados 
(Authorization Nr. 5982/2014 presented in appendix 3) and by the hospitals ethics 
committees. Written informed consent was obtained from all participants participating in 
face-to-face interviews. Data was kept in a secure platform, confidentiality was assured 






Chapter 5 – Research Findings  
This section is organized in two parts: main research findings and additional 
research findings. 
In the main research findings there are included three papers that aimed to 
investigate and characterize the impact of vision impairment in selected aspects of the 
healthcare system and the society.  
Adopting the healthcare system perspective we have studied the temporal and 
geographical diffusion of a new eye care treatment, anti-VEGF injections to better 
understand how was the access and diffusion of a new eye treatment in the Portuguese 
national health system. This paper was published in October 2015 by BMJ Open. 
Adopting the societal perspective we conducted a study to estimate the use of informal 
care and its determinants in visually impaired individuals. This paper was published in 
June 2018 by Plos One. We also developed a study to estimate and characterize 
productivity costs in persons with vision impairment. This paper was submitted in July 
2018 to Ophthalmic Epidemiology 
In the additional research findings are included two methodological papers. 
During the recruitment of participants and data collection phases two methodological 
papers were developed: 1) to compare two of the instruments used to characterize 
participant’s characteristics and 2) to analyse participants and non-participants profiles. 
The paper comparing visual and health outcomes measured with activity 
inventory and EQ5D was published in March 2017 by Acta Ophthalmologica. The first 
author of this paper was Professor Antonio Filipe Macedo. As expressed in the first 
author declaration presented in Appendix 4A my collaboration in this paper is associated 
with data collection, results analyses and providing help writing and reviewing the 
manuscript. 
The paper predicting participation of people with impaired vision in 
epidemiological studies was published in August 2018 by BMC Ophthalmology. The first 
author of this paper was the Researcher Pedro Lima Ramos. As expressed in the print 
version of the paper and in the first author declaration presented in Appendix 4B my 
collaboration in this paper is associated with data collection, results analyses and 




5.1 – Main research findings 
 
5.1.1- Diffusion of anti-VEGF injections in a National Health System 
 
 
Material in this Chapter has been published in: 
Marques AP, Macedo AF, Perelman J, Aguiar P, Rocha-Sousa A, Santana R. 
Diffusion of anti-VEGF injections in the Portuguese National Health System. BMJ 
Open. 2015 Nov 23;5(11):e009006 


















Purpose: To analyse the temporal and geographical diffusion of antivascular 
endothelial growth factor (anti-VEGF) interventions and its determinants in a National 
Health Service (NHS). 
Setting: NHS Portuguese Hospitals  
Participants: All inpatient and day cases related to eye diseases at all Portuguese 
public hospitals for the period 2002-2012 were selected on the basis of four International 
Classification of Diseases 9th revision. Clinical Modification (ICD-9-CM) codes for 
procedures: 1414, 1475, 1479 and 149. 
Primary and secondary outcome measures: We measured anti-VEGF treatment rates 
by year and county. The determinants of the geographical diffusion were investigated 
using generalized linear modelling. 
Results: We analysed all hospital discharges from all NHS hospitals in Portugal (98 
408 hospital discharges corresponding to 57 984 patients). National rates of hospitals 
episodes for the codes for procedures used were low before anti-VEGF approval in 2007 
(less than 12% of hospital discharges). Between 2007 and 2012, the rates of hospital 
episodes related to the introduction of anti-VEGF injections increased by 27% per year. 
Patients from areas without ophthalmology departments received fewer treatments than 
those from areas with ophthalmology departments. The availability of an ophthalmology 
department in the county increased the rates of hospital episodes by 243% and a 100-
persons greater density per square kilometre raised the rates by 11%.  
Conclusions: Our study shows a large but unequal diffusion of anti-VEGF treatments, 
despite the universal coverage and very low co-payments. The technological innovation 
in ophthalmology may thus produce unexpected inequalities, related to financial 












Age Related Macular Degeneration (AMD) is a chronic, progressive disease and 
the most common cause of visual impairment in developed countries in patients older 
than 65 years (28, 105, 147, 179-182). AMD requires lifelong observation and 
interventions (183). AMD can be divided into two stages: early AMD, characterized by 
sub-retinal pigmented epithelium deposits (drusen) and pigmentary changes and 
advanced AMD (28). Advanced AMD has atrophic and neovascular forms. Although 
neovascular AMD comprises only 10% of the burden of the disease, it is responsible for 
90% of severe vision loss years (105, 184-187). Vision loss leads to reduced quality of 
life and autonomy and is associated with large costs for health systems and the society 
(48, 185, 188, 189). 
Before the introduction of antivascular endothelial growth factor (anti-VEGF) 
treatments, AMD was largely untreatable (29). Anti-VEGF therapy for neovascular AMD 
has substantially changed the management of the disease (29, 30). These drugs are 
injected into the vitreous chamber to reduce neovascular formation in the macula (179). 
Currently the most common anti-VEGF therapies in Portugal are: 1) Ranibizumab 
(Lucentis, Novartis) which was licensed for the treatment of neovascular AMD by the 
Food and Drug Administration (FDA) in 2006 and by the European Medicines Agency 
(EMA) in 2007. In Portugal ranibizumab has been covered by the National Health Service 
(NHS) since 2008. Ranibizumab is the most widely used approved anti-VEGF drug in 
Europe (105, 180, 190); 2) Bevacizumab (Avastin, Roche) was licensed in 2004 by the 
FDA, and by EMA in 2005 for the treatment of metastatic colorectal cancer. It has been 
widely used for the treatment of neovascular AMD as an off-label alternative (29); 3) 
Pegaptanib sodium (Macugen, Eyetech/Pfizer) was approved by FDA 2004 and by EMA 
in 2006 for the treatment of neovascular AMD. It is less commonly used in clinical 
practice as it is not as effective as ranibizumab or bevacizumab (179, 191). In Portugal 
this therapy was approved but not marketed; 4) Aflibercept (Eylea, Bayer) was approved 
for wet AMD treatment by FDA in 2011 and by the EMA in 2012. Aflibercept is covered 
by the Portuguese NHS since 2014. 
Several clinical trials have shown that intravitreal injections prevent vision loss in 
the majority of patients and, in some cases, significantly improve vision (29, 192-194) 
with low numbers of serious adverse effects (183). Subsequently, anti-VEGF therapy 
has become the standard clinical option to treat AMD patients (190, 192). In 2011, anti-
VEGF therapy was also introduced as treatment for diabetic macular oedema and central 
retinal vein occlusion years (105, 190, 195).  
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New therapies such as anti-VEGF injections improve the clinical course of 
diseases but represent substantial expenditures for healthcare systems (120). To face 
rising costs of healthcare, copayments have been introduced during the period of this 
study in public Portuguese hospitals. If not exempt due to special circumstances, such 
as being disabled, patient receiving anti-VEGF injections have to pay typically €7.5 per 
appointment with their physician at the hospital. In a context of economic recession and 
tight public budgets the introduction and diffusion of these treatments can face 
substantial barriers (196). Despite the strong equity commitment of the Portuguese NHS, 
one of the expected barriers is likely to be geographical due to unequal distribution of 
resources across areas. 
The aim of this study was to examine the diffusion of anti-VEGF drugs in the 
Portuguese NHS by analysing the temporal and geographical diffusion patterns and its 
determinants. We conducted a longitudinal study in order to measure the evolution of 
hospital episodes related to anti-VEGF treatments per county from 2002 to 2012. 
Methods 
Data sources and extraction strategies 
We used an administrative database that includes demographic, administrative 
and clinical information from all in-patient and day case episodes performed at all 
Portuguese NHS hospitals during the years 2002 to 2012.  Authorization to use these 
information was obtained from Institutional Review Board from Escola Nacional de 
Saúde Pública/Universidade Nova de Lisboa. In order to select the episodes related to 
intravitreal injections for anti-VEGF treatments, we used the following International 
Classification of Diseases 9th revision. Clinical Modification (ICD-9-CM) codes for 
procedures: 1414, 1475, 1479, 149. These codes have been commonly used in the 
literature but they are likely to capture other treatments such as injectable antibiotic or 
corticosteroids (105). Cases were excluded even if the diagnosis was likely to be 
associated with anti-VEGF treatment but the code pf procedures was outside the 
selected group specified above. For example, for the five diagnoses shown in figure 2, 
there were 13.750 cases excluded from further analysis due to this filter. Effects to our 
estimation caused by the poor specificity of the code were reduced using two methods: 
1) years 2002-2006 were included as baseline as before 2006 intravitreal anti-VEGF 
treatments for ophthalmologic use were not licensed; and 2) we crossed information of 
age with principal diagnosis. Baseline years provide the picture of the number of cases 
associated with the codes but not related with anti-VEGF treatment. We considered that 
AMD only affects people in the range of 50-59 years or above (157) and anti-VEGF are 
used for specific diagnosis such as AMD or diabetic macular oedema. Supplementary 
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tables shown in appendix 5 show how this information was used in our methods. For the 
period studied, the only approved anti-VEGF drugs for use in public hospitals were 
Ranibizumab (Lucentis. Novartis) and Bevacizumab (Avastin). 
We used the indicators bellow: 
 The absolute values of the number of hospital episodes per year. Episodes were 
then disaggregated by: 1) sex, 2) age of the patients (under/over 60 years old), 
3) principal diagnosis. 
 The number of patient treated per year. To calculate the number of patients, we 
considered one treatment per person per year, regardless of the number of 
episodes of care (number of treatments) that occurred in each year. 
 The yearly rates of hospital episodes per 100.000 population [(number of 
episodes per year/annual average resident population per year) x 100.000].  
The age-standardized rates of hospital episodes per 100 000 population by counties 
per year [(number of episodes by county and year/annual average resident population 
per county and year)x 100.000] using general demographic information published by 
Statistics Portugal (197). County of residence was obtained from the administrative 
database used in the study. We used the direct method of standardization as described 
by Beaghole et al. (198) for standard Portuguese population. The age-standardisation 
was necessary to control the effect of age heterogeneity across populations living in 
different counties. Mainland Portugal is divided into 248 counties that correspond to local 
prefectures with specific administrative and political competences defined by the central 
government. 
Study analysis 
We first evaluated the diffusion of treatments across areas using the mean, 
minimum and maximum values of the rates of hospital episodes per 100.000 population 
in 2002. 2006 and 2012. The relative variation coefficient was used to measure the 
dispersion of the diffusion. 
Three time points were selected because they corresponded to: 2002 – the first 
year included in this study, 2006- the year before the approval of intravitreal injections 
with anti-VEGF by EMA and 2012 because it was the latest available information when 
this study started.  
To investigate the determinants of geographical diffusion of anti-VEGF treatments 
we used generalized linear modelling. Considering the longitudinal nature of the data 
and its non-normal distribution we used Generalized Estimating Equations (GEE) (199). 
The dependent variable was defined as the yearly rate of hospital episodes per county 
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per 100.000 population. We defined as independent variables: 1) the years during which 
the geographical diffusion was analysed (a linear trend); 2) a dichotomous variable to 
indicate the year where the drug was authorized in the European Union by EMA (Anti-
VEGF therapy availability: 0-not available; 1–available; 3) a dichotomous variable to 
indicate the availability of an ophthalmology department in the hospital of the patients’ 
county of residence (Ophthalmology department availability: 0-no ophthalmology 
department; 1–ophthalmology department) and 4) population density (population per 
squared kilometre) in the county. Information about the availability of ophthalmology 
departments was obtained in October 2014 from the Health Ministry official website. The 
referral pathway for ophthalmology starts with the general practitioner (GP) according to 
the local referral guidelines. The circuit of the treatment does not interfere with our 
calculations because we compute treatment ratios based in the country of origin of the 
patient and this is independent of the hospital where treatment was administered. The 
model was defined as gamma log link distribution regression model as the rate was 
expected to be positively skewed with an autoregressive first order matrix representing 
time dependence within repeated subject (200). A total of 278 counties were considered 
as “subjects” with repeated measures. Year and dichotomous variable “anti-VEGF 
availability” were defined as within subject independent variables. Dichotomous variable 
“Ophthalmology department availability” and “population density rates” were defined as 
between subject variables. The analysis was performed using IBM SPSS Statistics 21.0. 
 
Results 
The final sample included 98.408 hospital episodes. Figure 16 shows that the 
total number of episodes increased from 1.815 in 2002 to 25.106 in 2012. This 
corresponds to a mean annual increase of 32%. 
In 2012, the number of treated patients was six times higher than in 2002, 
corresponding to a mean annual increase of 24%. The ratio number episodes/number 
patients was 1.16 in 2002, 1.17 in 2006 and 2.1 in 2012. The most relevant demographic 
information was the percentage of patients treated who were older than 60 years of age. 





Figure 16 - Annual number of hospital episodes of antivascular endothelial 
growth factor (antiVEGF) treatments and annual number of treated patients from 2002 
to 2012 
Figure 17 shows the five principal diagnoses responsible for the episodes 
detected. The figure is expected to provide a picture of the growth of the number of 
episodes per year and number of patients treated per diagnoses. The most common 
diagnosis was exudative age -related macular degeneration, followed by diabetic 
macular oedema (diabetes with ophthalmic complications), oedema of the retina, retinal 
neovascularization and non-specific AMD. The cumulative percentage of episodes 
associated with these five diagnoses was 73% in 2012, in contrast with only 16% in 2002. 
These values corresponded to an increase in the yearly rates of hospital episodes per 





























Figure 17 - Number of hospital episodes associated with the top five diagnoses by year 
Table 19 gives a summary of the mean, minimum and maximum values in 3 
specific years of the rates of hospital episodes per 100.000 population. Both maximum 
and minimum rate values increased over time. The relative variation coefficient varied 
from 200% in 2002, to 204% in 2006 and 209% in 2012. The relative coefficient of 
variation indicates that rates per county have a great dispersion and that this dispersion 
did not reduce over time. The first quintile always contains rates equal to zero, which 
means that there are counties without events. In 2002 there were 58 counties in the first 
quintile (without episodes). The number of counties without episodes reduced over time 
to 33 in 2006 and 3 in 2012. All the mean values per quintile rose in the period analysed. 
Table 19 - Age-standardized rates of hospital episodes per 100.000 populations 
per county in the year 2002. 2006 and 2012. Values show quintiles mean, minimum 
and maximum values 
Quintile 
 2002   2006   2012  
Mean Min Max Mean Min Max Mean Min Max 
1st 0 0 0 0.0001 0 0.0002 0.0013 0 0.0024 
2nd 0.0002 0.0001 0.0003 0.0003 0.0002 0.0005 0.0037 0.0024 0.0051 
3rd 0.0005 0.0004 0.0008 0.0009 0.0006 0.0013 0.0069 0.0051 0.0091 
4th 0.0012 0.0008 0.0017 0.0019 0.0013 0.0026 0.0148 0.0093 0.0221 
5th 0.0048 0.0017 0.0231 0.008 0.0026 0.0459 0.0764 0.0222 0.3745 
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Results of the regression analysis are summarized in Table 20. In agreement with 
the initial prediction and consistent with the introduction of the new treatment with anti-
VEGF, the model shows a significant effect of the variable “year”, p<0.0001. For each 
additional year the rate of hospital episodes increased by 28%. The rate was significantly 
higher after the EMA approval; in Table 20 results for “Anti-VEGF therapy availability”. 
p<0.0001. With the approval of this treatment the rates of hospital episodes increased 
by 27%. The availability of an ophthalmology department in the hospital of the county (in 
Table 20 results for “Ophthalmology department availability”) significantly increased the 
rates of hospital episodes by 243% p <0.0001 (compared with counties without). The 
positive association between the variable “Ophthalmology department availability” and 
our dependent variable indicates that anti-VEGF treatments were more frequent to 
patients living near hospitals with ophthalmology departments, which are typically 
located in areas of median/high population density. There was a positive association 
between the dependent variable and population density. An increase of 100 persons per 
square kilometre raised the rates of hospital episodes by 11%. This results show that 
patients living in rural areas were less frequently treated.  
 
Table 20 - Results of the Generalized Estimating Equation for the rate of 
hospital episodes per 100.000 population per year and independent variables were: 
year. Anti-VEGF therapy availability (separating years before and after the drug was 
authorized by EMEA) Ophthalmology department availability (representing the 
availability of ophthalmology departments in the hospital of county residence) and 
population density (population per square Kilometre in the county); 
Parameter IRR* p- value 95%CI** 
Lower Upper 
Year (from 2002 to 2012) 1.281 <0.001 1.263 1.299 
Anti-VEGF therapy availability  
(0- not available; 1 – available) 
1.270 <0.001 1.183 1.362 
Ophthalmology department availability  
(0 - no ophthalmology dept; 1 –
ophthalmology dept) 
3.430 <0.001 2.566 4.583 
Density rate (per 100 persons) 1.113 <0.001 1.095 1.132 
Total number of counties is 278. 
*Incidence Rate Ratio  
**Wald chi-square test of significance (95% Confidence Interval)  
 
Discussion 
With this study we wanted to investigate the diffusion of anti-VEGF treatments for 
eye disease in Portugal looking for possible determinates and/or barriers. We performed 
this investigation by characterizing the temporal and geographical distribution of anti-
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VEGF treatments using codes for specific type of procedures from all episodes 
performed in public hospitals. Our results show that the number of episodes for the codes 
analysed was low before the introduction of anti-VEGF treatments. The numbers of 
episodes rose significantly since the treatment was introduced in the country in 2007. 
The most relevant finding was that patients from small areas without ophthalmology 
departments near their residence received fewer treatments as revealed by the 
geographical distribution of episodes. The unequal distribution is puzzling, given the 
equity-oriented nature of the Portuguese NHS. 
We consider three possible barriers for the equitable anti-VEGF diffusion related 
to legal, technical and financial factors. Following the EMA approval of this treatment in 
2007 and the NHS coverage decision in 2008, the treatment became legally available at 
all ophthalmology departments in Portugal. One can thus say that the legal problem was 
sorted out. However, technical conditions were imposed for the use of this treatment that 
included extra training for doctors and that the procedure needed to be performed in the 
operation theatre (190). These technical requirements possibly created financial and 
service capacity pressures on ophthalmology departments (105, 181). Indeed, higher 
rates of treatment were observed mostly in areas around big cities and specialized 
centres. Smaller hospitals may have taken longer to adopt this treatment due to budget 
limitations or technical conditions. It should also be mentioned that anti-VEGF therapy 
was first introduced to treat AMD, and then expended to diabetic macular oedema and 
central retinal vein occlusion treatment. This certainly increased the rate of hospital 
episodes, but the effect is expected to be similar in all counties. 
Regarding financial barriers, we can speculate about two main budget limitations 
that reduced the speed of diffusion of anti-VEGF treatments. The first financial challenge 
is the cost of the treatment of approximately €1.913 per episode, a figure similar to the 
United States (196, 201). In Portugal, hospitals receive a global budget from the 
government that covers the cost of all drugs and medical devices (190). During the period 
included in this study, the financing methodology used to allocate resources to the 
Portuguese NHS hospitals has been subject to several changes. This included the 
introduction of different unit payment and new incentive programs that rely on quality and 
cost indicators. These changes to hospital budgets and pressure for cost-containment 
may have reduced the availability of anti-VEGF treatments in small hospitals 
concentrating patients in big centres with limited capacity. A second financial barrier for 
hospitals is the fact that the intravitreal injections need to be administered in an operating 
room by an ophthalmologist. Typically, patients receive three injections in the first 3 
months, followed by monthly visits for assessment and further injections as necessary 
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(194). These surgical procedures and monthly appointments impose high demands on 
hospitals (staff and facilities). In a period of tight budgets expansions in the medical staff 
or facilities are difficult to implement. These problems have been recently reported by 
Marko Hawlina, a retinal specialist form Slovenia, quoting results of a survey of the 
European Union of Medical Specialists (202). Thus, some hospitals may have delayed 
the start of these treatments or they may still not be available. 
The reasons outlined above have implications for the geographical diffusion of 
the treatment leading to inequalities. Patients referred from distant cities or rural areas 
may have delayed access to treatments. The lower rate of treatments in patients living 
in areas of low population density may also indicate that these patients are more likely 
to miss follow-up appointments. Travelling distances may be a barrier to attending 
appointments as reported by other studies (203-205). These evidence are causes of 
concern because vision loss caused by eye diseases for which anti-VEGF treatments 
are indicated cannot be restored. That is, reduced number of treatments might lead to 
an increased number of people becoming visually impaired due to treatable causes. 
During this study we found some limitations: the lack of specific codes for anti-
VEGF injections, the inability to follow patients across different years, the exclusion of 
the activity in the private sector and the absence of individual data. Limitations caused 
by non-specific codes have been described in methods. The inability to follow patients 
across years might have had an impact on the ratio of episodes/patient that we found. 
Nevertheless, the county of residence remained unchanged across years ensuring 
temporal and geographical accuracy of treatment diffusion. Other studies analysing 
equivalent temporal periods also report treatments ratios under 3 per year. These 
authors explained the low ratios by a higher concentration of patients treated as required 
(105). Numbers from private treatments were likely to be small because this treatment is 
expensive and patients tend to look for care in the National Health System where 
treatment is free. The lack of individual data limited our analysis of socio-economic 
determinants such as patient income or education level or other clinical conditions that 
could restrict the prescription of anti-VEGF therapy. However, with the available data we 
were able to construct a complex and multivariable model to explain the geographical 
diffusion and time variation based on a nationally representative database with many 
types of hospital settings and geographic areas; this would have been difficult to perform 
with a limited sample number of cases.  
In brief, the use of anti-VEGF drugs in ophthalmology marked the beginning of 
effective treatments for age related eye diseases that can lead to severe visual 
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impairment. This study shows that the number of intravitreal procedures increased 
substantially since anti-VEGF treatments were approved in Portugal, but that the 
diffusion was inequitably distributed. Local restrictions to the temporal and geographical 
diffusion seem mostly imposed by financial aspects. These financial constraints may 
arise not only from cuts in budgets in the health care system but also from difficulties for 
families to fund travel costs. With the aging of the population and the expected growth in 
conditions, such as diabetic retinopathy and age-related macular degeneration, the 
demand for these treatments is likely to increase (147). The combination of these factors 
will maintain pressure on ophthalmology departments delivering eye care. Health 
authorities need to consider the equitable distribution when planning human and material 
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Purpose: To estimate and characterize the use of informal care by people with vision 
impairment in Portugal. 
Methods: A total of 546 visually impaired individuals were recruited from Portuguese 
hospitals. Clinical information was obtained from records, socio-demographic details and 
informal care use was collected during face-to-face interviews. In addition, participants 
responded to a functional vision questionnaire (activity inventory) to assess their visual 
ability. Logistic regression was used to determine independent factors associated with 
informal care use and linear regression was used to determine independent predictors 
of intensity of informal care use. 
Results: Informal care was reported by 39.6% of the participants. The probability of 
reporting informal care was higher in non-married, those with comorbidities, with lower 
visual ability and worse visual acuity. The median number of caregivers’ hours per year 
was 390 (mean = 470; 95%CI=488-407), which represent a median opportunity cost of 
€2.586. Visual ability was the only independent predictor of the number of hours of 
informal care received. 
Conclusions: Informal care was frequently used by individuals with impaired vision. 
Improving visual ability of people with impaired vision when performing valued activities 
may reduce the burden of visual loss at personal and societal level. This can eventually 





Vision impairment puts a burden on individuals, families and society. People with 
impaired vision require more informal care to perform activities of daily living, have more 
difficulties with mobility, have increased risk of falls and are more likely to require long 
term care than persons without vision impairment  (47, 48, 51, 206). 
Informal care is generally defined as “help provided to older and dependent 
persons by non-professional individuals such as, a spouse, parent, other relative, 
neighbour or friend, in a wide variety of activities and with no payment associated” (207, 
208). Some factors such as age, type of activities, type of disability and severity level 
can influence the demand for informal care (207, 209). In addition, it can be influenced 
by socio-cultural aspects such as familiar structures, levels of income per capita and 
availability of formal long-term care systems (207)  
In 2007 the Portuguese minister of health implemented a national network of 
integrated care to provide health and social support including long term care. Visually 
impaired persons may have access to the national network of integrated care when they 
meet the access criteria. Nevertheless, the access is difficult due to the limited capacity 
of the network and in some cases, due to the co-payment associated. Therefore, in 
Portugal, long-term care for people with impaired vision remains mostly informal, that is, 
provided by relatives or friends.   
Informal care tends to be a major contributor to the total costs of vision 
impairment (144). Some studies investigated informal care costs in people with impaired 
vision due to specific eyes diseases such as Age-Related Macular Degeneration or 
Diabetic Retinopathy (175, 210, 211) considering, in a few instances, self-reported 
difficulties (175, 210). However, one study relied in presumed visual acuity (210) and 
other failed to investigate the effect of self-reported difficulties in informal care (175). 
Other authors reported the use of informal care by people with impaired vision but did 
not used structured and validated questionnaires to assess limitations with daily 
activities. Although, some took in consideration limitation to mobility imposed by vision 
impairment (49, 50). In general, self-reported difficulties have been overlooked in past 
studies so investigating this topic and further research is needed to characterize the use 
of informal care and its predictors in this population.  
The aims of this study were to estimate and characterize informal care use in 




informal care, clinical and socio-demographic aspects. We used a bottom-up approach 
and administered validated questionnaires to a sample of people with impaired vision.  
 
Methods 
Study design, setting and participant selection 
Participants were recruited from 4 public hospitals with ophthalmology 
departments in the north of Portugal between July-2014 and January-2016. Outpatients 
at these hospitals with a latest recorded visual acuity of 0.30 logMAR (6/12) or worse in 
the better seeing eye were invited to take part in face-to-face interviews. Patients were 
invited by letter posted using the hospital mail service, the logo of the hospital was printed 
on the envelope and letters were sent directly to the patients ‘address. All documents 
were printed in font Arial – 16 point. The mail envelope include a letter of invitation signed 
by a physician from the local hospital, an information booklet and a consent form. Despite 
some letters were returned to sender due to incorrect address, we estimate at least 3000 
reached at the patient´s home, 546 returned a signed consent form on a reply-paid 
envelope addressed to Escola Nacional de Saúde Pública, Lisboa (National School of 
Public Health. Lisbon) with an updated phone number. After acceptance participants 
were contacted and an interview was scheduled at the hospital. 
Causes of visual impairment, principal diagnosis and secondary diagnosis, were 
retrieved from clinical records and classified according with the ICD9 CM (International 
Classification of Diseases 9th Clinical Modification) codes. The information was 
registered in a secure platform that is online at www.pcdvp.org.  
This study has been designed according to guidelines published by the 
Vancouver Economic Burden of Vision Loss Group (158). The study was conducted in 
accordance with the tenets of the Declaration of Helsinki, reviewed and approved by the 
ethical committee for Life Sciences and Health of the University of Minho and local ethics 
committees at Centro Hospitalar São João, Hospital de Braga, Centro Hospitalar do Alto 
Ave and Hospital de Santa Maria Maior. Written informed consent was obtained from all 
participants. Further details about the study have been described in our previous 
publications (212).  
Clinical measurements during face-to-face interviews 
Patients answered a functional vision questionnaire, the Activity Inventory (AI), to 
assess visual ability. The AI is an adaptive visual function questionnaire designed to 
provide an individualized assessment of difficulties of a visually impaired respondent 
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when performing valued activities. Disabilities, or activity limitations according to the 
World Health Organization’s International Classification of Functioning, occur when an 
individual reports abnormal difficulties in achieving important goals. Difficulties achieving 
a goal are said to depend on the difficulty experienced in the tasks that underlie each 
goal (165-168). In our translated version of the Massof activity inventory patients were 
questioned about difficulties with 46 goals and the “difficulty” responses were Rasch 
analysed to produce a continuous measure of visual ability given by the variable ‘person 
measure’ (Program Winsteps. v3.9) (167, 213). We use the term ‘visual ability’ to define 
the overall ability to perform activities that depend on vision (8). 
Participants also reported comorbidities based on a list of 16 categories as 
described in Appendix 6. Visual acuity with the habitual correction was re-assessed in 
both eyes separately using an internally illuminated ETDRS chart (Lighthouse 
International. NY. USA) at 4. 2 or 1 meter – the measuring distance was adjusted 
according with the severity of the expected vision loss. The room lights where 
extinguished during measurements. Letter by letter scoring was employed to specify final 
measured acuity (212). 
Informal care questionnaire and cost estimation 
A questionnaire to collect information about informal care was administered by 
trained researchers. We asked information about the use of informal care within a 2-
week recall time period. This period has been proposed by others to minimise recall 
biases (171, 172). The questionnaire was drawn from previously validated instruments 
(172, 173), it underwent pilot testing and revisions to clarify wording, to simplify data 
recording and to remove redundant items. The final version of the questionnaire is 













Table 21 - The table summarises the questions used to collect information 
about sociodemographic information and the use of informal care. In all questions, 
there was one option with: do not know or do not want to answer (not shown in the 
table for simplicity). 























1. What is your marital status? 
a) Single 
b) Married or living as married 
c) Divorced or separated 
d) Widowed 
e) Other (please specify) 
2. What best describes your living 
environment? 
a) Live alone 
b) Live with spouse (including children) 
c) Live with parents 
d) Live with children (sons / daughters)  
e) Live with other relatives 














3. Over the last two weeks have you 
been helped and/or cared for by a relative 
or friend because you have poor vision? 
b) Yes (ask question 3.1) 
c) No 
3.1. Over the last two weeks how many 
relatives or friends provided you care? 
Number of caregivers  
3.2. Over the last two weeks how many 
hours were spend by caregivers to help 
you? 
Number of hours 
3.3 What is the main occupation of the 
persons providing you care?  
 
a) Paid job 




f) Other (please specify) 
 
Informal care costs represent a monetary estimate of the hours spend by informal 
caregivers to help visually impaired persons. To estimate the economic impact of 
informal care we used the opportunity costs in which time spent providing informal care 
is valued based on competing time use, in this case paid labour. This method is 
commonly used for these estimates including in eye care and rehabilitation studies (174, 
175, 207, 214). The number of reported hours were extrapolated from 2 weeks to 12 
months. Total informal care costs were calculated by multiplying the number of annual 
hours by the mean Portuguese hourly wage rate of full time employees in the year 2014 





Statistical analysis  
Descriptive statistics was used to summarize socio-demographic and clinical 
characteristics of the participants. Participants were divided into 4 age categories: (1) 39 
years or younger; (2) 40-64 years; (3) 65-79 years; (4)80 years and older. Causes of 
visual impairment were divided in 11 categories (see Table 22). Visual acuity was used 
either as continuous variable or categorical variable whichever was deemed more 
appropriate. 
Chi-square tests were used to compare the composition of groups. T-tests were 
used to compare visual ability between groups and the Mann-Whitney–test or Kruskal-
Wallis was used for other non-parametric comparisons between groups. Spearman 
Correlation was used to determine the association between variables. 
Logistic regression was used to determine explanatory factors associated with 
the use of informal care. Linear regression was used to determine factors associated 
with the amount of informal care needed (intensity of care). A description of the models 
is provided in Appendix 7. Statistical analysis was performed with SPSS Statistics (IBM 
SPSS Statistics v.23). 
Results 
A total of 546 participants were included in this study, from those 216 (39.6%) 
reported informal care needs. The sample comprised a high percentage of old 
individuals, 50% (n=275) were older than 65 years. The most common causes of visual 
impairment were: diabetic retinopathy, age-related macular degeneration (AMD), 
glaucoma and other retinal disorders and detachments. Participants were divided in 2 
groups: “users” and “non-users” to identify sociodemographic and clinical independent 
predictors of the use of informal care. We compared the distribution of cases, between 
groups, according with several categories. These results are summarized in Table 22. 
The proportion of women and participants with comorbidities was higher in the users 









Table 22 - The socio-demographic and clinical characteristics of study 
participants (n=546). 
  Informal Care  
 Users  
n = 216 
 Non-users  
n = 330 
Group 
comparison  
n  (%) n  (%) 













Age categories (years)         Chi-
square=1.36; 
p=0.714 
- 39 years or younger 16 7% 32 10% 
- 40 to 64 92 43% 131 40% 
- 65 to 79 85 39% 136 41% 








- Not Married 91 42% 110 33% 








- Live alone 25 12% 35 11% 
- Live with others 191 88% 295 89% 
Cause of Visual 
impairment 
(principal diagnosis) 
        Chi-
square=12.9; 
p=0.228 
- Diabetic Retinopathy 82 38% 115 35% 
- AMD 20 9% 44 13% 
- Glaucoma 27 13% 32 10% 
- Other Retinal 
Disorders and 
Detachments 
25 12% 27 8% 
- Cornea 13 6% 28 8% 
- High Myopia 13 6% 28 8% 
- Cataracts 4 2% 15 5% 
- Disorders of Choroid 9 4% 8 2% 
- Optic Nerve 
Disorders 
9 4% 10 3% 
- Disorders of Globe 5 2% 4 1% 








- Yes 117 54% 160 48% 








- Yes 164 76% 218 66% 
- No 52 24% 112 34% 
 
Table 23 summarizes and compares visual ability and visual acuity in informal 
care users and non-users. Visual ability and visual acuity (both in the better eye and in 




Table 23 - Visual ability (person measures) and distance visual acuity of users 
and non-users of informal care in the sample. SD = standard deviation; IQR = Inter-
quartile range 
 
Informal care Group Comparison 
Users  Non-users 
Visual ability  (logits) 
Mean (SD)  -0.51 (1.48) 1.6 (2.01) t-test=14.1; 
p<0.001 Median (IQR) -0.52 (1.83) 1.42 (2.95) 


























Table 24 summarizes the results of a logistic regression to determine predictors 
of the use of informal care. Marital status, comorbidities, visual acuity, and visual ability 
were independent predictors of the use of informal care. When the odds ratio (OR) 
reported in Table 24 is less than 1, the reciprocal is used here in the text for consistency 
of interpretation. Non-married individuals were 1.85 times more likely to use informal 
care. Individuals with comorbidities were 2.17 times more likely to use informal care than 
those without.  An additional unit of visual acuity in the better eye increases the odds of 
using informal care 3.2 times (1 unit of visual acuity =1 LogMAR; higher values of acuity 
correspond to higher level of impairment). One unit reduction in visual ability increase 
the odds of using informal care 2.22 times (1 unit of visual ability = 1logit; lower values 
of visual ability are associated with increased difficulty to perform tasks that rely on 
vision). The deviance chi-squared goodness (residual deviance = 463.706; 524 degrees-
of-freedom) of fit test confirmed an excellent fit of the model. p=0.96.  
Table 24 - Explanatory variables of informal care usage. In the first column, 




95% C.I. for Odds 
Ratio p-value 
Lower Upper 
Gender (Male versus Female) 0.87 0.55 1.38 0.545 
Marital Status (not Married versus 
Married) 
1.85 1.14 2.99 0.013 
Presence of other comorbidities (No 
versus Yes) 
0.46 0.27 0.77 0.003 
Visual Acuity 3.2 1.71 6 <0.001 





Among those who needed informal care, 60% reported having only one caregiver 
and the main activity of the caregivers was homemaker (the person whose principal role 
is to do housework and other domestic concerns). The median number of caregiver 
hours was 390 hours per year and the mean number of caregivers’ hours was 470 hours 
per year (95%CI=488.1-406.6) which represent a median cost of €2,585.7 per year. 
Therefore, in our sample of 206 cases (10 out of the initial 216 cases were considered 
outliers) that would correspond to 92,144 hours of informal care per year, resulting in an 
annual cost of €610,915.0. 
The number of caregivers’ hours was statistically different between categories of 
vision impairment (Kruskal-Wallis=10.86; p-value=0.012). Categories: 1) visual acuity 
from 0.3 logMAR to 0.5 logMAR; 2) visual acuity from 0.51 logMAR to 1.0 logMAR; 3) 
visual acuity from 1.02 logMAR to 1.3 logMAR and 4) visual acuity from 1.32 logMAR 
and 3.0 logMAR. The pairwise comparison showed that participants in categories 1 and 
2 needed less informal care than participants in categories 3 and 4 (Mann-Whitney 
U=3200; p=0.002). These results show that the use of informal care tends to increase 
with the severity of vision impairment. Differences between groups according with 
gender, causes of visual impairment, presence of comorbidities, marital status and living 
arrangement were not statistically significant.  
There was a negative association between visual ability and the amount of 
informal care used, Spearman´s rho = -0.381(p<0.001). This means that lower visual 
ability was associated with increased use of informal care (intensity). Table 25 
summarizes results of the multiple linear regression analysis used to investigate 
predictors of the intensity of use of informal care. Visual ability was the only statistically 
significant independent predictor (p<0.001). These results show that one-unit change in 
visual ability corresponds, per year, to a variation of 67 hours in the intensity of informal 
care. The model also includes as explanatory variables age, gender and severity of 
visual impairment (2 categories) that were not statistically significant. The R-squared of 








Table 25 - Explanatory variables of intensity of use of informal care. In the first 




B Std. Error 
Visual ability -66.99 14.81 <0.001 
Age 0.93 1.28 0.468 
Gender (male) 48.70 38.64 0.209 
Severity of Visual Impairment (visual 
acuity in the better eye above 1 
logMAR) 
74.79 46.75 0.111 
Discussion 
In this study, we quantified and characterized the use of informal care in a sample 
of 546 visually impaired individuals. Informal care was reported by 39.6% of the 
participants requiring, each, a median of 390 hours of informal per year. Based on the 
median values, that corresponds to an estimated 92.000 hours per year for our 216 
users. The use of informal care was influenced by marital status, comorbidities, visual 
ability and acuity. The intensity of use of informal care was negatively associated with 
visual acuity. However, lower visual ability was the only predictor of higher informal care 
utilisation intensity after controlling for age, gender and severity of vision impairment. 
The percentage of informal care users found in our study is similar to other studies 
(49, 210). Some authors reported that 39.3% of participants with best corrected visual 
acuity worse than 20/40 (or 41 letters in the ETDRS chart) use community or family 
support (49). Others found that 36% of AMD patients use paid or unpaid assistance 
(210). The estimated intensity of use (amount of caregiver hours) per-week per individual 
in our sample was 9 hours. This value is between the 4.7 and the 17.4 reported in other 
studies (210, 211). 
The use of informal care was affected by marital status and comorbidities but not 
by gender. Non-married participants were more likely to report informal care, this may 
be because they cannot rely on their partners and the need to ask for help is more clearly 
defined for them. Those married not reporting may be because, although they rely in 
their partners for some tasks, they see any help received as a natural gesture of mutual 
help between members of a couple. It is also intuitive that those with other comorbidities 
face further difficulties in their daily life and therefore are more likely to require informal 
care. In a univariate analysis gender seemed to be a predictor but that effect disappeared 
in the logistic regression. This result is in contrast with some studies reporting that 




influenced by many factors and, in particular, by the organization of the society (207). 
Therefore, our results need to be interpreted in the Portuguese context and can be 
eventually applicable to similar societies (215). 
Visual ability was the only independent predictor of the intensity of use of informal 
care after adjusting for age, gender and severity of vision impairment. The association 
between visual ability and informal care shows a link between self-reported task 
difficulties and the amount of help needed. Others reported an effect of visual acuity; 
however, these studies did not considered self-reported levels of visual ability (50, 175, 
216, 217). We recognize that visual acuity gives a partial measure of visual performance 
and that the inclusion of a broader spectrum of visual tests, such as contrast sensitivity 
or visual field, could provide a better understanding of the association between visual 
performance and informal care. This would be particularly true in cases of impaired vision 
caused by diseases such as retinitis pigmentosa in which acuity is preserved but severe 
functional limitations are imposed by restricted visual fields. In line with our results, Wang 
et al. (49) found an increase in intensity with increased self-reported walking difficulties. 
Keefe et al (214) reported that people with impaired vision need help for vision-
dependent activities such as driving, reading documents and support for independent 
activities outside home. These are the tasks covered by the activity inventory to 
determine visual ability. In short, visual rehabilitation tailored to increase visual ability is 
likely to reduce simultaneously the use of informal care and its intensity. These findings 
suggest that the use of instruments such as the AI during clinical assessment would help 
to target resources at those with the greatest caring needs. 
One of the methodological dilemmas of this study was how to collect information 
about informal care. We used a questionnaire, the most common method, with a short 
recall time period to minimize recall bias (174, 207). Informal care is a frequent event 
and is known that, contrary to unusual events such as an inpatient stay at a hospital, 
short recall periods increase the accuracy of the reports (171, 218). Some participants 
may, accidentally, extend or reduce recall periods or we might have collected data during 
seasonal changes in the needs of informal care; however, this factors are unlikely to lead 
to systematic error in our estimation (218). Other factors, such as treatments or disease 
changes can alter visual acuity – a 2 week recall period may be beneficial to capture the 
informal care needed according with the acuity that we measured. Nevertheless, using 
a short recall period may result in an underestimation of the use of informal (171). 
Keeping a diary would minimize this limitation but would be significantly more expensive 
and time consuming (207, 219). In addition, the amount of missing data and the 
complexity of the information available may increase substantially with a diary (220, 221). 
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Thus, the method adopted can eventually lead to a conservative estimation of informal 
care usage. Conversely, to estimate the economic impact of informal care we used 
opportunity costs which can inflate the costs because it includes 6 caregivers that were 
retired. The method and value used in our study was used previously in various analysis  
(174, 175, 207, 214) and is within the interval used in studies using the opportunity cost 
method (176, 207). Therefore, it seems appropriate and ensures comparability with 
others studies (175, 214).  
Our participants were recruited at hospitals and therefore our sample includes 
only patients seeking eye care. Considering that informal eye care is used by patients 
who are under treatment or have stable eye diseases (207, 209, 214) we believe that 
the results reported can be generalized to all the Portuguese population with vision 
impairment. However, information about the characteristics of the Portuguese population 
with impaired vision is lacking and therefore there is no evidence to confirm this 
generalization. In addition, we compared the profile of patients who responded our 
questionnaire and those that declined participation and found some differences. For 
instance, we found that participation in our study was influenced by gender, distance to 
the hospital, number of years of education, number of visits to the hospital per year, 
marital status and visual acuity. This means that the profile of our participants was 
different from those declining participation. 
In summary, this study provides a comprehensive analysis of use of informal care 
in persons with impaired vision. In the context of the reviewed literature, this study is the 
first to show a strong link between self-reported ability and the use of informal care in 
large multi-centre study in an European country. Visual ability was a predictor of the use 
of informal care and the intensity of care. Therefore, visual rehabilitation interventions, 
alongside with usual eye care may reduce the economic burden of visual loss at personal 














5.1.3 - Productivity losses and their explanatory factors amongst people 
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Purpose: To estimate productivity losses amongst people with impaired vision in 
Portugal and to investigate explanatory factors associated with participation in the labour 
market.  
 
Methods: A total of 546 visually impaired individuals participated in face-to-face 
interviews. Participants were asked about their workforce participation (employment 
status questionnaire), health-related quality of life - HRQoL (EQ-5D) and about visual 
ability (Activity Inventory). Logistic regression was used to determine independent 
factors associated with participation in the labour market. 
 
Results: Fifty percent (50%) of the participants were retired. 47% were within working 
age and 3% were students. The labour force participation rate was 28% and the 
unemployment rate was 21% to the working age sample and 13% and 10% respectively 
for the total sample. For the sub-group within the working age productivity losses were 
estimated at €1.51 million per year (mean €5496 per participant.) The largest contributor 
for losses was reduced workforce participation estimated from 159 early retired or 
unemployed participants. After controlling for visual acuity and ability, younger 
individuals, with more years of education, without comorbidities and high HRQoL had 
higher chances of being employed. 
 
Conclusions: Vision impairment can cause disability and that can lead to significant 
productivity losses. The probability of being employed was associated with education. 
HRQoL and comorbidities. We speculate that promoting education and health through 
effective visual rehabilitation programs may be crucial to increase access to the labour 
market. These findings need to be considered when acting to reduce the burden of vision 












People with impaired vision are likely to have disability because reduced vision 
imposes barriers to acquisition and development of skills and abilities (10, 35, 55, 222-
224). Disability caused by vision impairment limits the ability to perform valued activities 
for example driving (225) or reading documents without the help of special devices or 
software (225, 226). In addition to the direct impact on health related quality of life 
through the impact on people’s ability to perform activities of daily living and self-care, 
difficulties to perform vision related tasks can also cause extra stress and anxiety in 
persons with impaired vision (227). These events may not only impact on health, but also 
alter the chances to find and retain jobs, reduce the range of jobs in which people with 
impaired vision can work (227-230), or may lead individuals to never look for a job or 
leave workforce prematurely leading to lower productivity among people with impaired 
vision (230). Being able to have a paid job is important to most individuals living in 
society. For example, work provides opportunities for maintaining or increasing one’s 
financial independence enables relationships and social inclusion and increases quality 
of life (231, 232). It is therefore important to understand the causes of reduced 
employment amongst people with impaired vision for both the financial and health burden 
for the individual and for the society. 
From the economic perspective, the burden for the society is captured by 
productivity costs. Productivity costs can be defined as “costs associated with production 
loss and replacement costs due to illness, disability and death of productive persons, 
both paid and unpaid” (233). Productivity costs can incorporate several components 
leading to different concepts and calculations. In this work, we consider two components: 
absenteeism and reduced workforce participation. These are considered two of the most 
relevant components of productivity costs and major contributors to the total costs of 
vision impairment. (144) Working with limitations due to illness, or presenteeism, is a 
further component of impaired productivity. However there is no consensus on the 
measurement of presenteeism meaning that it is rarely included in economic calculations 
of productivity costs (234). 
For those in the labour market absenteeism can be defined as the number of 
workdays lost due to health related issues (235). For those in working age, but out of the 
labour market, reduced workforce participation can be defined as production missed due 
to the premature exit of the labour market (136). Some studies found high productivity 
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costs and high rates of unemployment, job loss and early retirement amongst persons 
with vision impairment (144, 150, 153-155, 236).  
From our perspective, the information available from studies published in the past 
decade has some limitations in two aspects: 1) the samples studied were too restricted 
and 2) the explanatory factors used lacked accuracy. For example, one study used self-
reported vision impairment (236),other used exclusively blind individuals (153) and other 
used an unclear definition of vision impairment (154). When explaining productivity costs 
past studies also left out one or both of two relevant measures: patient-reported levels 
of visual ability and the impact of vision loss in quality of life (153-155, 236). We argue 
that employment has an impact on both productivity and health and therefore it is 
important to include measures of patient-reported HRQoL when investigating 
productivity. The type of patient-reported measures referred are likely to influence the 
ability to look for jobs and to retain them. Therefore we decided to include them when 
studying productivity costs. 
The aim of this study was to estimate productivity costs and investigate their 
explanatory factors in people with vision impairment. We collected information about 
employment status and analysed socio-demographic factors, patient-reported measures 
and clinical aspects that can be explicative of employment.  
 
Methods 
Study design, setting and participant selection 
Participants were recruited from 4 public hospitals with an area of influence of 
nearly 2 million inhabitants divided into 3 regions in Portugal: Porto, Braga and Viana do 
Castelo. Patients attending medical appointments at the department of ophthalmology in 
these hospitals with latest recorded visual acuity of 0.30 logMAR or worse were invited 
to take part in face-to-face interviews. Principal diagnosis, designated by causes of vision 
impairment, and secondary diagnosis, were retrieved from clinical records and classified 
according with the International Classification of Diseases 9th Clinical Modification codes 
(ICD9 CM). From clinical records we have also collected information about gender, date 
of birth and systemic diseases. The information was registered in secure platform that is 
online at www.pcdvp.org.  
The study was conducted in accordance with the tenets of the Declaration of 
Helsinki, approved by the local ethics committees of the participant hospitals and by the 




informed consent was obtained from all participants. More details about the study have 
been described in our previous publications (212, 237). 
Clinical and quality of life measurements during face-to-face interviews 
During face-to-face interviews patients were asked to respond to the EuroQol EQ-
5D 3 level (EQ5D-3L) to classify their perceived health-related quality of life (HRQoL). 
The EQ-5D is a generic preference-based measure of HRQoL that has five domains: 
mobility, self-care, usual activities, pain or discomfort, anxiety and depression (presented 
in Appendix 2). Each dimension is rated on a three-point scale with categories “no 
problems.” “some problems.” or “extreme problems.” producing a descriptive health 
profile. Respondents’ health states were converted to health utility scores using 
valuations derived from the general population in Portugal (170).  
Additionally, patients responded to a vision function questionnaire, the Activity 
Inventory (AI), to measure their visual ability.  The AI is an adaptive visual function 
questionnaire designed to provide an individualized assessment of difficulties of a 
respondent with impaired vision when performing valued activities (presented in 
Appendix 1). Participants are asked to rate goals which dependent on the difficulty 
experienced in the tasks that underlie each goal (165-168). Responses are then Rasch 
analysed to produce a continuous measure of visual ability given by the variable ‘person 
measure’ (Program Winsteps. v3.9). The term ‘visual ability’ defines the overall ability to 
perform activities that depend on vision (8). 
During the interview, visual acuity was (re)measured using an internally 
illuminated ETDRS chart (Lighthouse International. NY. USA) at 4. 2 or 1m according 
with the severity of the (expected) vision loss. Letter by letter scoring was employed to 
specify the final measured acuity (212).  
Comorbidities were also reported by participants and/or extracted from the clinical 
records and classified according with the 16 categories listed in Appendix 6. 
 
Productivity losses questionnaire 
We used a questionnaire administered by trained researchers and collected 
information about absenteeism and workforce participation. The questionnaire was 
drawn from previously validated instruments (172, 173). We conducted a pilot test to 
simplify data recording, to remove redundant items and to clarify words and questions. 
The questionnaire was written and administrated in Portuguese. Table 26 summarizes a 
translated version of the questionnaire.  
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Table 26 - Questions used to collect information about sociodemographic 
information and absenteeism. Absenteeism questions were applicable to participants in 
the working age range (17-64 years). In all questions there was 1 option with: do not 
know or do not want to answer 























1. What is your marital status? 
a) Single 
b) Married or living as married 
c) Divorced or separated 
d) Widowed 
e) Other (please specify) 
2.  How many years of education 
do you have? 
a) Up to university 3rd cycle (PhD) 
b) Up to university 2nd cycle (Master) 
c) Up to university 1stcycle (undergraduate)  
d) Up to 12 years of education 
e) Up to 9 years of education 
f) Up to 6 years of education 
g) Up to 4 year of education 
3. What best describes your living 
environment? 
a) Live alone 
b) Live with spouse 
c) Live with parents 
d) Live with child 
e) Live with other relatives 
f) Live with others 
4. What is your employment 
status? 
a) In full-time work  
b) In part-time work  
c) Currently seeking work 
d) Homemaker 
e) Retired 
f) Early retired 
g) Student 
h) Other (please specify) 
5. Please provide an estimate of 
your month household income from 
all sources (after tax and other 




a) less than €485* 
b) between € 485 and €1000 
c) above €1000 
 
*this is the national minimum monthly 











For those reporting employment 
(part-time or full-time) we asked 2 
questions 
 
6. Over the last two weeks how 
many hours per week do you spend 
working?  
Number of Hours 
 
7. Over the last two weeks how 
many days have been absent from 
work owing to your visual condition? 
Number of days 
- For those reporting two weeks of 
absenteeism in the last two weeks we 
asked 
7.1 How long were you in sick 
leave? 
 
a) less than three months 




The societal perspective was adopted to estimate productivity costs. Productivity 
costs encompass: absenteeism and reduction in workforce participation.  
Absenteeism was measured by the number of absent workdays due to health 
problems. The annual costs of absenteeism were calculated by converting the reported 
working days missed due to vision impairment into hours and then valued using the 
average hourly pay rate obtained by the three categories of income level reported by the 
participant. We extrapolated the 2-week recall period to an annual level multiplying by 
24 working weeks adjusting for annual leave and public holidays. Absenteeism was 
divided into short term absenteeism and long term absenteeism. Long term absenteeism 
includes all the individuals that reported being absent for more than three consecutive 
months. All the other cases were considered short term absenteeism. 
Reduced workforce participation (RWP) refers to the loss of production caused 
by having people with impaired vision out of the labour market. In Portugal, individuals 
(men or women) outside the age-range 17-64 are considered to be in mandatory 
education (less than 17) or retired (more than 65) (238, 239). RWP was calculated for 
participants within the working age 17-64 years that reported early retirement or 
unemployment due to impaired vision. It was calculated as the excess unemployment 
compared to the unemployment rate adjusted by sex and age of active population in 
Portugal in 2014 (reported by Eurostat) and the unemployment rate observed by sex and 
age in our sample. These two figures were in turn applied against the mean Portuguese 
monthly wage adjusted by sex and education level. More details about these 
assumptions are shown in Appendix 8. Some participants were out of the labour market 
categorized as homemaker and others (which includes students and other reasons not 
specified) that were not considered in this estimation because it can be a choice of the 
individual and therefore cannot be attributable to vision impairment.  
Statistical analysis  
Descriptive statistics regarding sociodemographic and clinical participant 
characteristics were analysed. Participants were divided into 4 age categories: (1) 17-39 
years. (2) 40-64 years and (3) 65-79 years; (4) 80 years or older. Causes of vision 
impairment were divided into 8 categories.  
Chi-square tests were used to test differences between participants working and 
non-working. Categorical binary variables included gender, secondary diagnosis and 
comorbidities. Independent t-tests were performed to compare visual ability and Mann-
Whitney tests were performed to compare visual acuity in the better eye and in the worse 
eye and HRQoL. 
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Logistic regression was used to determine explanatory factors associated with 
participation in the labour market. The dependent variable was employment status in 
working age participants (non-working = 0; working =1). Independent predictors were: 
age (categories: 40-64 years=0; 17-39 years=1); Education (categories: less than12 
years of education = 0; 12 years of education or more=1), comorbidities (categories: No 
= 0; Yes =1), visual ability (continuous predictor provided by the AI), visual acuity in better 
eye (continuous predictor using a logMAR scale) and HRQoL (continuous predictor 
provided by the EQ-5D). The graphic method was used to validate assumptions of the 
model for residuals independence and to identify extreme cases that were removed from 
the model (whenever it increases the goodness of fit of the model). Multicollinearity was 
analysed with variance inflation factor (VIF). Statistical analyses were conducted with 
SPSS Statistics (IBM SPSS Statistics v.23. for Windows). 
Results 
From the 546 participants. 47% (n=254) were within the working age. 50% were 
retired and 3% were students. Of those within working age 28% (n=71) were working 
full-time or part-time and 72% were not working because required early retirement 
(n=105), were unemployed (n=54), were homemakers (n=14), were students (n=4) or for 
reasons not specified (n=6). The labour force participation rate was 28% and the 
unemployment rate was 21% for those within the working age and 13% and 10% 
respectively for the all sample. Diabetic retinopathy, high myopia and diseases of the 
cornea were the major causes of vision impairment amongst participants within working 
age. We divided the group within working age in two subgroups: “working” and “non-
working” and compared the characteristics of the groups. These results are summarized 
in Table 27. 
The group of participants working had a higher proportion of individuals within the 
age group 17-39 years (p=0.023), a higher proportion of participation with up to 9 years 
of education or more (p=0.007) and a lower proportion of participants with other 
comorbidities (p=0.037) when compared with the non-working group. There were 
difference in causes of vision impairment between groups (p=0.003). The working group 
had a smaller proportion of patients with diabetic retinopathy and a higher proportion of 







Table 27 - The socio-demographic and clinical characteristics of study 
participants within the working age (n=254) 
  Working age participants  
Working 
n = 71 
Non-working 
n = 183 
Group 
comparison 
n  (%) n  (%)  













Age categories (years) Chi-
Square=5.2; 
p=0.023 
17 to 39 14 20% 17 9% 
40 to 64 57 80% 166 91% 




Do not Know/Do not answer 0 0% 12 7% 
Up to university 1st cycle 
(undergraduate) or more  
9 13% 6 3% 
Up to 12 years of education 9 13% 19 10% 
Up to 9 years of education 16 23% 32 17% 
Up to 4 years of education 37 51% 114 62% 
Marital status       Chi-
Square=1.1; 
p=0.301 
Not Married 20 28% 64 35% 
Married 51 72% 119 65% 
Living arrangement       Chi-
Square=1.5; 
p=0.219 
Live alone 3 4% 16 9% 
Live with others 68 96% 167 91% 




Diabetic retinopathy 16 23% 77 42% 
Other Retinal Disorders  7 10% 16 9% 
Cornea 13 18% 16 9% 
High Myopia 13 18% 16 9% 
Glaucoma 3 4% 15 8% 
Optic Nerve Disorders 2 3% 10 6% 
AMD 8 11% 6 3% 
Others 9 13% 27 14%  
Secondary eye diagnosis       Chi-
Square=1.5; 
p=0.214 
Yes 28 39% 88 48% 
No 43 61% 95 52% 
Other Comorbidities       Chi-
Square=4.4; 
p=0.037 
Yes 39 55% 126 69% 
No 32 45% 57 31% 
 
Table 28 summarizes visual ability, visual acuity and HRQoL in both groups, 
working and non-working. The median visual acuity in the better eye was higher in the 
non-working group (z-test= -2.03; p=0.042) meaning higher severity of vision 
impairment. The non-working group reported lower health-related quality of life (z-test= 




Table 28 - Visual ability, distance visual acuity and health related quality of life 
characteristics of the participants within working age (n=254) 
 Working age   
             Working Not-working Group Comparison 
Visual ability (Activity Inventory)  
Mean (SD)  1.78 (1.8) 0.55 (2.0) t-test=-45.04; 
p<0.001 Median (IQR) 1.91 (2.89) 0.30 (2.43) 














Mean (SD)  
0.52 
(0.43) 1 (0.77) 
0.69 













(0.60) 1 (1.10) 
Health Related Quality of Life (EQ5D Score) 
Mean (SD)  0.65 (0.29) 0.48 (0.28) z-test=-4.17; 
p<0.001 Median (IQR) 0.66 (0.55) 0.45 (0.38) 
a In a logMAR acuity scale higher values of acuity correspond to higher level of 
impairment 
 
Absenteeism was reported by 28 individuals out of 71 (39%). In total 22.296 hours 
of work were lost over 1 year, which represents a productivity costs of 102 thousand EUs 
based on the average hourly pay rate obtained by the income level reported by the 
participants. Long term absenteeism (absent for more than 3 consecutive months) 
reported by 8 individuals accounted for 15.840 hours of work lost. 71% of hours of work 
lost and 65% of the absenteeism costs. The distribution of costs of absenteeism was 
skewed to the right with a median of €1.635 and a mean of €3.646 (95%CI = [5.125; 
2.167]). 
RWP was estimated for 159 participants, early retired or unemployed, and 
represented an annual cost of 1.4 million EUs with a median of €9.151 and a mean of 
€8.855 (95% CI= [9.517; 8.194]) per participant. 
Results of the logistic regression with predictors of participation in the labour 
market are summarize in Table 29. HRQoL (p-value<0.001), age (p-value=0.013), 
education (p-value=0.027) and comorbidities (p-value=0.004) were independent 
predictors of employment status.  
A change of 1 unit of HRQoL measured by EQ-5D score is associated with odds 
of being in the labour market of 162.6. Since the EQ-5D score maximum value is 1, our 
results show that a change of 0.1 unit of health utility increase correspond to odds of 
being in the labour market of 16.3. The odds of being employed for individuals within the 




odds of being employed for individuals with 12 or more years of education was 2.7 higher 
than for individuals with less than 12 years of education. The odds of being employed for 
individuals with comorbidities were lower than for those without comorbidities. The 
deviance goodness of fit test confirmed an excellent fit of the model to the data (p-value 
= 0.99). 















17-39 years  40-64 years  3.93 1.33 11.61 0.013 
Education level 
12 years of 
education or 
more 
less than 12 
years of 
education 





0.29 0.12 0.67 0.004 
Visual acuity  0.35 0.08 1.53 0.163 
Visual ability  0.96 0.72 1.29 0.795 
Health Related 
Quality of life 
 
162.6 17.49 1511.87 <0.001 
 
Figure 18 shows the probability of participation in the labour market as a function 
of HRQoL (EQ-5D utility score) for 2 scenarios: best-case and worst-case, details of the 
computations are given in Appendix 9. The best-case scenario includes participants 
within the age 17-39 years, 12 years of education or more, no comorbidities and visual 
ability set as constant equal to the mean value of the group. Five curves were computed 
according to 5 categories of vision impairment. With acuity in logMAR, categories were: 
1) No VI= [-0.3.0.3]; 2) Minor VI=[0.32.0.5]; 3) Moderate VI=[0.5.1.0]; 4) Severe 
VI=[1.02.1.3]; 5) Profound VI or blind=[1.32. 3.0]. The worst-case scenario is defined as 
participants within the age 40-64 years, less than 12 years of education, comorbidities 




Figure 18 - Predictive probability of participation in the labour market as a 
function of health-related quality of life divided into 5 categories of vision impairment. A) 
best-case scenario, B) worst-case scenario. Best case scenario includes: participants 
within the age 17-39 years, 12 years of education or more, no comorbidities and setting 
visual ability as constant equal to the mean value of the group. Worst case scenario 
includes: participants within the age 40-64 years, less than 12 years of education, with 
comorbidities and visual ability the same as in the best scenario 
 
In both scenarios higher levels of HRQoL and better acuity increased the 
probabilities of being employed. For example, with a health utility of 0.6 given by the EQ-
5D utility score, in the best-case scenario, more than 34% of the participants would be 
employed against 1% in the worst-case scenario. In the worst-case scenario the 
probabilities of being employed ranged from 0 to 0.4. The maximum value of 0.4 was 
observed in participants included in category 1 (No VI) and with the highest possible 
score for level of HRQoL. In the best-case scenario, the probabilities of being employed 
ranged from 0.1 to 0.97. Here, the probability of participants in category 5 (Profound VI 
or blind) to be employed can reach more than 0.8. This is in contrast with the worst-case 
scenario in which persons with these levels of impairment would have a probability of 
employment around 0.07.  
Discussion 
In this study we quantified and characterized productivity losses in a sample of 




were working. Productivity losses would correspond to an estimated €1.51 million per 
year for this sample (median of €4.399 and mean of €5.495 (95% CI=[5.292; 6.598] per 
participant). The largest portion of losses were due to RWP estimated from a sample of 
159 individuals that were either unemployed or early retired due to vision impairment. 
The logistic regression model, controlling for visual acuity and visual ability, showed that 
individuals within the age range of 17-39 years, 12 or more years of education, no 
comorbidities and reporting higher HRQoL had higher probability of employment. 
Our rate employment of 28% was smaller than expected when we compared with 
the 38% employment rate for people with disabilities reported by Eurostat in 2015 and 
even smaller when compared with the 68% employment rate for people without 
disabilities (64% in Portugal)  (177, 240). However, the report of Eurostat is unspecific 
about the type of disability. In a Portuguese report considering only participants from the 
Portuguese blind association (ACAPO) the percentage of employed participants was 
33% which is in line with our findings (241). Our employment results are also in line with 
results reported by others. Rein found a gap of 41% in employment rates between people 
with impaired vision and the general population (136). In our sample the gap between 
people with impaired vision and the employment rates of the active population in the 
country was 36%.  
Several studies, adopting a top-down approach, reported RWP as the major 
contributor to productivity costs (136, 139). Through our bottom-up approach RWP also 
emerged as the main driver of productivity costs. Similar to our results, Cruess and 
colleagues, which adopted a top- down approach, also reported absenteeism costs that 
were substantial lower than RWP costs (140).  
Younger and more educated people with impaired vision are more likely to be 
employed. We found that the probability of being employed was higher in the age group 
17-39 years. These results are in line with the findings of previous studies showing that 
job loss occurs more frequently at older ages and that the duration of unemployment is 
longer for older individuals (156, 242). In our sample individuals with education of 12 
years or more had higher odds of being employed compared with less educated 
individuals which is consistent with the findings of other studies (154, 243). Therefore, 
we speculate that education is an important modifiable factor that can increase the level 
of participation in the labour market amongst people with vision impairment. 
The severity of vision impairment, as measured by visual acuity, and the 
proportion of individuals with other comorbidities was higher in the non-working group. 
Others found that more severe impairment and the presence of comorbidities were 
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associated with a lower probability of employment (154, 243, 244). However, in our 
study, in the logistic regression analysis only the presence of comorbidities showed 
statistically significant effect in employment status. Visual acuity had an odds ratio of 
0.35 (p-value=0.163), which points to a tendency to individuals with lower visual acuity 
(higher values in logMAR scale) having lower chances of participation in the labour 
market. While this effect was not significant, the trend is similar to the previous findings. 
We included patient-reported measures in our regression analysis to explain the 
employment status. The EQ-5D used to assess health-related quality of life includes 
questions about anxiety and depression and pain and discomfort which are known 
factors associated with the ability to work (245-247). Visual ability measured by the AI 
allowed us to incorporate also difficulties performing vision related tasks (168). Whilst 
the effect of visual ability was not statistically significant we found that EQ5D utility score 
was a strong predictor of employment and therefore of RWP. This possibility was also 
being raised in other studies who tried to predict absenteeism and presenteeism using 
EQ5D (248). Given this strong effect of the EQ5D utility score we performed the 
simulation with the equations given in Appendix 9 and obtained the scenarios shown in 
Figure 18. The results of the scenarios show that by increasing the perceived HRQoL 
the levels of participation can change for the same level of vision impairment. We cannot 
infer causality from this association and, indeed, the effect of HRQoL on employment 
may run in both directions: higher HRQoL may improve the chance of employment and 
higher employment may improve HRQoL. Regardless of causality, the benefits of 
enabling those with low vision to participate in the workforce are likely to lead to both 
productivity and health benefits. These findings should be taken in consideration when 
planning initiatives to promote inclusion of people with impaired vision in the labour 
market. This also shows how important is to monitor and prevent other health related 
aspects of people with impaired vision. 
We must acknowledge that the relationship between HRQoL and productivity 
losses is a controversial topic in economic evaluation (243, 249). Some authors consider 
that taking productivity loss as costs and quality of life as an outcome can be double 
counting because these two measures may capture the same reality (158, 250). Whilst 
this issue is important when interpreting estimates of productivity losses incorporated in 
cost-effectiveness studies our study was not designed to provide contributions for this 
discussion and it is addressed in detail elsewhere (251-253). 
A possible limitation of our study is lack of indicators about presenteeism which 




burden of visual impairment  found that in 5 studies that estimated indirect costs and 
productivity losses only 1 included presenteeism (144). There is no consensus on the 
best instruments to reliably measure presenteeism and empirical research showed that 
the use of different instruments can lead to large differences in outcomes (235, 254). 
Accordingly to the references used by Cruess (140) if we assumed an estimated of 
15.7% for reduced productivity at work our estimate of productivity costs (considering 
absenteeism and reduction in workforce participation) would increase in less than 8%, 
so the impact of presenteeism in our sample may not be substantial.  
Vision impairment can cause disability and that can lead to significant productivity 
losses. In our sample the main driver of these losses was reduced work participation. 
The probability of having impaired vision and being employed was associated with 
modifiable factors such as: education, HRQoL and comorbidities. We speculate that 
promoting education and health amongst persons with impaired vision through effective 
rehabilitation programs may be crucial to increase their access to the labour market, 
which can lead to productivity and health benefits. Our results provide information that 





5.2 - Additional research findings 
Material in this Chapter has been published Acta Ophthalmologica and BMC 
Ophthalmology. 
 
5.2.1 - Visual and health outcomes, measured with the activity inventory 
and the EQ5D, in visual impairment 
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Purpose: Generic instruments to assess health utilities can be used to express the 
burden of health problems in widely used indexes. That is in contrast with what can be 
obtained with condition-specific instruments, outcomes are very specific and difficult to 
compare across conditions. The purpose of this study was to assess health and visual 
outcomes and its determinants in patients with visual impairment (VI) using the EQ-5D-
3L and the Activity-inventory (AI). 
Methods: Participants were recruited in different hospitals during the PCVIP-study. A 
total of 134 patients with acuity 0.30 logMAR or less in the better eye were interviewed. 
The AI includes 46 goals split between three objectives: social functioning, recreation 
and daily living, was used to measure visual ability. The EQ-5D consists of five questions 
covering one domain each and was used to provide a measure of health states. 
Responses to each domain were combined to produce a single individual index.  
Results: The AI and the EQ-5D-3L showed enough discriminatory power between VI 
levels (p<.001) and their results were strongly correlated r(134)=.825, (p<.001). 
Explanatory factors for visual ability were level of VI in better eye, age and gender, 
R2=.43, (p<.001). Explanatory factors for the EQ-5D-3L were level of VI in the better eye, 
comorbidities and gender, R2=.36, (p<.001).  
Conclusions: Our results showed that the EQ-5D-3L is useful when characterizing the 
burden of VI and to compute, when necessary, quality-adjusted-life-years (QALY) 
changes due to VI. However, is important to consider that the EQ-5D-3L uses a coarse 
response scale, assesses a limited spectrum of domains and is influenced by 





Patient reported outcome measures are fundamental for evaluation of health 
technologies or interventions (255). To perform a complete assessment of the benefits 
of a health intervention, it is necessary to provide evidence of the effect of intervention 
on patients’ health status and/or health related quality of life. The type of instrument used 
to measure outcomes of health interventions must be designed to serve the specific 
requirements of the study question or the proposed application. Instruments to assess 
patient reported outcome measures can be divided into several categories, however, the 
divisions should not be regarded as rigid or mutually exclusive (256). The present study 
compares the performance of two categories of these measures, health utility and 
functional ability measures, in visually impaired patients.  
Health utility measures express preferences or values attached to individual 
health states as a single number. Instruments commonly used to collect data on utilities 
include the EuroQol-EQ-5D (227, 257-259), the SF-6D (164, 259), the Geriatric 
Depression Scale (260) and other rating scale questionnaires. Health utilities typically 
are estimated from time trade-off (261) or standard gamble methods (262), or from one 
of several stated-preference methods (e.g., discrete choice (263), pairwise comparison 
(264), best-worst scaling (265), or iterative bidding games (266) ). Health utilities are 
used to provide estimates of the overall value of health states to the individual and/or to 
society and are used in cost-utility analyses. 
To simplify data collection, all likely combinations of ratings of the five items in the 
EQ-5D-3L, each of which represents a different health state, have been mapped to 
community-based health utilities by a representative sample of the community population 
using a time trade-off method (170). Therefore, the EQ-5D-3L can be administered as a 
rating scale questionnaire and a utility tariff, corresponding to the pattern of responses 
to the 5 items, can be looked up in a table (or estimated from an algorithm). The assigned 
utility values then can be used to estimate quality-adjusted life-years (QALYs) (267). 
However, it often has been suggested that the EQ-5D-3L can have unreliable and 
unresponsive outcomes in the case of visual disorders (162, 268). 
The intent of health utilities is to have the scale referring only to the value of health 
states and not be disease-specific. The EQ-5D-3L, like most instruments, do not include 
items responsive to the effects of vision disorders when assessing health states. In the 




approach has been criticized because it overestimates the utility of vision relative to that 
of overall health (269, 270).  
Condition-specific (individualised) health state assessment instruments have item 
content targeted to specific symptoms and/or quality of life consequences, with many 
allowing respondents to select relevant items and/or rate the importance of each item 
(256). Self-report instruments used to assess visual functioning include the National Eye 
Institute Visual Functioning Questionnaire (NEI-VFQ) (271), the Impact of Vision 
Impairment Questionnaire (IVI) (272), and the Activity Inventory (AI) (166-168). In our 
study the AI was adopted to estimate person measures, mostly because it has been 
developed and used specifically for individuals with low vision and we had access to the 
item calibration file (8, 166, 167). The advantage of using an instrument calibrated with 
hundreds of low vision individuals is that the interaction between person's "ability" and 
item’s "difficulty" can be modulated. A strength of such individualised self-report 
instruments is that they address the concerns of individual patients rather than impose 
community standards that may not be well-informed or well-targeted to the patient 
population of interest. Although sometimes criticized by strict methodologists, in the case 
of assessing the effect of visual impairment or the impact of low vision rehabilitation, it 
often is necessary to administer self-report visual functioning assessment instruments 
by interview because of the patients’ vision limitations.  
Given the high and growing prevalence and incidence of visual impairments from 
age-related eye diseases, policy makers need evidence about the burden of visual 
impairment in order to develop effective and inclusive public health strategies (273). For 
example, with the aging of the population and elevated risks of adverse health events, it 
is necessary to know the impact of vision impairment on health states and the cost-utility 
of low vision rehabilitation. In many European countries, Portugal in particular, these two 
topics remain poorly studied. A recent exhaustive critical review of the relevant literature 
concluded that more cost-effectiveness studies are necessary in order to understand the 
effectiveness of current low vision rehabilitation practices (273). Without evidence of 
cost-effectiveness of interventions intended to tackle the burden of visual impairment, 
two scenarios are likely: i) decision makers will reduce the availability of resources for 
this purpose or ii) allocated resources might be poorly managed due to undefined 
priorities. Therefore, for the correct evaluation of the burden of visual impairment it would 
be desirable to use generic instruments to make estimated patient preferences directly 
comparable to other health state preferences. 
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The use of generic instruments to access health preferences of visually impaired 
people remains uncommon, but seems necessary. For example, Malkin and colleagues 
recently conducted one of the few studies to use a generic health state instrument, the 
EQ-5D-3L, to assess both the health utility of visual impairment and the impact of low 
vision rehabilitation (162). The authors concluded that the EQ-5D-3L was unresponsive 
to low vision rehabilitation, a conclusion supported by the results summarized by Tosh 
and colleagues who concluded that the EQ-5D-3L might have limited ability to distinguish 
between groups of patients, stratified by acuity, suffering from age-related macular 
degeneration or diabetic retinopathy (162, 268). These studies demonstrate that the use 
of health utility measures with visually impaired patients requires further investigation, in 
particular to determine which factors other than visual acuity can influence health utilities 
in visually impaired people. 
The purpose of our study was to investigate if the EQ-5D-3L and the AI have 
equivalent ability to discriminate between visual impairment categories and which factors 
can affect those measures. We hypothesize that generic (EQ-5D-3L) and condition-
specific (AI) instruments have different abilities to discriminate between levels of visual 
and that each instrument is influenced by a different set of visual and non-visual factors. 
METHODS 
 
Participant recruitment and data collection 
Participants were recruited in three public hospitals as a part of a study of 
prevalence and costs of visual impairment in Portugal (PCVIP-study). Outpatients at 
these hospitals with visual acuity, measured with latest refractive correction prescribed, 
in the better seeing eye of 0.30 logMAR or lower were invited to take part in face-to-face 
interviews. Visual acuity was assessed using an internally illuminated ETDRS chart 
(Lighthouse International, NY, USA) at 4, 2 or 1m according with the severity of their 
vision loss. The room lights where extinguished during measurements. Letter by letter 
scoring was employed to specify final measured acuity (274).  
During interviews participants were asked about 16 systemic health problems 
detailed in Appendix 6 that are consistent with those assessed in other studies (96, 275). 
Demographic information and other descriptive information for our sample of 134 
participants is summarized in Table 31. All questionnaires were administered during the 





The present study was conducted in accordance with the tenets of the Declaration 
of Helsinki, reviewed and approved by the ethical commission for Life Sciences and 
Health of the University of Minho and hospitals ethics committees. Written informed 
consent was obtained from all participants. 
 
Functional reserve given by the Activity Inventory 
The Activity Inventory (AI) is an adaptive visual function questionnaire designed 
to provide an individualized assessment of difficulties of a visually impaired respondent 
when performing valued activities. The AI consists of a hierarchal structure in which 
specific cognitive and motor vision-dependent tasks (e.g., pouring or mixing without 
spilling) underlie more global goals (e.g., preparing meals). Disabilities, or activity 
limitations according to the World Health Organization’s International Classification of 
Functioning, occur when an individual reports abnormal difficulties in achieving important 
goals (165). Difficulties achieving a goal are said to depend on the difficulty experienced 
in the tasks that underlie each goal (166). The investigators translated the AI into 
Portuguese (213). In the Portuguese version 46 goals divided among three objectives 
(social functioning, recreation and daily living) were used. Respondents first rated the 
importance of each goal with four possible responses ranging from “not important” to 
“very important”. Goals rated “not important” were skipped, for goals rated “slightly 
important” or above participants were asked to rate the goal’s difficulty on a five-point 
scale ranging from “not difficult” to “impossible to do”. The “difficulty” responses were 
Rasch analysed to produce a continuous measure of visual ability given by the variable 
‘person measure’ (Program Winsteps, v3.9). We use the term ‘visual ability’ to define the 
overall ability to perform activities that depend on vision. Visual ability is likely to be 
affected by other conditions apart from visual impairment such are chronic pain, fatigue 
or depression (161). 
Utility Values given by the EQ-5D-3L 
The EQ-5D-3L is a generic instrument for preference-based measures of health 
and is expected to provide a measure of health status (257, 276). The EQ-5D-3L consists 
of five questions, each describing a different health state domain. The five domains are 
mobility (D1), self-care (D2), usual activities (D3), pain or discomfort (D4) and anxiety or 
depression (D5). Difficulties in each domain are classified using a 3-point scale: 1= “no 
problems”, 2= “some problems” and 3= “extreme problems or unable”. A respondent’s 
overall health state is then defined by a vector representing the level for each domain; 
the combination of answers to 5 domains can generate 243 (35) unique vectors 
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representing overall heath states. For example, the heath state vector [11111] would be 
generated by someone who does not have difficulty in any domain, whilst [32211] would 
be the responses of someone unable to move, some problems in self-care and usual 
activities and no problems in the last two domains. Each response vector is then 
transformed to a health utility using the EQ-5D-3L index for which 0 corresponds to a 
state over which immediate death is preferred and 1 corresponds to the state of “perfect 
health”. A negative value would correspond to a health state “worse than dead”. Utility 
index values used here were obtained from Ferreira and colleagues who published 
community tariffs for the EQ-5D-3L in the Portuguese population (170). During the 
questionnaire administration, clear instructions were given to consider difficulties 
associated with visual impairment. 
Categories of visual impairment 
Visual impairment was categorized according to the guidelines of the International 
Council of Ophthalmology using visual acuity intervals on a logMAR scale (7). In a 
logMAR scale, acuity can be calculated by adding the number of letters read considering 
a score of 0.02 per correct letter. For example, in an ETDRS chart designed to measure 
distance VA at 4m, the top line corresponds to acuity 1.0 logMAR. Letters can be used 
to compute acuity using the formula: VA=1.1–0.02xNL, where NL represents the number 
of letters read (Table 30). 




Variables were tested for normality using the Kolmogorov-Smirnov test. ANOVA 
was used for multiple comparisons and t-test was used to compare two distributions 
when the variables were normally distributed. Kruskal-Wallis or Mann-Whitney U tests 











0.30 logMAR (0.5 decimal) -0.30 logMAR 0 
Minor VI 0.50 logMAR (0.32 decimal) 0.32 logMAR 1 
Moderate VI 1.00 logMAR(0.10 decimal) 0.52 logMAR 2 
Severe VI 1.30 logMAR (0.05 decimal) 1.02 logMAR 3 




was rejected for alpha values less than 0.05, when necessary Bonferroni correction was 
applied (0.05/number-of-comparisons). Associations between variables were tested with 
Pearson correlations when both variables were continuous and Spearman’s rank-order 
correlation when any of the variables was ordinal. Descriptions of correlations ranged 
from “very weak” (0.0-0.19) to “very strong” (0.8-1) using Swinscow’s classifications 
(277). Vision specific tools for quantifying visual ability and generic utility measures need 
to be compared with caution. But comparisons have been tried in the past because they 
are necessary to gather information about the overall impact of vision loss in health (164, 
278). To investigate whether final scores of our instruments were associated with the 
same factors we conducted a regression analysis using as explanatory factors: age, 
gender, visual impairment level in the better and in the worse eye and number of 
comorbidities. We included the level of visual impairment in the worse eye because a 
study from Finger and colleagues in 2013 has shown that this could be relevant to explain 




The ratio of male to female participants was 0.97. The median age of participants 
was 65.5 years (IQR: 55.7-74.2), five participants were less than 18 years old. For 
minors, when necessary, parents or guardians served as proxies for the interview. The 
median acuity in the better eye for the sample was 0.54 logMAR (IQR: 0.38-0.85) and 
was 1.02 logMAR (IQR: 0.64-1.68) for the worse eye, a more detailed summary is given 












Table 31 - Demographic characteristics of the participants and descriptive statistics 















Gender      
Male 66 [49%] 0.518 [0.281] 0.45 [2.03] 0.63 [0.31] 1.30 [0.84] 
Female 68 [51%] 0.368 [0.322] -0.09 [1.92] 0.75 [0.58] 1.24 [0.76] 
P value ---- 0.005 0.11 0.77 0.73 
Age (years)      
Below 40 10 [8%] 0.509 [0.297] 0.24 [1.38] 0.81 [0.56] 1.16 [0.78] 
41-80 116 [86%] 0.433 [0.321] 0.22 [2.07] 0.69 [0.47] 1.25 [0.81] 
Above 80 8 [6%] 0.491 [0.138] -0.59 [1.02] 0.54 [0.26] 1.68 [0.72] 
P value ---- 0.69 0.53 0.51 0.20 
Level of VI Better Eye      
1 60 [45%] 0.596 [0.281] 1.34 [1.85] 0.37 [0.06] 0.88 [0.63] 
2 50 [37%] 0.393 [0.270] -0.20 [1.29] 0.69 [0.13] 1.27 [0.65] 
3 24 [18%] 0.160 [0.220] -1.96 [1.38] 1.50 [0.52] 2.26 [0.58] 
P value ---- <0.001 <0.001 <0.001 <0.001 
Level of VI Worse Eye      
1 20 [15%] 0.669 [0.261] 1.85 [1.76] 0.35 [0.04] 0.40 [0.06] 
2 46 [34%] 0.511 [0.301] 0.80 [1.63] 0.50 [0.15] 0.76 [0.15] 
3 68 [51%] 0.329 [0.282] -0.74 [1.79] 0.92 [0.55] 1.87 [0.69] 
P value ---- <0.001 <0.001 0.001 <0.001 
Cause of VI       
DR 54(40) 0.410 [0.309] -0.26 [1.71] 0.74 [0.47] 1.33 [0.81] 
Other RD 30(22%) 0.421 [0.341] 0.57 [2.33] 0.66 [0.35] 1.32 [0.83] 
AMD 15(11%) 0.529 [0.296] 0.38 [1.83] 0.50 [0.26] 1.23 [0.74] 
Glaucoma 10(7%) 0.310 [0.258] -0.53 [1.68] 0.66 [0.31] 1.32 [0.88] 
Corneal disease 8(6%) 0.490 [0.322] 0.15 [2.23] 0.58 [0.37] 1.25 [0.97] 
Cortical/ON 13(10%) 0.495 [0.299] 0.59 [2.27] 1.03 [0.81] 1.16 [0.81] 
Cataract 4(3%) 0.719 [0.162] 2.21 [1.21] 0.34 [0.04] 0.69 [0.34] 
P value ---- 0.22 0.08 0.019 0.56 
Number of 
comorbidities 
     
0-3 100 [75%] 0.479 [0.294] 0.28 [1.85] 0.68 [0.39] 1.28 [0.76] 
3-6 34 [25%] 0.333 [0.334] -0.13 [2.36] 0.73 [0.65] 1.37 [0.90] 
P value ---- 0.017 0.30 0.31 0.85 
 
Results of visual ability scores 
 
Rasch analysis of AI difficulty ratings generates a single interval-scaled value for 
each person, the “person measure”, for which higher values correspond to higher levels 
of visual ability. The mean visual ability person measure across all participants was 0.17 
logit (SD=1.99). Table 31 provides a summary of these results and the distribution of 





Figure 19 - Histogram showing the distribution of visual ability person measure 
per age in the all sample 
A three-dimensional scatter plot of visual ability person measures as a function of 
logMAR acuity in the better and in the worse eye is shown in Figure 20. The difference 
between visual ability person measures for different groups, defined by the visual acuity 
in the better eye, was statistically significant, F(2,131)=39.57, (p<0.001; Bonferroni 
correction applied). Similar results for other factors are summarized in Table 31. For 
visual impairment groups 1 and 2 the mean difference between visual ability person 
measures was 1.54 logits (p<0.001); for groups 1 and 3 the mean difference was 3.30 
logits (p<0.001); and for groups 2 and 3 the mean difference was 1.76 logits (p<0.001). 
There was a moderate negative correlation between logMAR acuity in the better seeing 
eye and visual ability person measures, r(134)=-0.573 (p<0.001). This result shows that 
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higher levels of visual impairment given by acuity were associated with lower visual 
ability person measures.  
 
Figure 20 - Scatter plot showing the distribution of visual ability according with 
acuity in the better and worse eye 
 
Results for health states 
The most commonly observed health state vectors for the EQ-5D-3L were [11111] 
(index of 1.000) and [22222] (index of 0.288), reported by 14 participants each. The 10 
most common health state vectors are summarized in Appendix.10 The mean EQ-5D-
3L index for the entire sample was 0.442 (SD=0.311), comparisons between groups are 
given in Table 31. A 3-D scatter plot of the EQ-5D-3L index as a function of logMAR 
visual acuity in the better eye and the number of comorbidities is shown in Figure 21. 
The differences between EQ-5D-3L index for different visual impairment groups, based 
on the acuity of the better eye, tested with ANOVA, was statistically significant, 




and 2 the mean difference was 0.203 (p<0.001), for groups 1 and 3 the mean difference 
was 0.436 (p<0.001) and the mean difference between groups 2 and 3 was 0.233 
(p=0.001). There was a moderate negative correlation between logMAR acuity in the 
better eye and EQ-5D-3L index, r(134)=-0.506 (p<0.001). Higher values of logMAR (i.e., 
lower visual acuities) are associated with lower EQ-5D-3L index. A partial correlation 
between age (controlling for acuity in the better eye) and EQ-5D-3L index also was 
observed, r(131)=-0.183 (p=0.035). The negative correlation indicates that the index 
tends to reduce with age. 
 
Figure 21 - Scatter plot showing the distribution of EQ5D according with acuity 
in the better eye and number of comorbidities 
Comparison between instruments  
We observed a strong correlation between the EQ-5D-3L index and visual ability 
person measures, r(134)=0.779 (p<0.001).  
Factors associated with visual ability person measures  
Multiple linear regression analysis showed that gender, age, level of VI in the 
better eye and in the worse eye are significant independent predictors of visual ability 
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person measures. Basic descriptive statistics and regression coefficients are 
summarized in Table 32; the four predictors account for 45% of the variance in visual 
ability person measures. Those with higher visual acuity in the better eye have higher 
visual ability. The typical difference between visual impairment groups (stratified by 
acuity in the better eye) was approximately 1.4 logits (unstandardized beta coefficients 
in Table 32). Level of visual impairment in the worse eye, does not achieve statistical 
significance in our model (p=0.053).  
Table 32 - Factors associated with visual ability scores (person measures) in a 
multivariate regression model with forward selection of variables 
Predictor Un-standardized 
beta coefficients  


































































a reference category; b result collapsed with the reference category; Excluded 
variables: comorbidities; Multiple R-squared: 0.45; Adjusted R-squared: 0.43; F(5,128) 
= 21.1; p-value < 0.001. 
 
Factors associated with EQ-5D-3L index 
Multiple linear regression analysis showed that gender, level of VI in the better 
eye and number of comorbidities are significant independent predictors of EQ-5D-3L 
results. Basic descriptive statistics and regression coefficients are summarized in Table 
33; the 3 predictors account for 36% of the variance in the EQ-5D-3L index. In agreement 
with the visual ability person measures, those with higher acuity in the better eye had 
shown higher EQ-5D-3L scores. The difference between sequential groups of VI would 
be approximately 0.2. Females and those with 4 or more comorbidities have lower EQ-





Table 33 - Factors associated with EQ5D in a multivariate regression model 
with forward selection of variable 
Predictor 
Un-standardized 
beta coefficients  
p value Standard error 









































a reference category; Excluded variables: age, level of VI worse eye; Multiple R-
squared: 0.38; Adjusted R-squared: 0.36; F(4,129) = 20.01; p-value <0.001; 
 
Figure 22 shows response patterns for the EQ-5D-3L domains when the group 
with 0-3 comorbidities was compared with the group with 4-6 comorbidities; the number 
of people with “no problems” was reduced in all domains. With 4-6 comorbidities, the 
number of cases with some problems increased in D1 (mobility) and D4 (pain and 
discomfort). Also, with 4-6 comorbidities, there was an increased percentage of extreme 
problem for all but D1. The contrast is particularly visible in D3 (usual activities) and D5 





Figure 22 - Change in the percentage of participants reporting no problems 
(blue bars), some problems (orange bars) or extreme problems (grey bars) when 
comparing the group with 0– 3 comorbidities with the group 4–6 comorbidities in each 
of the five domains of the five domains of EQ-5D. D1 (mobility);D2 (self-care); D3 
(usual activities);D4 (pain and discomfort); D5 (anxiety and depression) 
 
DISCUSSION 
This study was conducted to determine which factors affect patient-reported 
measures of health utilities, estimated from EQ-5D-3L responses, and of visual ability, 
estimated from difficulty ratings of activity goals in the activity inventory. Both measures 
were related positively to visual impairment in the better eye. Regression analysis 
suggests that EQ-5D-3L utility index is associated with both, visual impairment level in 
the better eye and the number of reported comorbidities. Visual ability measures are 
associated with age and visual impairment in the better eye. Both utility and ability 
measures are associated with gender. These results are in agreement with the initial 
hypothesis that expected a different set of predictors for each of the two measures. 
However, contrary to initial expectations, results from both instruments were associated 
with visual impairment in the better eye.  
Our results indicate that the EQ-5D-3L index is responsive to visual impairments. 
In that sense, our results agree with previous observations by other investigators using 
the EQ-5D-3L (84, 227) and other health utilities instruments (278, 280). In contrast with 
our results, a study by Lloyd and colleagues found inconsistent associations of utilities 




for patients with acuity 6/12 to 6/18 than for patients with acuity 6/24 to 6/36. As 
suggested by Tosh et al., the association of EQ-5D-3L utility indices with visual 
impairments might depend on the visual disorder studied (268). However, our study 
included a range of disorder diagnoses and we found no evidence of disorder diagnosis 
dependence. van Nispen and colleagues have found index results slightly higher than 
ours in an observational study applying the EQ-5D-3L in mixed causes of VI (84). 
Differences between our results and van Nispen’s might be explained by the distribution 
of causes of VI, level of acuity in the better eye and age. The main cause of VI in their 
study was age related macular degeneration and in our study it was diabetic retinopathy. 
Also, our IQR of acuities was wider and our participants overall were younger compared 
to the van Nispen et al. study (median age of 65 years for our study vs 78 years for their 
study). As reported by others, younger subjects with visual impairment might feel, for 
example, more often anxious or depressed (227, 282). As shown in Appendix 10, 19 of 
our participants reported “severe depression or anxiety” and that was never reported in 
the van Nispen et al. study’s top ten health states. Another additional explanation for the 
difference between studies is that lower EQ-5D-3L utility indices are expected in Portugal 
than in the Netherlands because of differences in community calibrations. Ferreira and 
colleagues found that there is discrepancy between the EQ-5D-3L index in Portugal and 
other countries. Ferreira found mean absolute differences ranging from 0.090, compared 
with Spain, to 0.251, compared with the USA (170).  
Gender and the numbers of comorbidities were predictors of the EQ-5D-3L index. 
The effect of gender that we found in our multiple regression is not commonly observed; 
however, Langelaan et al. did report significance of gender (227) and that is in line with 
what has been found in the general population in some countries (283). Comorbidities 
also had an effect in the EQ-5D-3L; although, during the questionnaire administration 
clear instructions were given to consider difficulties caused only by VI. Generic 
questionnaires use broad questions and they are likely to capture effects of other health 
problems. Some studies have shown that people after stroke tend to report lower EQ-
5D-3L scores than people with VI (227). In our case, sometimes these two conditions (VI 
and stroke) were present in the same participant. As shown in Figure 22, there are 
noticeable changes in response patterns when comparing people with 4 or more 
comorbidities with people with 3 or less. The lack of control for type and number of 
comorbidities can be a problem when applying the EQ-5D-3L. Vision impairment has the 
potential to influence EQ-5D-3L responses only to 4 of the 5 domains: anxiety-
depression, mobility, self-care, and usual activities. Given the coarseness of the 
response scale, it is likely that vision impairment must be strong to affect the response. 
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Effects of co-morbidities combine with visual impairment effects to produce the final 
response.   
 In agreement with previous studies utility results were independent of the cause 
of VI and age (84, 278, 280). However, we observed a partial correlation (controlling to 
acuity in the better eye) between EQ-5D-3L index and age that pointed to some effect of 
age in this index. Langelaan and colleagues reported lower scores for people less than 
41 years compared with people aged 41 years or older. They attributed their result to 
problems in social inclusion faced by young people with VI such as finding a job (227) . 
Contrary to Langelann’s explanation, we consider plausible that lower scores with 
increasing age would be due to unemployment or early retirement that increase 
difficulties in dealing with vision loss (284, 285). Our results indicate that the EQ-5D-3L 
is an instrument that can be used to assess the impact of VI and to compute other 
important measures such as quality-adjusted life-years (QALY). However, its application 
requires caution because visual impairment can affect domains that are not currently 
included in the questionnaire such as sleep quality or concentration (286, 287).   
Results of the Activity Inventory provide a comprehensive assessment of the 
impact of VI. Our results for the AI are in agreement with what other authors found for 
patients with VI due to various causes (8, 288) or VI caused by specific eye diseases 
such as diabetic retinopathy (289). The effect of age on visual ability obtained with the 
AI has been found before and has been explained by the overall physical functioning 
decline explained by aging (8). In addition, the sensitivity of the AI to the effect of VI in 
the worse eye is a further explanation why lower visual ability scores were obtained in 
the older group. Vision in the worse eye of participants with 81 years or older was 
typically very poor, range 0.8-2.7 logMAR, whilst for the other age groups was slightly 
higher, range 0.32-2.7 logMAR. It is understandable that when vision in one eye is 
reduced the visual field tends to be also compromised; severe VI in the second eye is 
likely to increase activity limitations such as mobility due to constriction of the visual field 
(279). This effect seems to be captured by our results because a detrimental effect of 
the level of VI in the worse eye in visual ability was only observed when VI in the worse 
eye was 3 (severe VI or blindness).  
We acknowledge that a higher number of participants would have been ideal to 
have, for example, more subjects in the group with 81 years or more. Another advantage 
of a bigger sample would be a more detailed analysis by type of eye disease and type of 
comorbidity. A limitation that might reduce our explanatory power is that factors 




To conclude, our results show that the EQ-5D-3L is useful when characterizing 
the burden of VI and, when necessary, to compute QALY associated with visual 
impairment. Given the coarseness of the response scale of the EQ-5D-3L, the limited 
spectrum of domains assessed (286) and the influence of comorbidities it might be of 
limited use in vision rehabilitation (162). Further studies are necessary to investigate if 
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Purpose: The characteristics of the target group and the design of an epidemiologic 
study, in particular the recruiting methods, can influence participation. The aim of this 
study was to investigate participation rates and its determinants in epidemiologic studies 
involving participants with impaired vision.  
Methods: Participants were recruited in the context of a study of prevalence and costs 
of visual impairment in Portugal (PCVIP-study). Participants were recruited from 4 
Portuguese public hospitals. Inclusion criteria were: acuity in the better eye from 0.5 
decimal (0.30logMAR) or worse and/or visual field of less than 20 degrees. Recruitment 
involved sending invitation letters and follow-up phone calls. A multiple logistic 
regression model was used to assess determinants of participation. The J48 classifier, 
chi-square and Fisher’s exact tests were applied to investigate the possible differences 
between subjects in our sample. 
Results: Individual cases were divided into 3 groups: immediate, late and non-
participants. A participation rate of 20% was obtained (15% immediate, 5% late). Factors 
positively associated with participation included years of education, annual hospital 
attendance, and intermediate visual acuity. Females and greater distance to the hospital 
were inversely associated with participation.  
Conclusion: In our study, a letter followed by a phone call was efficient to recruit a 
significant number of participants from a larger group of people with impaired vision. 
However, the improvement in participation observed after the phone call might not be 
cost-effective. People with low levels of education and women were more difficult to 
recruit. These findings need to be considered to avoid studies whose results are biased 
by gender or socio-economic inequalities of their participants. Young subjects and those 
at intermediate stages of vision impairment, or equivalent conditions, may need more 











Epidemiologic studies involve collecting data from large number of individuals. 
However, participation rates in such studies, particularly in industrialised countries, have 
been falling in the past 3 or 4 decades. A study in Finland showed a decline in response 
rates from 84% (men) and 85% (women) in 1978 to 59% (men) and 71% (women) in 
2002 (290). High participation is necessary to ensure, for example, that the participating 
group is a representative sample of the population. When recruiting fails, statistical power 
of the results is reduced and conclusions may be distorted (291-294). In order to produce 
reliable outcomes, researchers need to consider possible problems arising during the 
recruitment process and, if possible, control for factors that lead to reduced participation. 
During recruitment general and study-specific challenges arise according with the 
topic and the target population. Some studies have shown that participation rates are 
influenced by: education (participation increasing with the level of education) (295-297)  
gender (women tend to participate more than men) (298-300) and marital status (married 
people participating more than others) (301). Another factor that has been found to 
influence participation is general health, as given by the index of comorbidities (297). 
There are other aspects such as age in which results are less consistent, with some 
studies showing that older people are more likely to participate (298, 299), whilst others 
found higher participation rates among young people (295). Less commonly reported 
determinants include, for example, ethnicity. In a study by Patel et al. black, asian and 
other ethnic minorities were less likely to participate (297). However, in addition to the 
characteristics of the target group, recruiting strategies can also influence rates of 
participation.  
Previous studies have shown that researchers, when contacting prospective 
participants, must sound trustworthy and must take into account the motivations of the 
subject. Slegers and Glass recommend the use of public phone numbers and clear 
references stating that the study is being carried out by a public institution (when this is 
the case), in order to increase credibility (302). They also recommend emphasizing that 
others invited have already responded to the study call and to provide open, clear and 
honest information from the onset (e.g. regarding monetary compensation or possible 
expenses). Personalised letters and reply paid envelopes are also known to improve 
response rates (303). Other researchers investigated the primary reasons to take part in 
epidemiologic studies and concluded that participation is, amongst others, driven by 
moral reasons (302, 304). In contrast, the actual effort required to participate has been 




with the amount of effort that participation requires (305). The findings mentioned so far 
have been reported for studies in general; however, there is a lack of information about 
the profile of people with eye diseases and/or vision impairment (VI) who participate in 
epidemiological studies. Although, there is one study by Rahi et al. which investigated 
the engagement of families with children with VI (306). However, this group was more 
interested in health service barriers for parents with children with VI (306).  
Studies involving directly people with VI have unique characteristics because 
those invited are often elderly and totally or partially dependent on help to complete daily 
activities such as travelling to study sites. This makes participation more unpredictable 
than for many of the studies referred. The purpose of the project from where this study 
originates was to determine the causes of vision impairment amongst patients attending 
outpatient eye clinics. In parallel we also wanted to conduct a cross-sectional study about 
the impact of VI and other clinical and social aspects (212, 237, 307, 308). 
Our goal with this study was to determine the probability of participation as a 
function of personal characteristics, including severity of vision loss. We conducted a 
detailed investigation to distinguish between those who accepted the invitation to take 
part immediately from those who needed further contact before agreeing to participate. 
According to the “continuum of resistance” model, the more contacts a subject requires 
in order to take part in a study, the more similarities he/she shares with non-participants 
(305, 309). The participation model was tested in our sample by comparing those that 
agreed to participate with non-participants. 
We hypothesized that: i) the lower the acuity is the less likely participation is; ii) 
participation is independent of the cause of VI; iii) participation is affected by the distance 
residence-hospital; iv) education increases participation; v) age and gender affect 
participation; vi) annual hospital attendance increases participation. 
To our knowledge this is the first study to investigate participation rates and its 
determinants in research involving people with VI. By studying participant’s profiles, we 
hope to provide a significant contribution to the scientific community when planning 
studies involving people with VI and similar conditions. 
Methods 
Study design 
The prevalence and costs of visual impairment in Portugal (PCVIP-study) was a 
hospital-based study whose aim was to determine, prevalence, causes and costs of VI 
in Portugal. The study gathered demographic, clinical, and economic information of 
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people with VI. Participants for this report were recruited at 4 Portuguese public 
hospitals; patients with VI attending outpatient appointments at each of the hospitals for 
a period of 12 months were invited to participate in the study. The inclusion criteria were: 
patients with visual acuity (VA) in the better eye of 0.5 decimal (0.30logMAR) or worse 
and/or visual field less than 20 degrees. Cases were entered in a database by qualified 
and trained clinical staff. The database is online at www.pcdvp.org. The study protocol 
required inviting patients to attend an in-hospital appointment with the research team for 
face-to-face interviews and additional visual measurements. The study was designed 
considering the recommendations of the Vancouver Economic Burden of Vision Loss 
Group (158). Basic demographic information was collected from administrative 
databases at the hospital. Information included: subject´s initials, date-of-birth, gender, 
and place of residence (“concelho”, in Portuguese, equivalent to district in many 
countries).  
Participants 
Letters were posted using the hospital mail service, the logo of the hospital was 
printed on the envelope and letters were sent directly to the patients’ address. All 
documents were printed in font Arial- 16 point. The mail envelope included a letter of 
invitation signed by a physician from the local hospital (1 page), an information booklet 
(3 pages), a consent form (1 page) and a reply- paid envelope addressed to Escola 
Nacional de Saúde Publica, Lisboa (National School of Public Health, Lisbon). 
Information was printed on both sides of the paper; consent forms were printed on the 
reverse side of the invitation letter. In addition to information about investigators, 
institutions, contact details and clinicians involved in the study the letter contained a clear 
and isolated sentence (in Portuguese) with the instruction: “If you agree to take part in 
this study, please tick the boxes in the flipside of this sheet, sign at the bottom of the 
page and provide a valid contact number for us to book your appointment at the hospital”.  
If a response was not received within 2 weeks, a follow-up phone call was made. 
Calls were made by an experienced hospital staff member trained and informed about 
the study with instructions to ask the following questions: i) did you receive our letter? ii) 
If yes, can I provide any further information about the study and the letter? iii) Would you 
be interested in taking part in this study? If the person declined the invitation to 
participate, they were asked questions about: 1) years of education; 2) marital status; 3) 
annual hospital attendance. 
For positive respondents, an appointment was booked at the hospital where they 




take part in the study are defined as “participants” and those that declined after all 
attempts are defined as “non-participants”. Those that dropped out after initially agreeing 
were not included in either of these categories. Participants were divided into 2 sub-
grougps: “immediate participants” - those who sent the reply paid envelope with the 
consent form without being contacted by phone, and “late participants” - those who 
agreed to take part in the study only after they were contacted by telephone. 
Data analysis 
A database was built with information about: age, gender, distance between 
residence and hospital where the participant was recruited (DISTH), years of education 
(EDU), marital status (MST), visual acuity in the better eye (VA), annual hospital 
attendance (AHATTEND), cause of vision impairment (CAUSE-VI), Charlson 
comorbidities index (CCI). Information about causes of vision impairment and 
comorbidities to compute CCI was retrieved from medical records. The CCI measures to 
which extent an individual is affected by comorbidities (310). 
Univariate differences in participation rates according to the independent 
categorical variables were assessed using chi-square tests. DISTH, EDU and CCI are, 
unless otherwise stated, continuous variables and the remainder are categorical. 
Multiple logistic regression (R data analysis software, v3.2.4 for Windows) was used to 
determine the effect of independent variables in participation rates. The final model was 
built upon a database with 600 individuals and the fit quality was firstly measured also 
within such database. That is, the sample was both the training data and the testing data. 
In addition, an internal validation of this model was performed, a 10-fold cross-validation 
using the logistic classifier of Weka 3.8. 
Results 
For the current study a group of 2130 individuals were contacted by letter. Of the 
initial 2130 letters sent, 31 were returned to sender and 349 individuals agreed to 
participate immediately (17% of 2099). Of these, 49 individuals eventually dropped out 
of the study for health reasons or transportation difficulties (the study only covered travel 
expenses up to 15 euro), this resulted in 300 immediate participants (15% of 2050).  
Phone calls were made to 1750 non-respondents in order to invite them to 
participate; 89 were unreachable by phone. From the 1661 contacted by telephone 84 
(5%) agreed to take part. Therefore, the final number of participants was 384 (20%) out 
of 1961 that could be successful reached by letter and/or phone call. 
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In total, 600 individuals (260 females or 43%) with a mean age of 66 years 
(SD=16.7) were included in this sample. In our analysis 325 (54%) were participants and 
275 (46%) were non-participants. Non-participants analysed are a random sample of the 
total (1577) selected from successive cases in our list with all the required information. 
From the 384 participants only 325 were included in this report because the remaining 
59 were waiting for the interview.  
The median CCI for the entire sample was 0.6 (IQR=1.8), amongst participants 
was 0.8 (IQR=1.75), for non-participants was 0.5 (IQR=1.5); this difference was not 
statistically significant (Mann-Whitney, U=1110, p=0.45).  
The median EDU in years for the complete sample was 4 (IQR=3), for participants 
was 4 (IQR=5), for non-participants was 4 years (IQR=1); this difference was statistically 
significant (Mann-Whitney, U=63752, p-value < 0.001).The number of years of education 
can be considered low but is expected for the age and geographical location of the 
participants (197). 
The median DISTH (in kilometres) for the complete sample was 9.6km 
(IQR=24.2), for participants was 1km (IQR=15.1) and for non-participants was 19.4 km 
(IQR=38.7); this difference was statistically significant (Mann-Whitney, U=24416, 
















Table 34 - Summary of the distribution of 600 subjects included in the analysis. 
Among 600, 325 are participants (immediate or late) and 275 non-participants 
randomly selected from 1577 total non-participants 








Gender            
Male 339 (56.6) 225/114 66.4 <0.001 
Female 261 (43.4) 100/161 38.3 
Age group 
<20 yrs 14 (2.3) 12/2 85.7 0.00535 
20 to <30 yrs 8 (1.3) 6/2 75.0  
30 to <40 yrs 28 (4.7) 27/1 96.4  
40 to <50 yrs 43 (7.2) 34/9 79.1  
50 to <60 yrs 137 (22.8) 80/57 58.4  
60 to <70 yrs 82 (13.7) 52/30 63.4  
≥ 70 yrs 288 (48.0) 114/174 39.6  
Number of Hospital Appointments per year (AHATTEND) 
Low - AHA (≤ 𝟒/ yr)  173 (28.8) 52/121 30.1 <0.001 
Medium - AHA (5 to 9/ yr) 178 (29.7) 86/92 48.3 
High – AHA (≥ 10/ yr)               249 (41.5) 187/62 75.1 
Marital Status (MST) 
Married 261 (43.5) 110/151 42.1 <0.001 
Living together 85 (14.2) 76/9 89.4 
Single 82 (13.7) 56/26 68.3 
Widow 131 (21.8) 48/83 36.6 
Divorced   41 (6.8) 35/6 85.4 
Visual Acuity- decimal scale (VA) 
0 42 (7.0) 26/16 61.9 <0.001 
0.1 80 (13.3) 51/29 63.8 
0.2 105 (17.5) 43/62 40.9 
0.3 87 (14.5) 35/52 40.2 
0.4 129 (21.5) 63/66 48.8 
0.5 157 (26.2) 107/50 68.1 
Aetiology of visual impairment (CAUSE-VI)  
Adult Macular Degeneration 76 (16.0) 31/45 40.8 0.4336 
Diabetic retinopathy 191 (40.1) 110/81 57.6 
Glaucoma 60 (12.6) 26/34 43.3 
Other 149 (31.3) 81/68 54.4 
Multiple or undefined 124   
a Participation here refers to any participation (immediate or late) 
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Table 35 - Summary of the distribution of all cases (n=600) according to 
participation 







Gender            
Male 183 (75.9) 42 (50) 114 (41.4) <0.001 
Female 58 (24.1) 42 (50) 161 (58.6) 
Age group 
<20 yrs 10 (4.1) 2 (2.4) 2 (0.7) 0.0053
5 20 to <30 yrs 2 (0.8) 4 (4.8) 2 (0.7) 
30 to <40 yrs 14 (5.8) 13 (15.5) 1 (0.4) 
40 to <50 yrs 27 (11.2) 7 (8.3) 9 (3.3) 
50 to <60 yrs 43 (17.8) 9 (10.7) 30 (10.9) 
60 to <70 yrs 64 (26.6) 16 (19) 57 (20.7) 
≥ 70 yrs 81 (33.7) 33 (39.3) 174 (63.3) 
Number of Hospital Appointments per year (AHATTEND) 
Low - AHA (≤ 𝟒/ yr)  42 (17.4) 10 (11.9) 121 (44) <0.001 
Medium - AHA (5 to 9/ yr) 70 (29) 16 (19) 92 (33.5) 
High – AHA (≥ 10/ yr)               129 (53.6) 58 (69) 62 (22.5) 
Marital Status (MST) 
Married 75 (31.1) 35 (41.7) 151 (54.9) <0.001 
Living together 76 (31.5) 0 (0) 9 (3.3) 
Single 35 (14.5) 21 (25) 26 (9.5) 
Widow 25 (10.4) 23 (27.3) 83 (30.2) 
Divorced   30 (12.4) 5 (6) 6 (2.1) 
Visual Acuity- decimal scale (VA) 
0 18 (7.5) 8 (9.5) 16 (5.8) <0.001 
0.1 28 (11.6) 23 (27.4) 29 (10.5) 
0.2 33 (13.7) 10 (11.9) 62 (22.5) 
0.3 31 (12.9) 4 (4.8) 52 (18.9) 
0.4 47 (19.5) 16 (19) 66 (24) 
0.5 84 (34.8) 23 (27.4) 50 (18.3) 
Aetiology of visual impairment (CAUSE-VI) 
Adult Macular Degeneration 18 (7.5) 13 (15.5) 45 (16.4) 0.4336 
Diabetic retinopathy 87 (36.1) 23 (27.4) 81 (29.5) 
Glaucoma 17 (7.1) 9 (10.7) 
 
34 (12.4 
Other 58 (24.1) 23 (27.4) 68 (24.7) 





Factors predicting participation using a logistic regression model  
All the results reported in this section compare participants (the group who agreed 
to take part in the study after an invitation letter or letter and a follow-up phone call) with 
the cases of non-participants (the group of cases that declined after both contacts). We 
used a diagnostic test for the multicollinearity of predictors, the variance inflation factor, 
calculated for each predictor. The highest inflation factor was 1.67 for AHATTEND. 
Which means that AHATTEND was slightly correlated with the other predictors; 
nevertheless, this value was below the critical value of 2.5 reported in the literature as 
the tolerable upper limit (311). 
In an initial model, with a binary dependent variable that assigned a value of 1 to 
“participants” and 0 to “non-participants”, some variables were independent predictors of 
participation (see appendix 11).  
Amongst categorical predictors we found an effect for gender (males participated 
more, p<0.001), AHATTEND (participation for AHA-high was different from participation 
for AHA-low, p <0.001), MST (co-habiting, single or divorced individuals were more likely 
to participate than married individuals, p<0.001), VA (individuals with VA of 0.2 or 0.3 
were less likely to participate than blind individuals, p<0.001) and CAUSE-VI (individuals 
with diabetic retinopathy were more likely to participate than individuals with AMD, 
p=0.03).  
Amongst continuous predictors we found statistically significant effects for DISTH 
(participation reduced with increasing distance, p <0.001) and EDU (participation 
increased with the number of years of education, p <0.001). 
The initial set of levels for each categorical variable were based on authors’ 
experience (see appendix 11). For the final model, non-significant variables were 
removed and other levels or categories were defined as summarized in appendix 12. We 
now give an example to explain the rational. In the initial model, appendix 11, we 
observed that the effect of “Medium-AHA” in participation was not statistically different 
(p=0.075) from the reference category “Low-AHA”, therefore we merged these 2 
categories and re-classified cases as “AHA-rare”, appendix 12. Cases classified as 
“High-AHA” in the first model were kept separately because there was a statistically 
significant effect of this category in the model (p<0.001). This category was renamed 
“AHA-frequent” to be consistent with the other category of the variable AHATTEND. 
The variance inflation factor was recalculated for each predictor. The highest 
value obtained was 1.079 for MST, which means that multicollinearity can be ignored. 
Results for the final model are summarized in Table 36. All independent variables 
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considered had a significant effect on the dependent variable. The deviance chi-squared 
goodness of fit test confirmed an excellent fit of the model to the data (p-value= 0.99). 
Table 36 - Multivariate logistic regression model used to predict the probability 
of participation 
Variables/Characteristic  Beta coefficient 
(SE) 




            Female vs. Male -1.27 (0.24) 0.28 (2.23-5.71) <0.001 
Distance to clinic - km 
(DISTH)  
-0.02 (0.004) 0.98 (1.01-1.03) <0.001 
Education – years (EDU)  0.21 (0.04) 1.23 (1.14-1.33) <0.001 
Annual number of hospital visits (AHATTEND) 
            ≥ 10 vs. <10 1.64 (0.24) 5.18 (3.24-8.69) <0.001 
Marital Status (MST)    
Living together vs. Others 






Divorced vs. Others (married, 
single or widowed) 
2.74 (0.56) 15.44 (5.15-
46.27) 
 
Visual acuity (VA)    
    Intermediate (0.2-0.4) 
    vs. extreme (0, 0.1 or 0.5) 
1.10 (0.23) 3.02 (1.92 -4.74) <0.001 
 
The likelihood of participation increased if individuals were male, had AHA-
frequent, had VA-extreme, if they were co-habiting or were divorced, with more EDU and 
less DISTH. Formula 1 and Formula 2 summarize these results: 
𝐿𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 
= −1.71 − 1.27 (𝐼𝑓 𝐺𝑒𝑛𝑑𝑒𝑟 = "𝑓𝑒𝑚𝑎𝑙𝑒") − 0.02𝐷𝐼𝑆𝑇𝐻 + 0.21𝐸𝐷𝑈
+ 1.64 (𝐼𝑓 𝐴𝐻𝐴𝑇𝑇𝐸𝑁𝐷 = "𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑡") + 3.26 (𝐼𝑓 𝑀𝑆𝑇 = "𝑐𝑜 − ℎ𝑎𝑏𝑖𝑡𝑖𝑛𝑔")
+ 2.74 (𝐼𝑓 𝑀𝑆𝑇 = "divorced")




1 + 𝑒𝑙𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟
                              [𝐹𝑜𝑟𝑚𝑢𝑙𝑎 2] 
 
A 10-fold (10 iterations) cross-validation of the prediction model was performed. 
Before the iteration the Weka 3.8 software splits the 600 cases into 10 subsamples (60 
cases each). For each iteration, during the validation process, each sample was chosen, 
at random, once as “testing data”. The remainder 9 (540 cases) were used to generate 




theoretical model which was tested against the real participation results for the 600 
cases. The coefficients of the resulting theoretical model were very similar to those 
summarized in Table 36. The theoretical model classified correctly 484 out of 600 cases, 
with a weighted average precision of 0.809, a weighted average F-Measure of 0.808 and 
a weighted average ROC area of 0.872. If taken together the results of the internal 
validation and the deviance chi-squared goodness of fit, we can say that the model fits 
the real data accurately. 
Table 36 provides the odds ratios (ORs) for study participation. It can be observed 
that, for example, the odds of a man participating in the study was 3.57 times higher than 
the odds of a woman.  
The model expressed in Formula 1 and Formula 2 was simulated using Matlab 
(v2014b, Matworks inc.). The simulation allows the visualization of the probability of 
participation estimated by the model for extreme cases.  
According with the final model, the worst profile regarding the probability of 
participation, was being female attending the hospital 10x or less a year, married, single 
or widowed, with VA 0.2-0.4. The best profile was being male; attending the hospital 10x 
or more a year, living in a non-marital partnership, and VA 0.1 or 0.5. The model was 
implemented for these two situations as a function of the continuous variables distance 






Figure 23 - Variation of the probability of participation predicted by our model 
according with the continuous variables DISTH and EDU. The two surfaces represent 
the most favourable and less favourable participation profiles defined according with 
the categorical variables used. The top yellow surface represents a male, with AHA-
frequent, living together, with VA-extreme. The bottom blue surface represents a 
female, with AHA-rare, married single or widow, with VA-intermediate 
 
In both cases the probability of participation increases when the distance 
residence-hospital decreases and education increases.  
For the best profile and for distances 0-150km, the participation probability 
reduces slowly. That is, the distance residence-hospital is almost irrelevant within the 
range 0-150km. For distance values greater than 150km the probability of participation 
decreases sharply. When living over 150km away from the hospital, distance would be 
a big barrier for participation, in particular for those with less than 10 years of education.  
Amongst individuals with the worst profile for participation, the distance-residence 
and hospital had little impact for those with less than 10 years of EDU; for EDU greater 
than 10 years the distance residence-hospital is an important factor for participation only 




The group with the best profile would always have a minimum participation 
probability of approximately 40% and the worst profile group a maximum participation 
probability of approximately 60%. 
Comparison between immediate participants (Ipar) and late participants (Lpar) 
Here we report results of a comparison between two sub-groups of participants 
(participants = Ipar+Lpar). Ipar = accepted to participate when invited by letter only; Lpar 
= accepted to participate after letter followed by a phone call.  
We found that the percentage of Lpar+Ipar was significantly higher than Ipar only 
(McNemar’s test, p<0.001). This shows that the number of participants increased 
significantly after the follow-up phone call. We investigated if there was a difference 
between Ipar and Lpar for the demographic aspects summarized in Table 37. 
Table 37 - Categories used to analyse differences between immediate (Ipar) 
and late participants (Lpar) and between late and non-participants (Npar) 
AGE  AGE1 = age less than 40 years 
 AGE2 = age between 40-69 years 
 AGE3 = age 70 or more years 
AHATTEND  AHA-rare = number of annual hospital appointments less than 10 
 AHA-frequent = number of annual hospital appointments 10 or more 
EDU EDU1 = less than 12 years of education 
EDU2 = 12 or more years of education 
DISTH DISTH1 = if distance residence-hospital was less than 40 Km 
DISTH2 = if distance residence-hospital was 40 Km or more 
VA VA-extreme; includes VA of 0.0 or 0.1 or 0.5 VA-intermediate; 
includes VA of 0.2 or 0.3 or 0.4 
MST 1 = Married; 2 = Together; 3 = Single; 4 = Widow; 5 = Divorced 
GENDER 1 = Male; 2 = Female 
 
To build the categories defined in Table 37, first we investigated the existence of 
optimal cut points for the variables using the J48 classifier (Weka 3.8). The resultant 
decision tree is shown in Figure 24  in which the oval nodes represent random variables 
and rectangular nodes represent decisions or predictions. This classification model has 
a weighted average precision of 0.821, a weighted average F-Measure of 0.813 and a 
weighted average ROC area of 0.792. With this method we can predict that a widow man 
will be an immediate (Ipar) instead of a late (Lpar) participant. It also predicts that an 




Figure 24 - Classification tree originated by the C4.5/J48 algorithm predicting 
immediate and late participation 
The decision about which demographic aspects would be compared was based 
on 3 criteria applied according with the sequence presented here: (1) specific hypothesis 
that the researchers wanted to test, (2) the cut-off points resulting from the J48 classifier 
analysis and (3) the number of subjects in each category.  
The percentage of males in the Ipar was 76% (183 of 241) and in the Lpar was 50% 
(42 of 84); the distribution by gender was different in both groups (chi-square=20.21, 
df=1, p<0.001).  
The percentage of males in the AGE1 group was 12% (22 of 183) amongst Ipar 
and 40% (17 of 42) amongst Lpar (chi-square=19.3, df =1, p <0.001, after Bonferroni 
adjustment). For males with AGE2, the percentage was 56% (102 of 183) amongst Ipar 
and 31% (13 of 42) amongst Lpar (chi-square=7.3, df=1, p =0.006, after Bonferroni 
adjustment).  
The percentage of participants with AHA-rare within the group of those who are 
males and AGE2 was 46% (47 of 102) amongst Ipar and 15% (2 of 13) amongst Lpar 
(Fisher´s exact test, p=0.04). 
The percentage of participants with EDU1 within the group of those who are 
females, AGE2 and AHA-frequent was 95% (18 of 19) amongst Ipar and 60% (6 of 10) 
amongst Lpar (Fisher´s exact test, p=0.036).  
Comparison between late participants (Lpar) and non-participants (Npar) 
Here we report an analysis comparing Lpar with Npar (Npar = those decline 
participation after two invitations). We wanted to investigate if the the profile of Npar and 




should be similar in both sub-groups. This analysis is similar to the one performed in the 
previous section. The J48 classifier originated the decision tree shown in Figure 25. 
 
Figure 25 - Classification tree originated by the C4.5/J48 algorithm late 
participation and non-participation 
This classification model has a weighted average precision of 0.801, a weighted 
average F-Measure of 0.803 and a weighted average ROC area of 0.688. The classifier 
predicts that someone younger than 40 that is not an Ipar will be a late participant (LPar) 
instead of a non-participant (NPar).The classification tree was used to define the levels 
summarized in Table 37. It was upon these levels that differences between Lpar and 
Npar were formally investigated. 
The first finding was a difference in age between Lpar and Npar. The percentage 
of individuals with AGE1 was 20% (17 of 84) amongst Lpar and was 2% (5 of 275) 
amongst Npar (Fisher´s exact test, p<0.001). For those in the group AGE3 the proportion 
was 39% (33 of 84) amongst Lpar and 63% (174 of 275) amongst Npar (chi-
square=12.82, df=1, p<0.001). The percentage of DISTH1 subjects within the group of 
those who are AGE2 was 97% (32 of 33) in Lpar and 78% (76 of 98) in Npar (Fisher´s 
exact test, p=0.009).  
The percentage of individuals with EDU1 within the group AGE2 was 73% (24 of 
33) in Lpar and 98% (96 of 98) in Npar (Fisher´s exact test, p<0.001). The percentage 
of individuals with EDU1 within the group of those who are AGE3 was 88% (29 of 33) in 
Lpar and 96% (167 of 174) amongst Npar (Fisher´s exact test, p=0.013).  
The percentage of AHA-rare subjects within the group of those who are AGE2 
was 9% (3 of 33) in the Lpar group and 45% (44 of 98) in the Npar group (Fisher´s exact 
test, p< 0.001). 
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The percentage of individuals AGE3 and AHA-rare was 18% (6 of 34) in the Lpar 
group and 45% (77 of 172) in the Npar group. (Fisher´s exact test, p=0.004).  
The percentage of VA-extreme subjects within the group of those who are AGE1 
was 76% (13 of 17) in Lpar and 20% (1 of 5) in Npar (Fisher´s exact test, p=0.039). The 
percentage of VA-extreme subjects within the group of those who are AGE2 was 61% 
(20 of 33) in Lpar and 35% (34 of 98) in Npar (chi-square=6.84, df=1, p=0.009). The 
percentage of VA-extreme subjects within the group of those who are AGE3 was 64% 
(21 of 33) in Lpar and 33% (58 of 174) in Npar (chi-square=9.44, df=1, p=0.002). 
Non-participants were asked to specify reasons for non-participation and the most 
commonly mentioned reasons were: 
 “I am too debilitated to participate” 
 “It is far away from my home” 
 “There are no benefits in participating” 
 “I have no one to go with me” 
Discussion 
In this study we investigated participation rates in the PCVIP study and its 
determinants. We obtained an overall participation rate of 20%, low participation was 
anticipated given that the target group of the population were people with impaired vision. 
Some of the interested group were not able to participate because travel arrangements 
were too expensive compared with the compensation offered by our study. Despite this, 
the participation rate was comparable to other studies involving participation in phone 
interviews in the Portuguese population (312). Correia et al. were only able to interview 
21.7% of those eligible for their study. When we analysed factors or determinants that 
are likely to affect participation rates in our study, we found that people at the extremes 
of VA (0.1 or less and 0.5) were more likely to participate than those with intermediate 
acuities (0.2-0.4). Participation was independent of age and cause of VI but influenced 
by gender (males were more likely to participate). People living together or divorced were 
more likely to participate than those in other categories of marital status. Participation 
reduced with increasing traveling distances to the hospital but increased with the number 
of years of education. A high frequency of hospital appointments was also favourable to 
participation. A decision to participate was independent of the Charlson comorbidities 
index. 
The initial hypothesis regarding the effect of acuity was partially confirmed and 
we were also able to confirm that the cause of VI was not a determinant of participation. 
Other results were in line with our initial hypothesis, specifically, we confirmed an effect 




determinants of participation in our study. Our model predicts that, for individuals with 
the best profile favouring participation, a minimum of 4 in 10 contacted would participate. 
For the worst profile, the maximum participation would be 6 out of 10. These profiles 
need to be considered when designing studies and planning recruitment. 
Surprisingly subjects with severe vision loss, acuity 0.1 or less, were more likely 
to participate than those with better acuity, VA in the range 0.2-0.4. This finding seems 
to contradict the idea that the sustained willingness of individuals to participate can be 
inferred from the effort that participation requires (305). It would be expected, from the 
effort perspective, that someone with a worse acuity would have more difficulties 
participating than someone with better acuity. A possible explanation is that individuals 
at more advanced stages of their conditions may perceive a greater benefit in responding 
to study participation than those at less advanced stages. People at more advanced may 
have a stronger moral drive to help others in a similar situation (313). Another 
explanation for this result can be the level of adjustment to vision loss. Individuals with 
worse acuity might be better adjusted to vision loss whilst those in the medium range 
may still be in the process of adjusting and; therefore, less inclined to participate (284, 
285).  
The participation rate in our study was higher amongst men than women, which 
contrasts with some studies (298-300). This is a result that needs further investigation 
but we acknowledge that this might be related to cultural factors because Correia also 
found, in Portugal, higher participation amongst men (312). Another result that is in 
contrast to other studies was the higher participation amongst subjects that were 
divorced or single when compared with married individuals. In a study by Sahar and 
colleagues married people were more likely to participate than people with other marital 
status (301). We do not have a clear explanation for this result, but it could be related to 
the spectrum of relationships of the target group of the population. 
Factors such as distance to the hospital, education or annual hospital attendance 
are important when planning recruitment. Individuals living further away from the hospital 
were less likely to participate. This result seems to be explained by the “principle of the 
effort” that predicts an inverse relationship between effort and participation probability 
(305). In line with our results for education status, increased participation with the number 
of years of education has been reported in other studies (295-297). The most likely 
reason for this is the ability to understand the purpose of the study and the contribution 
that studies can provide to the progress of knowledge. The participation odds for people 
visiting the hospital 10 or more times per year were higher than the participation odds of 
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those who attend the hospital less than 10 times per year. Differences found are likely to 
be due to the development of an acute civic awareness and/or familiarity with the hospital 
environment.  
In this study we also looked at systematic differences between immediate and 
late participants. This analysis provides information regarding the spectrum of individuals 
in which a follow-up phone call can be effective. Overall, we can say that the phone call, 
as others have found, seems to be important in increasing the moral obligation to 
participate (302, 304). Our operators noted that a substantial number of individuals 
changed their minds and eventually decided to take part in the study after the importance 
of their participation has been emphasized. Compared with the initial letter, the follow-up 
call captured more women, more males younger than 40 years but fewer males within 
the age 40-69 years. Groups in which participation increased need more incentives or 
clarification than the groups that did not change in participation. Our results are in 
agreement with other studies showing that Lpar tend to be younger than Ipar (314, 315). 
Other differences between Ipar and Lpar that we found involve very small groups with 
specific characteristics that seem to show only scattered combinations of patterns of 
participation. 
By comparing late participants (Lpar) with non-participants (Npar), we 
investigated if the model of “continuum of resistance” was valid in our sample. According 
with the “continuum of resistance” model the more contacts an individual requires to 
participate in a study the more similar he/she is to Npar (305, 309). However, similar to 
results in other studies (316, 317), we found many differences between the structure of 
the group of Lpar and Npar. In particular, the age distribution was different, Lpar were 
younger than Npar (314, 315). Overall, there were several differences between the 
structure of the group Lpar and Npar which somewhat contradicts what would be 
expected from the model “continuum of resistance” (314-316, 318).  
A limitation of our study was the lack of information concerning the economic 
status of the subjects that could potentially clarify some of the unexplained findings. 
Another aspect that we believe would strengthen our results would be the inclusion of 
responses from more subjects in both groups. Amongst others reasons, some non-
participants were excluded from the analysis because they were unable to answer our 
questions by telephone (for example due to dementia, staying in nursing homes, 
hospitalization) or the clinical information was of poor quality (to determine, for example, 
the Charlson comorbidities index). Therefore, the included cases may be slightly different 





In conclusion, participation rates in our study were influenced by gender, distance 
to the hospital, number of years of education, annual hospital attendance, marital status 
and visual acuity. There were considerable differences between immediate participants 
and late participants and between late participants and non-participants. Individuals with 
low levels of education and women were more difficult to recruit. These facts need to be 
taken in consideration in order to avoid studies that are biased by gender or socio-
economic inequalities of the participants. Young subjects and those at intermediate 




















































Chapter 6 – Discussion  
The aim of this thesis was to investigate and characterize the impact of vision 
impairment in selected aspects of the healthcare system and the society. Our work 
investigated characteristics of vision impairment including barriers to access to care that 
can lead to an increase number of cases of vision loss. The work reported in this thesis 
can be considered as aspects of eye diseases and vision loss and their implications to 
the health system and the society.  
The thesis is a compilation of study results that have been reported before as 
research papers. In one study, we studied the number of intravitreal procedures 
performed in Portugal during the period 2002 to 2012.That is, we investigate the raise in 
the number of intravitreal procedures as a proxy to understand the diffusion of anti-VEGF 
treatments. Anti-VEGF treatments are a revolutionary treatment in ophthalmology which 
reduced the number of people losing vision due to acquired eye diseases such as age 
related macular degeneration and diabetic macular oedema. In another paper we 
estimate the use of informal care and its determinants in people with impaired vision. We 
also investigated productivity losses in a sample of people with impaired vision. To 
support and complement our methodological options adopted in some of the papers in 
which I am the first author, the thesis also reports two papers in which we: 1) analysed 
the results produced by EQ5D and activity inventory to assess health and visual 
outcomes and 2) compared our study participant’s profiles with non-participants. The key 
findings are summarized and discussed below. 
6.1 - Key Findings and discussion 
6.1.1 - Diffusion of anti-VEGF injections in a National Health System 
In Chapter 5 section 1 we reported results of the study “Diffusion of anti-VEGF 
injections in the Portuguese National Health System”. This study investigates how a sight 
saving treatment reached different regions in Portugal and was motivated by 1) expected 
problems with inequities concerning access to new treatments and 2) for the potential of 
this treatment to reduce the number of cases of vision impairment in Portugal. Ensuring 
equal access to eye care and reducing vision loss is a duty of the health care system; 
therefore, in this thesis we consider that this work explore the perspective of the health 
care system. In other words, this paper explores the role of the health care system when 
tacking the problem of sight treating disease that would lead to vision impairment. We 
performed a temporal and geographical analysis of the patterns of diffusion of 
antivascular endothelial growth factor (anti-VEGF) treatments in the Portuguese National 
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Health System. We analysed 98,408 hospital discharges from NHS Portuguese hospitals 
that corresponded to 57,984 patients and found that: 
 The total number of episodes increased from 1815 in 2002 to 25106 in 2012. 
 The yearly rates of hospital episodes per 100 000 population varied from 17.4 in 
2002 to 238.77 in 2012. 
 Between 2007 and 2012, the rates of hospital episodes related to the introduction 
of anti-VEGF injections increased by 27% per year. 
 Patients from areas without ophthalmology departments received fewer 
treatments than those from areas with ophthalmology departments. 
 The availability of an ophthalmology department in the county increased the rates 
of hospital episodes by 243%.  
 A 100-persons greater density per square kilometre raised the rates of hospital 
episodes by 11%. 
 Results show potential inequalities in eye care access that can lead to irreversible 
sight loss caused by treatable eye diseases.  
A detailed discussion of our results has been given in section 5.1.1. In section 5.1.1 
we considered three possible barriers for the equitable anti-VEGF diffusion related to 
legal, technical and financial factors. The EMA approval of this treatment in 2007 and 
the NHS coverage decision in 2008 fixed the legal barrier. Technical conditions regarding 
the need of extra training for doctors and the mandatory performance of this procedure 
at the operation theatre formed the technical barrier (190). These technical requirements 
possibly created financial and service capacity pressures on ophthalmology departments 
(105, 181). Higher rates of treatment were observed mostly in areas around big cities 
and specialized centres. Smaller hospitals may have taken longer to adopt this treatment 
due to budget limitations or technical conditions. Conversely, teaching hospitals, with 
urban location and the presence of competition may have helped the spread and rate of 
diffusion (131). Regarding financial barriers two main budget limitations may have 
reduced the speed of diffusion of anti-VEGF treatments. The first is related to the cost of 
the treatment, to changes in hospital budgets and pressure for cost-containment that 
may have reduced the availability of anti-VEGF treatments in small hospitals 
concentrating patients in big centres with limited capacity. A second financial barrier for 
hospitals is related to the fact that intravitreal injections need to be administered in an 
operating room by an ophthalmologist. Typically, patients receive three injections in the 
first 3 months, followed by monthly visits for assessment and further injections as 




demands on hospitals (staff and facilities). In a period of tight budgets expansions in the 
medical staff or facilities are difficult to implement. Thus, some hospitals may have 
delayed the start of these treatments or they may still not be available. 
Our findings are causes of concern because vision loss caused by eye diseases 
for which anti-VEGF treatments are indicated cannot be restored. That is, reduced 
number of treatments might lead to an increased number of people becoming visually 
impaired due to treatable causes in Portugal.  
 
6.1.2 - The use of informal care by people with vision impairment 
We investigated informal care utilization amongst people with impaired vision using 
innovative approaches such as taking into consideration self-reported difficulties when 
performing daily living activities. The needs of informal care amongst people with VI are 
considered here as part of the impact of the condition in the society. Difficulties 
performing daily living activities have a huge impact on autonomy and can lead to an 
increased need of informal care. Our study fills into this lack of knowledge by including 
in our analyses a characterization of self-reported measures of visual ability obtained 
with an activity specific inventory. This has been used in combination with clinical 
measures such as visual acuity and socio-demographic characteristics that can influence 
the needs of informal care. We quantified and characterized the use of informal care in 
a sample of 546 visually impaired individuals, as detailed in section 5.1.2. In short, we 
found that: 
 Informal care was reported by 39.6% of the participants requiring, each, a median 
of 390 hours (mean=470; 95% CI=488-407) of informal per year. 
 In total we estimated 92.000 hours of informal care per year that corresponded 
to an opportunity annual cost of €610,915. 
 Informal care was influenced by marital status, comorbidities, visual ability and 
acuity. 
 The intensity of use of informal care was negatively associated with visual acuity 
and visual ability i.e. the ability to perform daily living activities that depend on 
vision.  
 Visual ability was the only predictor of informal care utilisation intensity after 
controlling for age, gender and severity of vision impairment. With one-unit 
change in visual ability corresponding to a variation of 67 hours in the intensity of 
informal care per year. 
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 With this study we were the first to show a strong link between self-reported visual 
ability and informal care in a large multicentre study in a European country.  
We concluded that visual ability, a measure of functional disability/dependency 
related to vision, was a predictor of the use of informal care and of its intensity. We 
suggested that visual rehabilitation alongside with usual eye care would help to alleviate 
the burden of vision impairment at this level.  
A detailed discussion of our results can be found in section 5.1.2. In section 5.1.2 
we have compared our estimates regarding the percentage of informal care users, the 
amount of hours of informal care and found that our findings were similar with other 
studies(49, 210, 211). Regarding the determinants of informal care use our results 
showed that the use of informal care was affected by marital status and comorbidities 
but not by gender. Non-married participants were more likely to report informal care 
presumably because they cannot rely on their partners and the need to ask for help is 
more clearly defined. Those with other comorbidities may also face further difficulties in 
their daily life and therefore are more likely to require informal care. In our study the users 
of informal care had a higher proportion of women compared with non-user and in the 
logistic regression women had a higher odd of needing informal care although this was 
not statistically significant. This result is in contrast with some studies reporting that 
women are more likely to use informal care (49, 50). As informal care can be influenced 
by many factors and, in particular, by the organization of the society (207) our results 
need to be interpreted in the Portuguese context and can be, eventually, applicable to 
similar societies (215). 
Visual ability was the only independent predictor of the intensity of use of informal 
care after adjusting for age, gender and severity of vision impairment. This association 
shows a link between self-reported task difficulties and the amount of help needed. 
Others reported an effect of visual acuity; however, these studies did not considered self-
reported levels of visual ability (50, 175, 216, 217). In line with our results, Wang et al. 
(49) found an increase in intensity with increased self-reported walking difficulties. Keefe 
et al. (214) reported that people with impaired vision need help for vision-dependent 
activities such as driving, reading documents and support for independent activities 
outside home. These are the tasks covered by the activity inventory to determine visual 
ability. We speculate that visual rehabilitation tailored to increase visual ability is likely to 





6.1.3 - Productivity losses and their explanatory factors amongst people with impaired 
vision 
We also investigated productivity losses caused by VI to characterize the impact of 
vision loss from a societal perspective. Results of this analysis have been reported in 
section 5.1.3. Again, there has been an effort to introduce innovative approaches. 
Previous studies analysed productivity losses associated with vision impairment with 
some limitations. We identified low samples and incomplete set of explanatory variables 
as the main limitations in the available literature. We believe that employment has an 
impact on both productivity and health and therefore we decided to include patient-
reported outcomes measures when investigating productivity losses together with clinical 
and socio-demographic variables. We estimated and characterized productivity losses 
in a sample of 546 visually impaired individuals and found that: 
 From 546 participants 47% were within the working age and from those 28% were 
working. 
 Productivity losses were estimated in €1.51 million per year (median of €4.399 
and mean of €5.495 (95% CI=[5.292; 6.598] per participant) in this sample. 
  The largest portion of losses were due to reduced workforce participation 
estimated from a sample of 159 individuals that were either unemployed or early 
retired due to vision impairment. 
 Individuals within the age range of 17-39 years, 12 or more years of education, 
no comorbidities and reporting higher health-related quality of life had higher 
probability of employment. 
 There was a strong association between employment status and self-reported 
levels of health-related quality of life.  
We have compared our estimates regarding rate of employment and workforce 
participation and concluded that our results were similar to previous reports (136, 139, 
177, 240, 241). More details were given in section 5.1.3. Regarding the determinants of 
participation in the labour market our results show that, after controlling for visual ability 
and acuity, younger individuals without comorbidities, higher levels of education and high 
health-related quality of life had higher chances of being employed. Results about age 
and education were corroborated by several studies that demonstrated that younger and 
more educated individuals with impaired vision were more likely to be employed (154, 
156, 242, 243). One possible explanation may be because job loss occurs more 
frequently at older ages and that the duration of unemployment is longer for older 
individuals (156, 242). Another explanation comes from the perception that many jobs 
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which are available to less qualified people require sight (154). Others studies have 
found that more severe impairment and the presence of comorbidities were associated 
with lower probability of employment (154, 243, 244). However, in our study, in the 
logistic regression analysis only the presence of comorbidities showed statistically 
significant effect in employment status. Visual acuity had an odds ratio of 0.35 (p-
value=0.163), which points to a tendency to individuals with lower visual acuity (higher 
values in a logMAR scale) having lower chances of participation in the labour market. 
While this effect was not significant, the trend is similar to the previous findings. We have 
also included results from EQ5D and AI in our regression analysis to explain the 
employment status. The EQ-5D used to assess health-related quality of life includes 
questions about anxiety and depression and pain and discomfort which are known 
factors associated with the ability to work (245-247). Visual ability measured by the AI 
allowed us to incorporate also difficulties performing vision related tasks (168). Whilst 
the effect of visual ability was not statistically significant, we found that the EQ5D utility 
score was a strong predictor of employment and therefore of reduced workforce 
participation. This possibility was also being raised in other studies who tried to predict 
absenteeism and presenteeism using EQ5D (248). 
 
6.1.4 - Complementary findings 
In Chapter 5 section 2.1 we reported results of the study “Visual and health outcomes 
measured with the activity inventory and the EQ5D, in visual impairment”. This study 
analysed the outcomes produced by a condition-specific instrument, activity inventory 
(AI), and by a generic instrument, EQ5D to assess health and visual outcomes in patient 
with visual impairment and, in short, we found that: 
 Both measures were related positively with visual acuity in the better eye. 
However, which measure had different association with other patient 
characteristics.  
 EQ5D was also associated with gender and number of comorbidities while AI was 
also associated with age and gender.  
In agreement with previous studies EQ5D was found to be responsive to VI (84, 227, 
278). Van Nispen et al.(84) found slightly higher results applying EQ5D in mixed causes 
of VI. These slightly different results may be explained by a different distribution of 
causes of VI (more age macular degeneration than diabetic retinopathy compared with 
our sample), narrow inter-quartile range of visual acuity and older participants in their 




in Portugal compared to the Netherlands because of differences in community 
calibrations (170). Gender and the numbers of comorbidities were predictors of the EQ-
5D scores. The effect of gender that we found in our multiple regression is not commonly 
observed; however, Langelaan et al. (227) did report significance of gender and that is 
in line with what has been found in the general population in some countries (283). Our 
results for the activity inventory  are in agreement with what other authors found for 
patients with VI due to various causes (8, 288) or VI caused by specific eye diseases 
such as diabetic retinopathy (289). The effect of age on visual ability obtained with the 
AI has been found before and has been explained by the overall physical functioning 
decline explained by aging (8).  
Because of these different association with other patient characteristics we concluded 
that EQ5D and AI produces complementary information about visually impaired 
individuals and therefore should be used in conjunction to assess the wider impact of 
vision impairment.  
We have also compared our study participant’s profiles with non-participants to 
investigate participation rates and its determinants. Results of this analysis have been 
reported in section 5.2.2. The main findings were: 
  Participation was independent of age and cause of vision impairment but 
influenced by visual acuity, marital status, educational level, frequency of hospital 
attendance and traveling distances to the hospital.  
 People at the extreme of visual acuity (0.1 or less or 0.5 in a decimal scale) were 
more likely to participate than those with intermediate visual acuities (0.2 to 0.4 
in a decimal scale).  
 Males were more likely to participate than women, people living together and 
divorced were more likely to participate than people included in any other marital 
status category (married, single or widowed).  
 Participation increased with higher levels of education, higher frequency of 
hospital appointment but decreased with increasing traveling distances to the 
hospital.  
Our results regarding visual acuity were in contrast with what we previously 
hypothesized. Participants with severe vision loss (visual acuity of 0.1 or less) were more 
likely to participate than those with visual acuity of 0.2 to 0.4. A possible explanation is 
that individuals at more severe stages may perceive a greater benefit and a higher moral 
obligation than those at less severe stages (313). Another explanation can be related to 
the level of adjustment to vision loss. Participants with worse acuity might be more 
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adjusted to vision loss than those in the middle range and that may explain lower 
participation in subject the middle range (284, 285). Our finding related to gender were 
in contrast with previous studies. Regarding gender we recognize that the results need 
further investigation although we speculate that this might be related to cultural factors 
since another study performed in Portugal also found higher participation in men (312). 
Individuals living further away from the hospital were less likely to participate. This result 
seems to be explained by the “principle of the effort” that predicts an inverse relationship 
between effort and participation probability (305). In line with our results for education 
status, increased participation with the number of years of education has been reported 
in other studies (295-297). The most likely reason for this is the ability to understand the 
purpose of the study and the contribution that studies can provide to the progress of 
knowledge. 
6.2 - Strengths and limitations of this thesis 
This section provides the strengths and methodological limitations of this thesis. 
The section is divided in two parts, in the first part we present in detail the advantages 
and disadvantages of our databases. In the second part we discuss some of the 
characteristics of the instruments used during face-to-face interviews and the methods 
used to valuate informal care providing an overview of their strengths and limitations. 
6.2.1 - Strengths and limitations due to data collection strategies and databases used 
To study the diffusion of a new eye treatment we used an administrative database 
with inpatient and day cases stays from all Portuguese public hospitals during period 
2002-2012. This database has the benefit of gathering information through a consistent 
format and using ICD-9-CM to describe specific diagnoses and procedures. Portuguese 
public hospitals have the obligation to report inpatient and day cases in order to be paid 
for their services therefore this database is an abundant and standardized source of 
patient information. 
Using administrative data allowed us to eliminate selection bias and enabled us 
to construct a complex and multivariable model to explain the geographical diffusion and 
time variation (319). We included all the procedures provided in public hospitals with 
different differentiation levels which increased generability of our findings because 
different clinical practice and different patient complexity are incorporated in our data. 
Because all patient identifiers such as name and address are removed from the database 
and an anonymized patient unique identification is given by the national agency that 
provides the data anonymization previously, confidentiality and patient anonymization is 




incomplete, inaccurate, or missing data, the lack of specific billing codes for some 
procedures and the less sensitivity to evaluate the appropriateness of care (319). In our 
study it also implicated that we did not have access to some individual socioeconomic 
characteristics such as patient income or education level that could have been 
incorporated in our model. In addition, because this database is restricted to Portuguese 
Public hospitals, we could not include patients treated in the private sector although we 
believe that the number of patients that seek care in the private sector is small because 
the treatment is expensive and is available at public hospitals.  
To collect information about informal care and productivity costs we used a 
questionnaire. Accordingly to Bhandari et al. (218) accuracy of self–reported data 
through questionnaires may be affected by three main factors: 1) recall time frame; 2) 
type of utilization;3) utilization frequency. We will discuss these factors since they support 
our option for a questionnaire with a 2-week time-frame to capture information about 
informal care use and productivity losses. 
Recall time frame is define by the length of recall (eg. 1 week; 1 months or 1 year). 
Accuracy of recall may be influenced by telescoping and memory decay and poor 
accuracy of recall leads to inaccurate data and conclusions. Telescoping occurs when 
an individual lengthens the recall period beyond the timeframe in question and reverse 
telescoping occurs when individual shortens the recall period. Both telescoping and 
reserve telescoping applies to any time frame and does not produce a consistent bias 
(218). However, memory decay, defined as a failure to remember an event, always 
results on under-reporting. The shorter the recall period the more accurate individuals 
are at reporting use of healthcare services, absenteeism and worker productivity (218, 
320). In particular, a shorter time frame between absence to work and the application of 
the questionnaire may result in a lower discrepancy between the real number of days 
missed from work  and self-reported data (321). 
Underreporting utilization is positively associated with increased frequency since 
people tend to fail to remember as frequency increases (320). Informal care may be 
frequent and occur on a daily basis and for that reason people tend to get use to that 
help and forget its frequency when they are asked to report the number of hours of care. 
We adopted a short recall time because asking the use of informal care in a shorter 
period may minimize underreporting. 
The type of utilization and whether it is associated with stigma also influences the 
capacity to recall events. Usually, stigmatized care such as mental health visits are 
underreported. More important, salient visits such as inpatient hospitalization are more 
152 
 
likely to be reported accurately than typical and frequent visits such as visits to the 
primary care physician (218). Since informal care it is not a rare or salient event and, 
especially on old population, it is not associated with stigma. Therefore, we believe that 
the questionnaire is an adequate instrument to collect information. 
An alternative method to collect data regarding informal care would be to use the 
diary. With the diary with would be possible to reduce recall time bias but this method is 
not exempt of disadvantages. Mainly it is necessary to have a higher budget to collect 
the information and the method is time intensive and can be straining for respondents 
(207, 219, 322). Being time consuming may bias the results in favour of less busy 
respondents (323).  Additionally, there are also the risk of high levels of item missing 
data, complexity of data processing and analysis and dependence on participants 
motivation to repeatedly record their data (220)  which can be even harder for people 
with impaired vision (221). 
Regarding productivity losses and more specifically absenteeism, sick leave 
registers would be a reliable source of information to collect the number of days missed 
to work. However, the purpose of our study was to estimate the absenteeism in a group 
of participants that worked in many different locations and therefore this approach would 
unrealistic (171).  
In short, based on these assumptions we decided to use the most common 
method, a questionnaire (174, 207) with a small recall time period to minimize recall bias. 
We have also conducted a pilot test to simplify data recording, to remove redundant 
items and to clarify words and questions in order to decrease potential biases. 
6.2.2 - Other strengths and limitations of this thesis 
To assess participant’s ability to perform daily activities we used a functional 
vision questionnaire, the activity inventory. In this self-reported method participants are 
first questioned about the importance of performing a determined daily activity (goal 
importance). If the activity as at least some importance participants are asked to rate 
how difficult is it to perform that activity (tasks difficulties). In this type of inventory each 
participant responds to a relevant set of questions that is unique to her/him, meaning 
that each participant as personalized functional assessment. For minors, when 
necessary, parents served as proxies for the interview. Activity inventory can be describe 
as a custom-tailored questionnaire since is adapted to the individual preferences (166, 
167). 
In our study we wanted to include functional vision because two individuals with 




different ability levels to perform daily activities. Furthermore, functional vision is a major 
determinant of whether a person can live independently and provides important 
information about the level of assistance that is needed if a visually impaired person is 
not fully independent (324). By collecting information about difficulties performing tasks 
that are considered of some importance to the individuals the AI is suitable to produce 
an personalized functional assessment, that can use be use to assess dependency level, 
to define an individualized rehabilitation plan, as well as to assess the outcomes of 
assessment of vision ability after rehabilitation. Therefore, we consider the inclusion of 
the AI an innovative approach characterizing, for example, informal care or productivity 
losses. 
An alternative to self-reported methods would be observation. That implies, 
classify how participants performed a sample of daily living activities (direct method or 
performance based method) or we could have collected information by asking to 
someone close to the visually impaired individual how they rate participant’s ability 
(indirect method or proxy report method). With direct performance observation we would 
capture real difficulties rather than perceived difficulties and reports from someone close 
to the visually impaired individual might be useful in cases of depression or cognitive 
impairment. By directly observing performance we could obtain a more precise 
estimative of ability and eliminate some issues related both to underestimate and 
overestimate of ability usually  found respectively in depressed individuals or in healthy 
older individuals living in the community (324, 325). For example, a study on visual 
function in older adults found that about 10% of individuals had a considerable 
discrepancy between their self-reported reading difficulties and measured reading speed 
(326). 
Direct methods are often time consuming and cost intensive. This approach 
requires specialized training to the observer, acquisition of materials to recreate the 
environment, special space for administering the performance test, designing  an 
appropriate protocol, and may be considered intrusive from the patient perspective (327). 
Additionally, direct performance measures also possess their own limitations since no 
single "gold standard" exists to implement this data collection strategy (325). 
Interestingly, some authors have demonstrated that although direct performance 
measurement provide detailed information about individual’s ability, both, direct 
measurements and self-reported measures, were found to be independent predictors of 
nursing home placement (327, 328). Some authors have also demonstrated that direct 
performance measurement are neither superior nor mutually exclusive compared to self-
reported measures (329, 330). Direct performance measurement may measure different, 
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although related, attributes therefore provide complementary information (327, 329). 
Direct performance measurement may be more sensitive to detect slight ability decline 
in some older persons, while in some functional tasks the patient may detect an impeding 
problem earlier (329).  
By asking someone close to the visually impaired individual rate their ability could 
also be influenced by, for example: i) an unconscious exaggeration of their caregiving 
role, an overprotective behaviour, ii) an overburdened feeling if dependency occur for a 
long time or if there is no other backup support, iii) a conscious process to gain sympathy 
or to encourage recommendation to a long term care/nursing home placement (324). 
Although a high level of agreement was found between self- reports and reports from 
others family/friends, for physical activities of daily living, instrumental activities of daily 
living and social functional (Interclass correlation coefficient above 0.6) at an aggregate 
level (summary measure), a consistent discrepancy was found at the item level (331). In 
general, reports from others indicate a higher level of disability when compared both to 
self-report as well as to direct performance observation (331).  
To assess the existence of comorbid conditions we asked participants to report 
comorbidities based on a list of 16 categories that included, amongst others, diabetes, 
hypertension, cancer and heart conditions. The completeness of data obtained by this 
method depends on the patients’ ability to remember their comorbidities (227). This 
ability is influenced by age, education level and memory capacity (332, 333). Young and 
highly educated people are likely to report comorbidities accurately, but that is more 
unlikely in old people or people with low education. Therefore, it is possible that in our 
study participants did not report comorbid conditions because the symptoms were absent 
and; therefore, they did not remember which results in a increased risk of under-report. 
Nevertheless, several studies showed data from interviews or questionnaires are a valid 
and practical source to collect this information (332, 333). 
To estimate economic impact of informal care we used opportunity costs in which 
time losses are valued based on the value of competing time use for example, paid 
labour. The same approach was use by others authors in the field of vision impairment 
such as Keeffe et al. (214) and Schmier et al. (175) and in others diseases like 
Alzheimer´s (334) or Parkinson´s (335). An alternative method would be “proxy good 
method” (also known as the replacement cost method) in which the value of time spend 
on unpaid activities is based on a close market substitute, for example, the wage of a 
household helpers or a specialized nurse (336, 337). Although both methods are 
extensively used to value time, the opportunity costs method is used more often usually 




method and informal care was valued with the average Australian hourly pay rate (A$ 
11.25; US$ 8.73). In our study we used  the average Portuguese hourly pay rate of full 
time employees in the year 2014 (EU$6.32) which accordingly with Costa et al (176) is 
within the interval used in studies reporting opportunity cost method that goes from 
EU$4.10 to EU$19.18. By using an average pay rate we valued time spent providing 
informal care equally regardless the occupational position or education level of the 
caregiver. That means that our method does not raise equity concerns that arises when 
different social values are attributed when care is provided by, for example, an health 
economist or by an administrative assistant (337). The method and value used to 
estimate informal care in our study was used previously and seemed appropriate and 
ensured comparability with others studies. 
We also did not distinguish the number of hours spent providing care by the type 
of activities sacrificed: paid work, unpaid work, leisure time and we recognize that it is 
difficult to distinguish between normal housework and additional housework due to health 
problems of the care recipient. These issues may cause under or overestimates in our 
estimates. Without a proper distinction between normal housework and additional 
housework due to health problems the time spent on informal care may be overestimate 
(338). In contrast, if the caregiver and the patient live in the same household and have a 
social relationship (eg. spouse, parent, child) and/or if the starting point of informal care 
occurs gradually with the decline of patient autonomy. The way informal care is perceived 
by both, patients and caregivers, may be affected and this may result in an 
underestimation of informal care (323). We believe that both situations reported here 
















6.3 - Implications of the findings of this thesis 
With this thesis we concluded that vision impairment in Portugal has substantial 
socioeconomic implications since it affects individual’s autonomy that leads to high use 
of informal care. It also affects individual’s participation in society namely individual’s 
employment status and health related quality of life which results in productivity losses. 
We also found that the diffusion of a new eye care treatment was large but unequally 
distributed and associated with availability of healthcare delivery services.  
From a health policy and healthcare organizational delivery system viewpoint 
more actions are needed to reduce the burden of vision impairment in Portugal. The 
Portuguese healthcare system should improve the capacity to provide comprehensive 
care to this population investing in preventive, curative and rehabilitation care.  
Preventive care including screenings, check-ups, providing information about risk 
factors and preventive measures to avoid risks should be reinforced. Many eye diseases 
that lead to vision loss are asymptomatic in the beginning therefore individuals may not 
be aware of the risks and of the alert signals (119). Screening programs to those at 
higher risks are needed. The number of participants with diabetic retinopathy in our 
sample shows that in Portugal there are many patients with diabetic retinopathy at young 
age (working age 17 to 64 years old), with visual acuity bellow 0.5 decimal that are not 
working. The cost-effectiveness of screening programs in eye diseases and in 
particularly in diabetic retinopathy is well documented in the literature (339, 340). 
Systematic screening for diabetic retinopathy versus “no screening” is cost‐effective in 
terms of sight years preserved (340) so investing in screening programs is considered a 
good investment. However, screening programs will not produce benefits if detected 
cases are not monitored or treated in a timely and adequately way.  
Access to medical treatments that restore and prevent vision loss should be 
provided. The unequal geographical distribution of anti-VEGF treatments found in 
Portugal seems to indicate that the access to these treatments is being provided at a 
suboptimal level. Because we considered that one possible barrier is related to financial 
factors, we advocate that it is not enough to evaluate the cost-effectiveness of a new 
healthcare technology to decide whether it should be reimbursed or not. A cost-
effectiveness analysis (more specifically a cost utility analysis) tell us if the benefits 
(effects) are higher than the costs or more precisely tell us the cost per quality adjusted 
life years gain but, it is out of the scope of these analysis to determine the impact to 
healthcare system budget and sustainability. An assessment about the impacts to the 




accommodate health innovation and improve population health, adjustments are 
required. 
Adapting healthcare financing mechanism to better accommodate healthcare 
innovation is one possible measure. Healthcare financing mechanism may be used to 
distribute financial resources differently between providers. There are several options to 
incorporate instruments into hospital payment system to support the introduction of 
medical innovations. These options may be divided into short-term instruments and long-
run mechanisms (134, 341). Short-term payment instruments should only be 
implemented in special cases, for instance when no other treatment option exists to treat 
a specific condition, for a limited period of time and under the supervision of continuing 
evaluation in terms of effects and type of cases treated (134). This instrument allows 
shared financial risk between healthcare providers and the financing agency (341).  
Long-run mechanism, a preferable option, are implemented through updates and 
adjustments in the DRG system. Frequent updates and adjustments of DRG system, 
including the introduction of new codes to incorporate current practice patterns or the 
adjustment of costs weights reflecting new treatment costs are important mechanisms to 
the introduction of new healthcare technologies and therefore to help to provide 
adequate access to patients who may benefit from this innovation (134, 342).  
Planning the dissemination of healthcare innovation is also important to ensure 
that innovation is available to whom may most benefit. On the contrary, a passive, 
untargeted and unplanned spread of innovation may result in an unequal access to a 
new treatment. Monitoring the spread of innovation is crucial to guarantee that the 
dissemination is done based on the patient needs rather than on the healthcare 
organizational or professional characteristics and needs. Monitoring the spread of new 
treatment is crucial to ensure an equitable access. One of the aspects of this monitoring 
process should focus on the distribution of and access to eye care services in rural areas 
of Portugal since we found that patients living in rural areas had lowest levels of anti-
VEGF treatments. 
A comprehensive or integrated delivery of healthcare services is also important 
to this population. Vision impairment has substantial impacts on visual, physical and 
mental health (47, 48, 66). In our results we found that visual acuity and having 
comorbidities increased the chances of having a caregiver and that individuals with 
comorbidities had lower chances of being in the labour market. Therefore, besides eye 
diseases diagnosis, treatment and follow up it is necessary to take into consideration 
extra care needs related with complications associated to vision loss and with 
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comorbidities (52, 83).Vision impairment may affect the management of other 
comorbidities and comorbidities may also affect the management of ocular diseases that 
cause vision impairment.  
Without an integrated vision care it will be more difficult to provide adequate care 
to the complex needs of individuals with vision impairment. The lack of continuity of eye 
care, the lack of awareness of this problem from the community or public health services, 
insufficient or inadequate screening services and/or provision of affordable care and 
delays in access to specialist eye care are some of the factors related to an increase 
number of cases of avoidable vision loss worldwide (11, 17).  
Investing in vision rehabilitation is important to help all the patients with 
uncorrectable and unrestored vision loss to be as autonomous as possible. With this 
study we found that visual ability, i.e, patients ability to perform activities that depends 
on vision, was associated with having informal care, with the number of hours of informal 
care provided by caregivers and with employment status. Vision rehabilitation is useful 
whenever vision loss interferes with the activities of daily living, process of learning, 
social interaction and/or professional pursuits. Vision rehabilitation focus on the 
acquisition of alternative skills that will improve independence. Examples of interventions 
developed in vision rehabilitation programs include the orientation and mobility training, 
the provision of assistive devices (e.g. magnifying devices, haptic devices) and training 
to support assistive devices utilization, occupational therapy among others (273). 
Because vision loss leads to many short or long term penalties that goes beyond 
the healthcare system namely loss of opportunities in education or employment, income 
losses and quality of life losses (11, 17, 18) actions to reduce vision loss impact should 
also include educational and labour market systems. In our study a higher education was 
associated with a higher chances of employment after controlling for age, visual acuity, 
visual ability, the presence of comorbidities and health related quality of life. The 
educational system and the labour market regulation should be adapted to the needs 
and ensure equal opportunities to visually impaired individuals.  
In terms of clinical and administrative decisions, the focus is still the patient as an 
“isolated individual” (343) and the needs and preferences of others namely caregivers 
are easily ignored. This must change at the different levels of decision making. In terms 
of health policy, some initiatives for signalling informal care and registering caregivers 
have emerged in Portugal and worldwide. However, there is a lack of support programs 





It is also important and necessary to increase awareness among health 
professionals and policy makers about the important contribution of informal care to the 
healthcare system and about the benefits of maintaining and supporting caregivers 
(209). For many patients, their families and the healthcare system, staying at home for 
as long as possible is the preferred alternative. Informal care may not only help to 
maintain the patient in the community, reducing the demand for home care but also 
facilitate an earlier discharge from hospitals both from inpatient acute episode or from 
outpatient surgery (337, 344-346). In this sense, promoting and supporting informal care 
is a win-win situation for the individuals, healthcare system and society. 
 
6.4 - Future research 
There are several challenges which need to be addressed in order to obtain a detailed 
evaluation of the impact of vision impairment.  
In Portugal studies to estimate the prevalence and direct costs of vision impairment 
are needed. Even in a developed country vision loss imposes a tremendous cost 
therefore scientific evidence is essential to better define and implement policies and 
management plans, to rationalize and to direct health resources towards the areas that 
can reduce the burden of vision loss. Further research on prevalence and direct costs of 
vision impairment in Portugal should be conducted. 
Regarding direct costs it is important that future studies includes ophthalmology and 
non-ophthalmology resource utilization and costs. Sight threatening disease are 
expected to be associated with direct medical ophthalmological cost. Non-
ophthalmological costs in patients with vision impairment and blindness are also 
important to analyze since vision loss is associated with several clinical consequences 
and can be a comorbidity of chronic diseases, such as diabetes, arthritis and stroke. It is 
also important that direct costs studies include different care providers such as primary 
care facilities, hospitals and long-term care institutions. 
Regarding informal care utilization further research should investigate the impact of 
vision impairment on caregivers. A wide body of research shows that informal care may 
require an intensive investment of time and effort for a long period of time depending on 
the characteristics of the patients such as age, type of activities provided, type of 
disability and severity level. Providing care may have a considerable impact on 
caregivers’ time use (time for work, for leisure or social activities), finance, health and 
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wellbeing. By investigating the impact of informal care in caregivers it will be possible to 
have a more comprehensive characterization of the consequences of vision impairment.  
Further research should also focus on the development of effective models of care 
provision that can provide for greater numbers of people with impaired vision. The 
increase number of visually impaired persons is driven not only from the ageing of the 
population but also from the emergence of new eye care technology and hopefully from 
more effective referral services. It will also be crucial to developed cost effectiveness 
studies to better understand which of these new models is more effective and produces 






















Chapter 7 – Conclusion 
The research papers developed in this thesis tried to introduce innovative approaches 
to analyse the impact of vision impairment in the healthcare system and the society. By 
studying the access to a new anti-VEGF treatment, we have performed a unique analysis 
of temporal and geographical patterns of the diffusion of anti-VEGF treatment during one 
decade including all public hospitals in a National Health System. In our analyses of the 
determinants of informal care we introduced self-reported difficulties performing daily 
living activities measured by the Activity Inventory, in combination with clinical measures 
and socio-demographic characteristics, which was disregarded in previous studies. 
Previous studies analysed productivity losses associated with vision impairment with 
some limitations regarding the sample and the explanatory factors used to studied this 
association. We decided to include patient-reported health related quality of life when 
investigating participation in the labour market which no one, to the best of our 
knowledge, as done before. 
 We found that the diffusion and consequently the access to new eye care treatment 
was large but unequally distributed and associated with availability of healthcare delivery 
services. The reduced number of treatments found in some counties is worrisome since 
it can lead to an increased number of people becoming visually impaired due to treatable 
causes. We also found that vision impairment in Portugal has substantial socioeconomic 
implication since, it affects individual’s autonomy levels that are associated with an 
intensive use of informal care. It also affects individual’s participation in society, namely 
employment status and health related quality of life that led to significant productivity 
losses.  
To conclude, much more can be done to reduce the burden of vision impairment in 
Portugal. It is never too much to say that, in many cases, vision loss may be preventable 
with the currently available healthcare technology.  Eye care has a range of proved, low 
risk, high success and cost-effective interventions so the key element is to guarantee 
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Table 1 – Activity Inventory goals designation, questions about importance and difficulties and answers categories  
Number and Goal 
Designation 
Question to infer the 
importance - How important is it 
for you to be able to …. without 





Question to infer the 
difficulties - How difficult is it for 
you to …. without the assistance 
of another person? 
Answer 
categories 
















moved to the 
next Goal;              
If the Goal 
was rated 























groom yourself (shave, trim nails, 
apply makeup, etc.) 
groom yourself (shave, trim nails, 
apply makeup, etc.) 
3 
Dressing 
choose your clothes and dress 
yourself 





take care of your health take care of your health 




prepare your daily meals prepare your daily meals 
7 
Household tasks 
perform household tasks such as 
cleaning, laundry, or setting a 
thermostat 
perform household tasks such as 




recognize people, see expressions, 
and make eye contact during 
personal communications 
recognize people, see expressions, 
and make eye contact during 
personal communications 
9 Correspondence read mail and write letters read mail and write letters 
10 
Follow the news 
follow the news and keep up with 
current events 





read the time and follow a 
schedule 






pay bills, balance accounts, or 
manage personal or household 
finances 
pay bills, balance accounts, or 




go shopping for food, clothes or 
other necessities 
go shopping for food, clothes or 
other necessities 
14 Child care care for young children care for young children 
15 Drive drive drive 
16 Adult care provide home care for an adult provide home care for an adult 
17 Pet care provide care for a pet provide care for a pet 
18 Use phone use a telephone use a telephone 
19 Go to parties attend parties or other functions attend parties or other functions 
20 Entertain guests entertain guests entertain guests 
21 Prepare food for 
guests 
cook or bake for social functions 
(for example, Thanksgiving or 
other holidays) 
cook or bake for social functions 
(for example, Thanksgiving or 
other holidays) 
22 Dining out dine out dine out 
23 
Spectator events 
attend plays, concerts, movies, 
sporting events, etc 
attend plays, concerts, movies, 
sporting events, etc 
24 
Attend meeting 
attend meetings of a club, church, 
civic group, etc. 
attend meetings of a club, church, 
civic group, etc. 
25 
Play games 
play cards, board games, Bingo, or 
other games 
play cards, board games, Bingo, or 
other games 
26 
Perform in public 
sing in a choir or play an 
instrument publicly, perform in 
plays, speak publicly or perform 
before a group 
sing in a choir or play an 
instrument publicly, perform in 
plays, speak publicly or perform 
before a group 
27 
Attend church 
attend church or house of worship 
services 
attend church or house of worship 
services 






provide yourself with leisure 
entertainment 









sew or do needlework sew or do needlework 
32 Woodwork do woodworking do woodworking 
33 Metalwork do metalwork do metalwork 





cook or bake for recreation cook or bake for recreation 
36 Electrical work do electrical work do electrical work 
37 Play music play a musical instrument play a musical instrument 
38 Sightseeing travel travel 
39 Fishing fish fish 
40 Outdoor 
activities 
perform outdoor recreational 
activities; i.e., boating, hiking, 
fishing, etc. 
perform outdoor recreational 





garden for pleasure or work in the 
yard" 




play sports; such as, golf, bowling, 
tennis, etc. 





use a computer use a computer 
44 
Collect antiques 
collect things; i.e., antiques, 
stamps, coins, cards, dolls, etc. 
collect things; i.e., antiques, 
stamps, coins, cards, dolls, etc. 
45 Read newspaper read the newspaper read the newspaper 






Table 1 – EQ5D – 3L 




I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
 
Self-care 
I have no problems with self-care 
I have some problems washing or dressing my self 
I am unable to wash or dress my self 
 
Usual Activities 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
 
Anxiety/Depression  
I am not anxious or depressed 
I am moderately anxious or depressed 







































Table 1 shows episodes distribution per age category and year. There is an increase in the absolute number of episodes for patients older 
than 50 years and percentage of patients with this age range also increases. In the age range 20-39 there is a reduction in the proportion of cases 
per year. It changes from 10.9% in 2002 to 2.7% in 2012 and the overall percentage for all years is 4.1%.  
 
Age category 40-49 represents 5% of total cases (table 1). This age category also shows a decline in the proportion of cases per year although 
the mean average episodes per years increases from 210.5 in 2002/2007 to 744.4 in 2008/2012. The absolute number of cases increases but is 
associated with diagnosis compatible with anti-VEGF treatment as shown in Table 2.  
 
Overall patients older than 50 years represent 90.0% of cases. Patients below 19 years of age remain constant in absolute values and the 
proportion reduced from 3.6% in 2006 to 0.4% in 2012.  
 
Table 1 – Episodes per Year and Age Category. 2002-2012 
Year/Age 
range 
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
n % n % n % n % n % n % n % n % n % n % n % n % 
0-19 66 3.6% 44 2.3% 62 2.7% 38 1.6% 67 2.3% 45 0.9% 76 0.9% 94 0.7% 105 0.7% 102 0.5% 90 0.4% 789 0.8% 
20-39 197 10.9% 208 11.0% 223 9.8% 200 8.7% 243 8.2% 275 5.8% 374 4.4% 468 3.6% 520 3.3% 654 3.3% 666 2.7% 4028 4.1% 
40-49 171 9.4% 165 8.7% 192 8.4% 191 8.3% 242 8.2% 302 6.4% 437 5.2% 620 4.8% 758 4.8% 822 4.1% 1085 4.3% 4985 5.1% 
> 50 1381 76.1% 1482 78.% 1808 79% 1876 81.% 2416 81.% 4128 87% 7535 90% 11793 91% 14535 92% 18387 92% 23265 93% 88606 90% 




Table 2 shows episodes distribution by diagnosis and age categories for two selected: years 2007 and 2012. These years were chosen 
because 2007 represents the year before the treatment was approved and 2012 because was the most recent year with complete information 
available. Diagnoses presented in this table represent 75% of episodes in 2012. Comparing 2007 with 2012 there is an increase of 391 episodes 
in the age range 20-39 years and 783 cases in the age range 40-49. The seven diagnosis in Table 2 correspond to 81% of extra cases found in 
in the age range 20-39 and to 76% of the extra cases found in the age range 40-49. The reminder cases were scattered by several diagnosis. 
The seven diagnoses below all have indication for treatment with anti-VGEF.  
 
Table 2 – Episodes by Principal Diagnosis and Age Category. 2007 and 2012 
 
Principal Diagnoses 2007 2012 2012 vs 2007 
ICD 9 
CM Designation 0-19 20-39 40-49 > 50 Total 0-19 20-39 40-49 > 50 Total 0-19 20-39 40-49 > 50 Total 
36252 Exudative Senile Macular Degeneration 0 19 20 1200 1239 0 23 54 8549 8626 0 4 34 7349 7387 
25050 Diabetes with Opthalmic Manifestation 0 13 46 740 799 2 117 335 5696 6150 2 104 289 4956 5351 
36283 Retinal Oedema 0 4 4 39 47 2 32 53 895 982 2 28 49 856 935 
36216 Retinal Nevascularization 6 5 2 14 27 0 94 121 726 941 -6 89 119 712 914 
36250 Macular Degeneration Senile (unspecified) 0 0 4 77 81 0 12 10 847 869 0 12 6 770 788 
36235 Retina Central Vein Occlusion 0 0 0 17 17 0 6 23 508 537 0 6 23 491 520 
36236 Retina  Veinous Tributary  Occlusion 0 0 0 4 4 0 4 16 605 625 0 4 16 601 621 
Others 39 234 226 2037 2536 86 378 473 5439 6376 47 144 247 3402 3840 







Table 1 – List of comorbidities 
1. Cancer 
2. Diabetes 
3. Heart condition 
4. Hypertension 
5. Musculoskeletal disorder 
6. Pulmonary disease 
7. Stroke or brain haemorrhage 
8. Hearing impairments 
9. Thyroid condition 
10. Psychological problems 
11. Neurologic problems 
12. Chronic allergies 
13. Gastrointestinal condition 
14. Liver disease 
15. Autoimmune diseases 



















Regression models description 
Logistic regression - to find determinants of informal care utilisation. The dependent 
variable was informal care use (non-user=0; user=1) and the independent variables 
were: gender (dummy variable: Female= 0; Male =1), marital status (dummy variable: 
Married= 0; Not Married=1), presence of other comorbidities (more than one comorbidity 
=1; no comorbidities = 0), visual ability (measured by AI), visual acuity in better eye 
(logMAR scale). The graphic method was used to validate model assumption for 
residuals independence and to identify extreme cases that were removed from the model 
whenever it increased the goodness of fit of the model. Multicollinearity was analyzed 
with Variance Inflation Factor (VIF). 
Multiple linear regression - to find predictors of informal care utilisation intensity. 
Depend variable was hours of informal care. Independent variables were visual ability, 
age, gender (dummy variable: Female= 0; Male =1), and severity of visual impairment 
transformed into a dummy variable (visual acuity in the better eye equal or below 1 
logMAR = 0; visual acuity in the better eye above 1 logMAR = 1). The model assumption 
for normality and homoscedasticity of residuals were tested using the Kolmogorov-






Monthly wage adjusted by sex and education for year 2014 
 
Monthly wage adjusted by sex and education for year 2014 
Education level Male Female 
Did not attend school        731,60 €         604,40 €  
4 years of education        858,60 €         639,60 €  
6 years of education        878,70 €         653,70 €  
9 years of education        954,60 €         728,80 €  
12 years of education     1.267,40 €         923,80 €  
University undergrad or more     2.259,20 €      1.580,00 €  
                                                                      Source: GEE/ME, Quadros de Pessoal Trabalhadores por conta de outrem 
                                                                      a tempo completo que trabalharam o horário completo no período de referência (outubro) 
 







Unemployment by sex and age - annual average, 2014 
 
Unemployment by sex and age (% of active population) - 
annual average, 2014 
  Total Male  Female 
PT 14,10% 13,80% 14,50% 
less than 25 years old 34,70% 33,90% 35,50% 
25-74 years old 12,50% 12,20% 12,80% 
Source: Eurostat.v3.4.1-20170407-5840-PROD_EUROBASE 










Logistic regression estimates the probability of the outcome occurring given that the predictor assumes certain values. In our case logistic 
regression was used to determine explanatory factors associated with participation in the labour market.  
The dependent variable was employment status in working age participants (non-working = 0; working =1). The general equation of the 
linear predictor was: 
𝐿𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟
= −3.838 − 0.039 𝑉𝑖𝑠𝑢𝑎𝑙 𝐴𝑏𝑖𝑙𝑖𝑡𝑦 − 1.05 𝑉𝑖𝑠𝑢𝑎𝑙 𝐴𝑐𝑢𝑖𝑡𝑦 + 1.369 𝐴𝑔𝑒 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑖𝑒𝑠 − 1.25 𝐶𝑜𝑚𝑜𝑟𝑏𝑖𝑡𝑖𝑒𝑠 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑖𝑒𝑠
+ 1.05 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑖𝑒𝑠 + 5.091 𝐻𝑅𝑄𝐿  
Where:  
- Visual Ability is a continuous predictor given by the Activity Inventory 
- Visual acuity in better eye is a continuous predictor using a logMAR scale  
- Age is divided in two categories: 40-64 years=0; 17-39 years=1;  
- Comorbidities is divided in two categories:  No = 0; Yes =1; 
- Education is divided in two categories: less than 12 years of education = 0; 12 years of education or more=1; 
- Health related quality of life is a continuous predictor provided by the EQ5D utility score. 
When a logistic regression is calculated, the regression coefficient (for example Visual ability) is the estimated increase in the log odds of the 
outcome per unit increase in the value of the exposure. In other words, the exponential function of the regression coefficient (exponential visual 
ability) is the odds ratio associated with a one-unit increase in the exposure. 
So the probability of Working will be given by: 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑊𝑜𝑟𝑘𝑖𝑛𝑔 = 1) =
𝑒𝑥𝑝𝑜𝑛𝑒𝑡𝑖𝑎𝑙𝑙𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 
(1 + 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙𝑙𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟)
+ 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑟𝑟𝑜𝑟 
 
Probability is the ratio between the number of events favourable to some outcome and the total number of events. It is constrained between 
zero and 1.To illustrate our logistic regression model we have built to 2 scenarios: best-case and worst-case. For both scenarios 5 curves were 
computed according to 5 categories of visual acuity in the better eye. 
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The best-case scenario includes participants within the age of 17-39 years, 12 years of education or more, no comorbidities and visual ability 
set as constant equal to the mean value of the group. Table 1 shows categorical variables and linear predictor equations computed for the 5 
categories of visual acuity in the better eye for best-case scenario: 
 




Linear predictor equation 
Visual acuity in the 
better eye Categories 
Linear predictor according with 
vision impairment categories 
Visual ability  = 
Mean value of the 
group = 0.96 
Age categories =17-
39 years  =1  
Comorbidities= No = 
0 
Education= 12 years 
or more = 1 
 
𝑙𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 = 𝜀
= −3.838 − 0.039 𝑉𝑖𝑠𝑢𝑎𝑙 𝑎𝑏𝑖𝑙𝑖𝑡𝑦
− 1.05 𝑉𝑖𝑠𝑢𝑎𝑙 𝐴𝑐𝑢𝑖𝑡𝑦
+ 1.369(𝐴𝑔𝑒 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑖𝑒𝑠 = 1)
+ 1.05( 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑖𝑒𝑠 = 1)
+ 5.091 𝐻𝑅𝑄𝐿 
 
No VI: from -0.3 to 0.3 
logMar 
Mid point   ACUITY=0 
𝜀 = −3.838 − 0.039 × (0.96) + 1.369
+ 1.05 + 5.091𝐻𝑅𝑄𝐿 
Minor VI: from 0.32 to 0.5 
logMar 
Mid point  ACUITY=0.41 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 
× (0.41) + 1.369 + 1.05
+ 5.091𝐻𝑅𝑄𝐿 
Moderate VI: from 0.5 to 
1.0 logMar 
Mid point  ACUITY=0.76 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 
× (0.76) + 1.369 + 1.05
+ 5.091𝐻𝑅𝑄𝐿 
Severe VI: from 1.02 to 1.3 
Mid point ACUITY=1.16 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 
× (1.16) + 1.369 + 1.05
+ 5.091𝐻𝑅𝑄𝐿 
Profound VI or blind: from 
1.32 to 3.0 
Mid point ACUITY=2.16 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 








For example if a patient as a HRQL of 0.6 and visual acuity classified as Profound VI or blind the probability of working will be given by:  
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑢𝑠 = 1) =
𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙−3.838−0.039×(0.96)−1.05 ×(2.16)+1.369+1.05+5.091𝑥(0.6)
(1 + 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙−3.838−0.039×(0.96)−1.05 ×(2.16)+1.369+1.05+5.091𝑥(0.6))
+ 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑟𝑟𝑜𝑟 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑢𝑠 = 1) = 0.339 + 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑟𝑟𝑜𝑟 
A patient with age within 17 to 39 years old, with 12 years of education or more, no comorbidities and visual ability equal to 0.96, health related 
quality of life of 0.6 and visual acuity classified as profound VI or blind would have a probability of working of 0.339. 
The worst-case scenario is defined as participants within the age 40-64 years, less than 12 years of education, comorbidities and visual ability 
set as constant equal to the mean value of the group. Table 2 shows categorical variables and linear predictor equations computed for the 5 
categories of visual acuity in the better eye for Worst-case scenario: 
 




Linear predictor equation 
Visual acuity in the better 
eye Categories 
Linear predictor according with vision 
impairment categories 
Visual ability  = Mean 
value of the group = 0.96 
Age categories= 40 -
64 years = 0 
Comorbidities=Yes =1 
Education= less than 
12 years  = 0 
𝜀
= −3.838 − 0.039𝑉𝑖𝑢𝑎𝑙 𝑎𝑐𝑢𝑖𝑡𝑦 
− 1.05 𝑉𝑖𝑠𝑢𝑎𝑙 𝑎𝑏𝑖𝑙𝑖𝑡𝑦
− 1.25(𝐶𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑖𝑒𝑠 = 1)
+ 5.091𝐻𝑅𝑄𝐿 
 
No VI: from -0.3 to 0.3 
logMar 
Mid point  ViLogmar=0 
𝜀 = −3.838 − 0.039 × −1.25 + 5.091𝐻𝑅𝑄𝐿 
Minor VI: from 0.32 to 0.5 
logMar 
Mid point ViLogmar=0.41 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 × (0.41)
− 1.25 + 5.091𝐻𝑅𝑄𝐿 
Moderate VI: from 0.5 to 1.0 
logMar 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 × (0.76)






Linear predictor equation 
Visual acuity in the better 
eye Categories 
Linear predictor according with vision 
impairment categories 
Mid point  VI LogMar=0.76 
Severe VI: from 1.02 to 1.3 
Mid point VI LogMar=1.16 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 × (1.16)
− 1.25 + 5.091𝐻𝑅𝑄𝐿 
Profound VI or blind: from 
1.32 to 3.0 
Mid point VI LogMar=2.16 
𝜀 = −3.838 − 0.039 × (0.96) − 1.05 × (2.16)
− 1.25 + 5.091𝐻𝑅𝑄𝐿 
 
For example if a patient as a HRQL of 0.6 and visual acuity classified as Profund VI or blind the probability of working will be given by:  
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑢𝑠 = 1) =
𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙−3.838−0.039×(0.96)−1.05 ×(2.16)−1.25+5.09 𝑥 (0.6)
(1 + 𝑒𝑥𝑝𝑜𝑛𝑒𝑡𝑖𝑎𝑙−3.838−0.039×(0.96)−1.05 ×(2.16)−1.25+5.09 𝑥 (0.6)
+ 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑟𝑟𝑜𝑟 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑢𝑠 = 1) = 0.009 + 𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑟𝑟𝑜𝑟 
 
A patient with age within 40 to 64 years old, with less than 12 years of education, comorbidities and visual ability equal to 0.96 health related 







Health state EQ-5D index N of participants Percentage 
11111 1.000 14 10% 
22222 0.288 14 10% 
22223 0.129 10 7% 
21223 0.287 9 7% 
11112 0.767 7 5% 
11121 0.694 7 5% 
21222 0.446 7 5% 
21221 0.482 6 4% 
11122 0.657 5 4% 

























Intercept -1.27 1.44 0.377 
*Gender: Male    
Female -1.04 0.29 <0.001 
*Age: <20    
[20,30[ -0.76 1.73 0.66 
[30,40[ 2.12 1.62 0.189 
[40,50[ 0.36 1.33 0.328 
[50,60[ 0.67 1.29 0.604 
[60,70[ -0.15 1.25 0.904 
>=70 -0.22 1.24 0.859 
DISTH (km) -0.02 0.006 <0.001 
EDU (years) 0.22 0.05 <0.001 
*Low-AHA    
Medium-AHA 0.65 0.37 0.075 
High-AHA 2.16 0.36 <0.001 
*MST: Married    
Living together 3.12 0.6 <0.001 
Single 0.25 0.49 <0.001 
Widow -0.14 0.34 0.678 
Divorced 3 0.77 <0.001 
*VA: 0    
0.1 -0.74 0.6 0.218 
0.2 -2.14 0.58 <0.001 
0.3 -1.99 0.63 0.002 
0.4 -0.94 0.54 0.084 
0.5 -0.29 0.53 0.58 
CCI 0.18 0.52 0.729 
*Aetiologies: AMD    
Diabetic 
retinopathy 
0.88 0.41 0.031 
Glaucoma 0.6 0.55 0.271 










Sup-Table 1: The table summarizes new categories that were defined after 
having run the first logistic regression. The categories were used for our final 
model.  
Variables Categories (levels) 
Gender - Male 
- Female 
DISTH (km) - Continuous 
EDU (years) - Continuous 
AHATTEND - AHA-rare = number of hospital visits was less than 10 per year;  
- AHA-frequent = number of hospital visits was 10 or more per 
year; 
MST - Living together 
- Divorced 
- Others (married, single or widowed) 
VA - VA-extreme (includes VA of 0.0 or 0.1 or 0.5) 
- VA-intermediate (includes VA of 0.2 or 0.3 or 0.4) 
 
 
 
